Effects of iodine supplementation in mild-to-moderately iodine-deficient pregnant women on thyroid function, pregnancy outcomes and newborn development in Thailand by Gowachirapant, S.
  
 
Effects of iodine supplementation in 
mild-to-moderately iodine-deficient 
pregnant women on thyroid function, 
pregnancy outcomes and newborn 
development in Thailand 
 
 
 
Sueppong Gowachirapant 
  
  
 
 
 
Thesis committee 
Promotor     
Prof. Dr M.B. Zimmermann 
Professor of Micronutrients and International Health, Wageningen University 
Laboratory for Human Nutrition, Swiss Federal Institute of Technology (ETH) Zurich, 
Switzerland 
 
Co-promotors 
Dr A. Melse-Boonstra 
Assistant professor, Division of Human Nutrition                          
Wageningen University 
 
Dr P. Winichagoon 
Associate professor, Community Nutrition Division 
Mahidol University, Thailand 
Other members 
Prof. Dr T. Vulsma, University of Amsterdam, the Netherlands 
Prof. Dr P. Laurberg, Aalborg University Hospital Science and Innovation Centre,     
Denmark 
Dr M. Andersson, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland 
Prof. Dr H.C. Boshuizen, Wageningen University 
   
This research was conducted under the auspices of the Graduate School VLAG        
(Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health 
Sciences).  
  
Effects of iodine supplementation in 
mild-to-moderately iodine-deficient 
pregnant women on thyroid function, 
pregnancy outcomes and newborn 
development in Thailand 
 
Sueppong Gowachirapant 
 
Thesis 
submitted in fulfilment of the requirements for the degree of doctor 
at Wageningen University 
by the authority of the Rector Magnificus 
Prof. Dr M.J. Kropff, 
in the presence of the 
Thesis Committee appointed by the Academic Board 
to be defended in public 
on Tuesday 1 July 2014 
at 4 p.m. in the Aula. 
  
  
 
 
 
 
 
 
 
 
 
 
 
Sueppong Gowachirapant 
Effects of iodine supplementation in mild-to-moderately iodine-deficient pregnant 
women on thyroid function, pregnancy outcomes and newborn development in 
Thailand, 162 pages. 
PhD thesis, Wageningen University, Wageningen, the Netherlands (2014)                                        
With references, with summaries in English, Dutch and Thai 
ISBN 978-94-6257-029-0 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
To my beloved parents 
Choochart and Korbkul 
and three sisters 
Chutima, Chidchom, Sompong 
their support always encouraged me  
  
 7 
ABSTRACT 
Background: Iodine deficiency (ID) during pregnancy has been recognized as a major 
cause of hypothyroidism and adverse health consequences in both mothers and 
children. Although urinary iodine concentration (UIC) in school-aged children is 
recommended as an indicator to assess ID in the general population, it may not be a 
good surrogate for directly assessing iodine status in pregnant women. Iodine 
supplementation of mildly iodine-deficient pregnant women has been recommended 
worldwide; however, long-term benefit and safety of iodine supplementation in this 
group is uncertain. Finally, pre-pregnancy body mass index (BMI) and gestational 
weight gain (GWG) may negatively affect thyroid function and pregnancy outcomes.         
Objectives: 1) to measure UIC in pairs of pregnant women and their school-aged 
children living in the same household; 2) to investigate the effects of iodine 
supplementation on maternal thyroid function, pregnancy and birth outcomes, and 
newborn development; 3) to evaluate the association between pre-pregnancy BMI and 
GWG with thyroid function and pregnancy outcomes.  
Methods: 1) In a cross-sectional pilot study, UIC was measured in spot urine samples 
from pairs (n=302) of healthy pregnant mothers and their school-aged children in 
Bangkok; 2) A randomized controlled trial was conducted with 200 µg iodine per day 
or placebo given to mildly ID pregnant Thai women from <14 weeks to term. 
Anthropometrics, maternal thyroid function, UIC and thyroid volume were measured at 
baseline, 2nd and 3rd trimester, at delivery and 6-week postpartum. Birth outcomes were 
collected from hospital records. Neonatal thyroid function, UIC and thyroid volume 
were measured at delivery and 6 weeks after birth. The Neonatal Behavioral Assessment 
Scales (NBAS) was used to assess newborn development.   
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Results: 1) In the pilot study, median UIC in the pregnant women was 108 (11–558) 
µg/L and was lower than UIC in their school-aged children [200 (25–835) µg/L] 
(P<0.001); 2) In the RCT, median UIC increased significantly from baseline in both 
groups, and the increase was higher in the iodine group (p<0.001). At 30 weeks of 
gestation, only 2% of the women in the placebo group and 7% in the iodine group 
reported a median UIC >500 µg/L. Maternal thyroid function, thyroid volume and the 
prevalence of all thyroid dysfunction subtypes did not differ significantly between 
treatment groups during the study (p>0.05). At 6-week postpartum, the prevalence of 
postpartum thyroiditis (hyperthyroidism) was significantly lower in the iodine group 
(3%) as compared to the placebo group (9%) (OR: 95%CI, 0.17: 0.04-0.70). There were 
no significant differences between newborn groups in thyroid function, thyroid volume, 
birth characteristics, UIC and NBAS score (p>0.05); 3) Pre-pregnancy BMI was a 
negative predictor of free thyroxine (fT4) (β=-0.20, P<0.001) in early gestation (<14 
weeks). Compared to normal weight women, the prevalence ratio (95% CI) of a low fT4 
in overweight women was 3.64 (2.08–6.37) (P<0.01). In addition, secondary data 
analysis showed that overweight women had an 11-fold higher risk of delivering a 
large for gestational age infant compared to normal weight women, while women who 
had excessive GWG were 5.6 times more likely to deliver a macrosomic infant 
compared to women with normal GWG. 
Conclusion: 1) UIC in school-aged children should not be used as a surrogate for 
monitoring iodine status in pregnancy; 2) iodine supplementation (200 µg/d) in mildly 
iodine-deficient pregnant Thai women was effective in increasing iodine intakes into 
the adequate range but had no benefit on antenatal maternal thyroid function or 
newborn outcomes out to 6 weeks; however, it significantly reduced the risk of 
maternal postpartum thyroid dysfunction; 3) excess maternal body weight both before 
and during pregnancy may have adverse impacts on maternal thyroid function as well 
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as birth weight. Therefore, maintaining normal body weight before and throughout 
pregnancy should be recommended.  
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Background 
 
Iodine deficiency (ID) is a global public health problem and it is estimated that almost 
two billion individuals have an insufficient iodine intake (1). Currently, severe ID is 
uncommon, but mild-to-moderate ID is still widespread on a global level including 
Europe, Africa, Latin America and Asia (1). Iodine deficiency can lead to multiple 
adverse effects on growth and development in all age groups especially in pregnant 
women who have the highest daily iodine requirement. Children born in iodine 
deficient areas are at risk of neurological disorders and mental retardation because of 
the combined effects of maternal, fetal, and neonatal hypothyroxinemia (2). For nearly 
all regions affected by ID, salt iodization is the most cost-effective way of delivering 
iodine and improving cognition. In some areas, iodization of salt may not be practical 
for control of ID; in those cases iodine supplementation as KI or KIO3 tablets or oil are 
recommended. In 2005, 49% of mild ID and 25% of moderate ID was reported in 
pregnant Thai women (3). Several studies of iodine supplementation in pregnant 
women with mild-to-moderate ID have been published and summarized. It can be 
concluded that iodine supplementation improved urinary iodine concentration and 
lowered thyroid gland volume in the iodine supplemented group (4). However, all of 
these studies had small simple sizes and none of the studies reported a clear 
amelioration on maternal thyroid function. Therefore, the benefits and safety of iodine 
supplementation in pregnancy in areas of mild ID remains controversial (5,6).  
 
The research that is described in this thesis focuses primarily on the effects of daily 
iodine supplementation in mild-to-moderately iodine-deficient pregnant Thai women 
on thyroid function, pregnancy outcomes and newborn development. 
 
Iodine characteristics and metabolism  
 
Iodine is an essential micronutrient that forms a vital component of the thyroid 
hormones thyroxine (T4) and triiodothyronine (T3), which are crucial regulators of the 
metabolic rate and physical and mental development in humans. Dietary iodine is 
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absorbed efficiently in the gastrointestinal tract and converted mostly to iodide before 
absorption. In healthy adults, the absorption of iodide is greater than 90% (7). Unlike 
the majority of trace elements, iodide in the blood does not appear to be bound to 
plasma protein and is available for uptake by all the tissues of the body. The majority of 
the circulating iodide (80%) is rapidly taken up by the thyroid gland, but significant 
amounts are also accumulated by the salivary glands, choroid plexus and the lactating 
mammary gland. Uptake of iodide by all of these tissues employs a similar mechanism 
utilizing a sodium/iodide symporter, which is stimulated by the thyroid stimulating 
hormone (TSH) released from the pituitary gland. Total body iodine levels are 15-20 mg 
in the body of healthy adults, of which 70-80% is in the thyroid (8). Once the iodine 
requirements for thyroid hormone production have been met, excess circulating iodide 
is removed from the blood by the kidney and excreted in the urine.  
 
Iodide is taken up from the circulation by the follicle cells of the thyroid and passes into 
the inner colloidal space where it is rapidly oxidized to iodine (I2), by thyroid 
peroxidase, and reacts with the thyrosin residues on thyroglobulin (Tg), a large 
glycoprotein, to produce monoiodotyrosin (MIT) and diiodotyrosin (DIT). These two 
precursors can condense to form the thyroid hormones triiodothyronine (T3) and 
thyroxine (T4) (9). These remain bound to Tg and are stored within the colloid until the 
thyroid is stimulated by TSH, whereupon Tg is taken up by the follicle cells and active 
T3 and T4 are liberated by lysosomol enzymes which are subsequently released into the 
circulation. The half-lives of T4 and T3 in the circulation are approximately one day for 
T3 and seven days for T4. Degradation of T4 and T3 in the periphery, releases iodine 
that enters the plasma iodine pool and can again be taken up by the thyroid or excreted 
by the kidney (10). The iodine pathway in the thyroid cell is presented in Figure 1.1 
(11). 
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Iodine and brain development 
 
The thyroid gland secretes mainly two iodinated products, triiodothyronine (T3) and 
thyroxine (T4). Triiodothyronine is the active form of thyroid hormone, and acts in the 
brain by binding to specific intracellular receptors which are proteins located in the cell 
nucleus associated to DNA. The receptors are ligand-dependent transcription factors 
that modulate the rate of transcription of the target genes (12). Conversion of T4 to T3 
requires the action of specific cellular enzymes. In situations where the T4 supply is 
low,there is an increase in the efficiency of T4 to T3 conversion in the brain, together 
with a decrease in the periphery. This regulatory mechanism tends to increase T4 
availability to the brain and T3 production from its precursor. These mechanisms are 
very important since 80% of brain T3 is generated locally from T4 (13).  
  
Human fetal thyroid ontogeny begins at 10-12 weeks of gestation and continues to 
develop until delivery. However, during early gestation, fetal thyroid hormone 
requirement is dependent on maternal supply. Timing of expression of T3 receptors 
during development has given some insight into when the brain becomes sensitive to 
thyroid hormones. In the human fetal brain the receptors are already present at the end 
of the first trimester of pregnancy before full development of the thyroid gland (14). 
During the second trimester, the human fetal brain receptors are already occupied by 
Figure 1.1 Iodine pathway 
in the thyroid cell 
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the hormone, which is not the case for the receptors in other tissues, such as lung and 
liver. This suggests that maternally-derived T4 could reach the fetal brain and be 
converted locally to T3. Thus it is very likely that maternal hormone can influence fetal 
brain development during the second trimester of pregnancy and that therefore severe 
maternal hypothyroxinemia is a causative factor in the genesis of neurological cretinism 
(15). The role of the fetal thyroid gland is important from the third trimester of 
pregnancy onwards (13). 
 
Recommended dietary allowance of iodine 
 
The recommended dietary allowance (RDA) of iodine per age group is 50 µg/day from  
0 to 6 months, 90 µg/day from 6 months to 6 years, 120 µg/day from 7 to 10 years,  
150 µg/day during adolescence and adulthood, and 250-300 µg/day during pregnancy 
and lactation (16). The Institute of Medicine (IOM) of the US Academy of Sciences 
recommends a somewhat lower iodine intake of 220 g/day for pregnant women (17). 
 
The requirement of iodine is increased during pregnancy because of at least three 
factors: 1) the requirement of T4 in order to maintain a normal global iodine 
metabolism in the mother increases by 10 to 150% during pregnancy; 2) transfer of T4 
from the mother to the fetus, before and after the onset of fetal thyroid function; it has 
been estimated that up to 40% of the T4 measured in cord blood at birth is still of 
maternal origin. The transfer of iodide is difficult to quantify but considering that the 
iodine content of the fetal thyroid increases progressively from less than 2 µg at 17 
weeks of gestation up to 300 µg at term, it can be estimated that the transfer of iodide 
from mother to fetus represents some 50 µg/day; 3) an increased loss of iodide through 
the kidney due to an increase in the renal clearance of iodide (18). 
 
Dietary sources of iodine 
 
The amount of iodine found in most natural foods is typically quite small and varies 
depending on environmental factors such as the soil concentration of iodine, the use of 
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 Table 1.1 Iodine content in Thai foods (µg/100 g edible portion) 
Food items Iodine content 
Cereals  
     Rice, unpolished 16 
     Glutinous rice 12 
Vegetables & Fruits  
     Chinese cabbage 6 
     Pumpkin 4 
     Cauliflower 3 
     Cabbage  4 
     Carrot 12 
     Seaweed, dried 350 
     Banana 7 
     Fig 11 
Meat  
     Chicken, cooked 19 
     Beef, meat, cooked 17 
     Pork, meat, cooked 16 
     Dwaref prawn           129 
     Catfish, dried 67 
     Giant seaperch 51 
     Mackerel, steamed 48 
     Anchovy 12 
     Splendid squid 15 
Egg  
     Egg, hen 12 
     Egg, duck 15 
Milk and products*  
     Milk, whole, pasteurized 10 
     Milk, whole, UHT 7 
     Milk, low fat, pasteurized 6 
     Milk, low fat, UHT 13 
     Yoghurt, cream       20 
* µg iodine/100 ml.                   
Source: MOPH Thailand, 2001                                      
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fertilizers and livestock feed. Some of the richest food sources of iodine are often 
processed foods that contain iodized salt, and breads that contain iodate dough 
conditioners. Foods of marine origin have higher iodine content because marine plants 
and animals concentrate iodine from seawater. Major dietary sources of iodine in the 
USA and Europe are bread and dairy products (19,20). Boiling, baking, and canning of 
foods containing iodated salt cause only small losses (≤10%) of iodine content (21). In 
2001, iodine content in Thai foods was reported in the Table for Thai Food Composition 
(22); some examples for frequently consumed Thai foods are shown in Table 1.1. 
 
Iodine status assessments 
 
Assessment of iodine status in populations living in areas at risk of ID is based on a 
number of methods. The size of the thyroid can be measured by palpation or by 
ultrasound; subsequently the number of goiters can be classified in accordance with 
WHO/UNICEF/ICCIDD guidelines. Urinary iodine concentration (UIC) can be measured 
by a simple colorimetric assay. Neonatal levels of TSH in the serum are used routinely in 
most developed countries to give an indication of congenital hypothyroidism. ID 
indicators and their cut-off levels are summarized in Table 1.2. 
 
Table 1.2 Iodine deficiency indicators* 
Iodine deficiency None Mild Moderate Severe 
Iodine intake, µg/d ≥100 50-99 20-49 <20 
Median urinary iodine, µg/L >100 50-99 20-49 <20 
Goiter prevalence <5% 5-19.9% 20-29.9% ≥30% 
Neonatal TSH >5 IU/mL whole blood <3% 3-20% 20-40% >40% 
Cretinism 0 0 + + 
* Adapted from the World Health Organization (WHO) / United Nations Children's Fund (UNICEF)/ International Council 
for Control of Iodine Deficiency Disorders (ICCIDD).   
 
However, each of the indicators mentioned in Table 1.2 have limitations. Urinary iodine 
is an indicator of recent iodine intake but not of thyroid function. The median UIC in 
school-aged children is recommended as a proxy for assessment of iodine nutrition in a 
population as a whole, but it still needs to be proven if UIC in school children also 
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reflects iodine status of pregnant women. Thyroid size decreases only slowly after iodine 
repletion, and therefore goiter incidence may remain high for several years after 
introduction of iodized salt. TSH is a sensitive measure of iodine status, but only in 
newborns (16).  
 
Thyroglobulin is a thyroid-specific protein that is a precursor in the synthesis of thyroid 
hormone. Stimulated by TSH, transcytosis of Tg-containing endosomes across the 
thyrocyte results in small amounts of Tg being released into the blood (23). Tg 
concentrations can be measured in serum with commercially available assays, which 
requires venipuncture, centrifugation, and the transport of frozen samples, which may 
be difficult in remote IDD-affected areas (24). Therefore, measurement of Tg 
concentrations in dried blood spots collected on filter paper has been developed and 
used for many years. This method offers the following advantages: 1) sample collection 
is relatively painless and less invasive; 2) blood spot samples do not need to be 
centrifuged, separated, and immediately frozen following collection; and 3) these 
samples remain stable in laboratory freezers for long periods of time. Recently, 
international reference data of DBS-TG have become available from iodine-sufficient 
children (25), but such data for pregnant women in mild-to-moderately 
iodine-deficient populations are not available. 
 
In 2008, Zimmermann et al (26) summarized indicators of iodine status by age group 
including advantages and disadvantages, as shown in Table 1.3. 
 
Iodine deficiency disorders  
 
Like other trace elements, iodine intake should be within a normal range. Either 
deficiency or excess will lead to metabolic disturbances. The adverse consequences of ID 
on growth and development are collectively known as iodine deficiency disorders (IDD) 
(27). ID is the leading preventable cause of brain damage and mental retardation 
worldwide. The most severe condition associated with ID is neurological cretinism, 
characterized by mental retardation, deaf mutism, and severe neurological deficits (27).   
INTRODUCTION 
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Table 1.3 Indicators of iodine status by age group 
Indicators Age group Advantages Disadvantages 
Urinary iodine  
concentration 
(µg/L, median) 
School-aged 
children, 
Adults, and 
pregnant 
women 
Spot urine samples are easy to 
obtain 
Low cost 
External quality control program 
in place 
Not useful for individual 
assessment 
Assess iodine intake only over the 
past few days 
Meticulous laboratory practice 
needed to avoid contamination 
Sufficiently large number of 
samples needed to allow for 
varying degrees of patient 
hydration 
Goiter rate by 
palpation (%) 
School-aged 
children 
Simple and rapid screening test 
Needs no specialized equipment 
Specificity and sensitivity are low 
because of a high interobserver 
variation 
Responds only slowly to changes 
in iodine intake 
Goiter rate by 
ultrasound (%) 
School-aged 
children 
More precise than palpation 
Reference values established as a 
function of age, sex, and body 
surface areas 
Need expensive equipment and 
electricity 
Operator needs special training 
Responds only slowly to changes 
in iodine intake 
TSH (mU/L) Newborn 
babies 
Measures thyroid function at 
particularly susceptible age 
Minimum costs if congenital 
hypothyroidism screening 
program is already in place 
Heel-stick method to obtain 
sample, and storage on filter 
paper is simple 
Not useful if iodine antiseptics 
used during delivery 
Needs standardized sensitive 
assay 
Should be taken by heel-prick at 
least 48 h after birth to avoid 
physiological newborn surge 
Serum or 
whole blood 
thyroglobulin 
(µg/L) 
School-aged 
children, and 
adults 
Finger-stick approach to obtain 
sample, and storage on filter 
paper is simple 
International reference range 
available 
Measures improvement in 
thyroid function within several 
months after iodine repletion 
Expensive immunoassay 
Standard reference material is 
available, but needs validation 
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However, even moderate forms of ID may lead to a certain degree of mental retardation. 
It has been a significant public health problem in more than 118 countries with about 
1.6 billion people at risk globally. Most populations at risk of IDD are concentrated in 
Asia, Africa, Latin America and South America (28). 
 
In 2008, WHO reported the number of countries, proportion of population, and 
estimated number of individuals with insufficient iodine intake in school-aged children 
and in the general population, by WHO region (Table 1.4) (29). 
 
Table 1.4 Number of countries, proportion of population, and number of individuals with insufficient 
iodine intake in school-aged children (6-12 years) and in the general population (all age groups), by WHO 
region, 2007 
 
WHO regiona 
Insufficient iodine intake (UI<100 µg/L) 
Countries (no.) School-aged children General population 
Proportion 
(%) 
Total no. 
(million)b 
Proportion 
(%) 
Total no. 
(million)b 
Africa 
Americas 
SE Asia 
Europe 
Eastern   
 Mediterranean 
Western Pacific 
13 
3 
0 
19 
7 
 
5 
40.8 
10.6 
30.3 
52.4 
48.8 
 
22.7 
57.7 
11.6 
73.1 
38.7 
43.3 
 
41.6 
41.5 
11.0 
30.0 
52.0 
47.2 
 
21.2 
312.9 
98.6 
503.6 
459.7 
259.3 
 
374.7 
Total 47 31.5 266.0 30.6 2,008.8 
a. 193 WHO Member States 
b. Based on population estimates in the year 2006 (2004 revision) 
Source: de Benoist, 2008 
 
From Table 1.4, the iodine intake of 31.5% (266 million) of school-aged children 
worldwide is insufficient. Iodine intake is below requirements in 73 million children in 
South-East Asia and in 57.7 million children in Africa. In the European, Eastern 
Mediterranean, and Western Pacific regions, the figure is approximately 40 million 
children, whereas in the Americas, 12 million children do not have enough iodine in 
their diet. The greatest proportions of children with inadequate iodine intake live in the 
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regions of Europe (52.4%) and the Eastern Mediterranean (48.8%), and the smallest 
proportions are found in the Western Pacific (22.7%) and the Americas (10.6%). 
Extrapolating from the proportion of school-aged children to the general population, it 
is estimated that 2 billion people have an insufficient iodine intake (29). 
 
Currently, in 2012, the global and regional iodine status has been updated again by 
Andersson et al (1). The authors concluded that the global iodine situation has markedly 
improved over the past decade and the number of iodine-deficient countries decreased 
from 54 in 2003 to 32 in 2011. However, 1.88 billion people of the world, including 
241 million school-aged children, are still living with ID. 
 
Iodine deficiency disorders (IDD) in Thailand 
 
IDD have been recognized as one of Thailand’s critical public health problems for many 
years. In the early 1950s, surveys in the north of Thailand showed a high prevalence of 
endemic goiter, identifying a defined ‘goiter belt’. The goiter rate was found to be as 
high as 58% in the north, and a level of 15-21% was later reported in the northeast 
(30,31). In 1965, a pilot project on salt iodization was implemented in the endemic area 
(Phrae province in the north). The production capacity was 20,000 tons per year. As a 
result, the goiter rate declined and salt iodization was expanded to a national program 
in 1968.  
 
In 1995, the Thai government and UNICEF made an agreement to accelerate activities to 
achieve the mid-decade goal of eradicating IDD in Thailand (32). Activities launched in 
each area depended upon severity mapping and targeting of households of 
schoolchildren, pregnant women and women of childbearing age (33). The cyclic 
monitoring of UIC in Thai pregnant women has been conducted since 2000 in all 
provinces within 5 years (15 provinces/year) except for Bangkok. A systematic random 
sampling method was used to collect 300 urine samples/province/year. In 2005, the 
Ministry of Public Health (3) reported data on ID in pregnant women from the 1st cyclic 
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monitoring program (Table 1.5). From 2000 to 2004, the percentage of mild and 
moderate ID increased from 34.4% to 49.4% and from 14.9% to 25.5%, respectively.  
In 2011, the Ministry of Public Health (34) presented UIC data of Thai pregnant women 
from the 2nd cyclic monitoring program which was conducted in 2006-2010 (Table 
1.6). Although, the positive results both of median UIC of pregnant women and 
percentage of ID were noted, however, the ID problem in this population still persisted. 
 
Table 1.5 Iodine deficiency in Thai pregnant women by region (1st cyclic monitoring program) 
 
Region 
% ID 
2000 2001 2002 2003 2004 
<50 
µg/l 
<100 
µg/l 
<50 
µg/l 
<100 
µg/l 
<50 
µg/l 
<100 
µg/l 
<50 
µg/l 
<100 
µg/l 
<50 
µg/l 
<100 
µg/l 
North 12.9 29.7 12.5 35.9 16.6 40.3 21.6 47.2 26.4 50.0 
NE 26.5 51.9 34.1 56.9 33.0 51.8 33.7 57.3 34.9 58.0 
Central 11.1 32.6 20.4 49.5 22.5 46.5 16.4 43.1 23.6 51.6 
South 7.9 22.4 12.6 36.7 - - 7.5 25.3 11.0 29.4 
Total 14.9 34.4 19.7 45.2 24.4 47.0 20.9 44.5 25.5 49.4 
 Source: MOPH Thailand, 2005 
 
 
Table 1.6 UIC of Thai pregnant women by region (2nd cyclic monitoring program) 
 
Region 
Urinary iodine concentration (µg/L)* 
2006 2007 2008 2009 2010 
Median 
 
< 150 
(%) 
Median 
 
< 150 
(%) 
Median 
 
< 150 
(%) 
Median 
 
< 150 
(%) 
Median 
 
< 150 
(%) 
North 92.5 66.5 106.5 64.1 133.4 55.3 117.7 57.0 229.5 34.6 
NE 61.1 75.9 95.9 61.3 104.6 64.6 97.7 72.7 122.5 59.6 
Central 84.4 73.3 88.5 71.2 118.1 61.6 117.7 58.4 196.3 38.6 
South 101.0 68.0 177.4 43.3 138.4 53.5 164.0 50.0 217.2 34.7 
Total 82.5 71.8 108.2 61.3 125.5 58.5 117.8 59 178.4 42.6 
* percentage of median UIC<150 ug/L; if >50% indicating as ID area 
Source: MOPH Thailand, 2011 
 
In 2013, the latest UIC information of pregnant Thai women was collected (35). The 
survey was conducted in 2012 and covered all provinces of the country. The report 
showed that there were 31 provinces out of 77 provinces in Thailand reported pregnant 
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women had median UIC <150 µg/L and 46.4% of this population living with 
mild-to-moderate ID. 
 
Furthermore, Rajatanavin (36) reported data on the relationship between the 
concentration of TSH in whole blood or serum from neonates and the concentration of 
iodine in their mother’s urine collected at birth. In 2000, paired samples of cord serum 
and urine were collected from 203 infants and their mothers at Ramathibodi hospital, 
Bangkok. In 2002-2003, 1,182 of DBS samples from a heel prick of infants and urine 
samples of their mothers in six rural provinces were collected. Iodine was measured in 
the mothers’ urine and TSH was measured in blood samples. The UIC of mothers in 
rural Thailand was adequate, with a median of 103 µg/L but the median UIC of mothers 
in Bangkok was only 85 µg/L. With regard to TSH values, 31% of neonates had a TSH 
concentration >11.2 mIU/L, which was in the range of moderate ID. The authors 
concluded that the concentration of TSH in whole blood collected on filter paper from 
neonates was not sensitive enough to be used as a monitoring tool for iodine nutrition in 
the neonates, as there was no relationship with the concentration of iodine in the urine 
of mothers. In contrast, neonatal TSH screening using cord sera showed a significant 
relationship with the UIC of the mothers. Therefore, cord sera TSH can be used to assess 
iodine nutrition of the neonates. 
 
It can be concluded from the information above that Thailand is still facing ID 
problems. Therefore, the Ministry of Public Health (MOPH) launched an IDD 
Elimination Program in order to combat this problem, with the following strategies: 
1. Monitoring program (UIC among pregnancy): 1) during 2000-2010, cyclic 
monitoring program in all provinces within 5 years (15 provinces/year) except 
Bangkok; 2) since 2011, UIC monitoring program in all provinces yearly; 
2. IDD surveillance system: 1) UIC of pregnant women and school children; 2) TSH 
concentration of newborns; and 3) household coverage of iodized salt; 
3. Household coverage of iodized salt should be ≥90%; 
4. Nutrition promotion in poverty zone (under the patronage of HRH 
MahaChakriSirindhorn); 
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5. Campaign of National Iodine Day (June 25). 
(http://nutrition.anamai.moph.go.th/temp/who/index.php?id_con=1) 
In addition, in October 2010, during the intervention phase of the trial described in this 
thesis, MOPH launched a new iodine supplementation program for Thai pregnant 
women by using two types of daily prescribed iodine tablets: 1) triferdine150 (iodine, 
iron and folate); 2) Iodine GPO150 (only iodine) for pregnant women having 
thalassemia. 
  
Iodine excess 
 
Iodine excess is occurring more frequently during the last decade, particularly when 
salt iodine concentrations are too high or are poorly monitored (37). Various drugs and 
food preservatives contain a large quantity of iodide that is either absorbed directly or 
released after metabolism of the drug. High dietary iodine can also come from natural 
sources, such as seaweed in coastal Japan, iodine-rich drinking water in China, and 
iodine-rich meat and milk in Iceland from animals fed fish products. Iodophors contain 
large quantities of iodine and are used as udder antiseptics in the dairy industry, 
resulting in contamination of the milk with iodine (38).  
 
The World Health Organization / International Council for Control of Iodine Deficiency 
Disorders (WHO/ICCIDD) cautioned that a median UIC >300 µg/L in school-aged 
children and UIC ≥500 µg/L in pregnant women are excessive (39). An increase in 
iodine intake in populations with chronic iodine deficiency might lead to 
iodine-induced hyperthyroidism (IIH). Symptoms of IIH include weight loss, 
tachycardia, muscle weakness, and skin warmth, without the ophthalmopathy of 
Graves’ disease. This hyperthyroidism is nearly always transient, and the incidence 
reverts to baseline after 1-10 years of intervention. However, it is dangerous when 
superimposed on underlying heart disease, and might be lethal (40). In Thailand, there 
is no evidence that iodine excess is present. 
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Iodine nutrition and thyroid function during pregnancy 
 
The importance of an adequate iodine status for maintenance of adequate thyroid 
hormone production in pregnancy has been described in the literature (41). The daily 
requirement of iodine for a normal adult is 80 µg for thyroid hormone synthesis. Once 
the pregnancy takes place, there is a significant increase in renal iodide clearance by 
approximately 30-50%, and consequently the daily need for iodide increases from 80 to 
120 µg in order to sustain an increase of thyroid hormone production by 50%.  
 
Concerning the changes of thyroid hormone concentrations during pregnancy, three 
phenomenons have been described (42). First, from early gestation until term, the rapid 
and marked rise in serum thyroxine-binding globulin (TBG) levels, under the influence 
of elevated estrogen concentrations, is accompanied by a reduction trend in free T4 
(fT4) and free T3 (fT3) concentrations. Second, an increase of human chorionic 
gonadotropin (hCG) concentrations results in lower serum TSH concentrations during 
the first trimester. The possible explanation for this phenomenon is that hCG shares a 
common alpha subunit with TSH but has a unique beta subunit, so that hCG can bind to 
the TSH receptor on the thyroid cell membrane and acts as a TSH agonist (43,44). Third, 
three enzymes including type 1 monodeiodinase (MID-1), type 2 monodeiodinase 
(MID-2), and type 3 monodeiodinase (MID-3) catalyze the deiodination of thyroid 
hormones in human tissues. This enzymatic activity especially MID-3 may explain the 
increased T4 turnover of maternal origin and also the low T3 / high reverse-T3 pattern 
during pregnancy.  
 
Maternal ID and pregnancy outcomes 
 
Hypothyroidism is a condition in which the thyroid gland does not make enough 
thyroid hormone and the most common cause of hypothyroidism worldwide is iodine 
deficiency. Several studies have reported that maternal hypothyroidism is associated 
with increased risks of abortions, stillbirths, congenital malformations, 
pregnancy-induced hypertension, postpartum hemorrhage and fetal distress (45-48).  
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In 2003, Blazer et al (49) compared the results of serum TSH and fT4 levels, birth 
weight and head circumference between the newborns born to hypothyroid mothers 
(n=246) and control newborns from healthy mothers (n=139). Early neonatal serum 
TSH and fT4 levels were both significantly higher in a large subgroup of infants of 
hypothyroid mothers as compared to control neonates (p<0.001). The newborns of the 
hypothyroid study group were relatively smaller at birth and had a relatively smaller 
head circumference than the normal control newborns (p<0.001). This finding 
confirmed a study published in 1999, when Haddow et al (50) showed that infants of 
untreated hypothyroid mothers had a higher birth weight than controls, but this was 
not statistically significant. 
 
The association between subclinical hypothyroidism and adverse pregnancy outcomes 
in 17,298 Texan women was evaluated by Casey et al (51). Thyroid function tests were 
performed at or before the 20th week of gestation, and women were followed 
prospectively to determine pregnancy outcomes. Preterm delivery, defined as gestational 
age less than or equal to 34 week at delivery, was almost 2-fold significantly increased 
in women with subclinical hypothyroidism compared with the controls (p<0.05). Also, 
a significant 3-fold increase in the incidence of placental abruption was reported in 
women in the subclinical hypothyroid group compared with the healthy controls 
(p<0.05). In addition, related to these findings, admission to the neonatal intensive care 
nursery and respiratory distress were twice as likely in infants delivered by women with 
subclinical hypothyroidism (RR: 1.8, 95% CI: 1.1–2.9 and 1.0–3.3, respectively). On the 
other hand, women who had a fT4 below 0.86 ng/dL and a TSH concentration in the 
normal range (isolated hypothyroxinemia), had no adverse perinatal outcome (52). 
 
Maternal ID and infant development 
 
Combined maternal and fetal hypothyroidism occurs mostly in regions with dietary ID. 
The most severely affected infants have neurologic cretinism, manifested by mental 
retardation (mean IQ ~29) and impaired gait and motor function (53). Whereas 
children from these areas may have normal school performance, impaired motor and 
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visual perceptive abilities have been reported (54). These abnormalities have been 
associated with maternal T4, but not T3 levels during pregnancy (55). In recent years 
the potential impact of mild to moderate ID on the fetus has been recognized. Effects on 
the mother and fetus include thyroid enlargement and an increase in serum Tg. 
Although the mother also may have relative hypothyroxinemia, the fetus maintains 
normal fT4 and TSH (56). However, school achievement may be impaired, and a variety 
of neuropsychointellectual deficits have been described (2).   
 
Presumably, all degrees of ID affect thyroid function of the mother and the neonate as 
well as the mental development of the child. The damage increases with the degree of 
the deficiency, with overt endemic cretinism as the severest consequence (57). In a 
cross-sectional study in the USA (50), children of women (n=62) with high serum 
thyrotropin concentrations averaged 4 points lower on the Wechsler Intelligence Scale 
for Children than children of matched control women (n=124) (p=0.06); 15 percent of 
children from mothers with high thyrotropin concentration had low scores as 
compared with 5 percent of the matched control children.   
 
Pop et al (58) reported a neurodevelopment assessment at 10 months of age in a cohort 
of 220 healthy children, born after uncomplicated pregnancies and deliveries, using the 
Bayley Scales of Infant Development. Children of women with fT4 levels below the 5th 
and 10th percentiles at 12 weeks’ gestation had significantly lower scores on the Bayley 
Psychomotor Development Index (PDI) scale, compared to children of mothers with 
higher fT4 values. After correction for confounding variables, a fT4 concentration 
below the 10th percentile at 12 weeks’ gestation was a significant risk factor for 
impaired psychomotor development (RR: 5.8, 95% CI: 1.3-12.6).  
 
In addition, in a prospective 3-year follow-up study of pregnant women and their 
children up to the age of 2 years (59), child development was assessed by means of the 
Bayley Scales of Infant Development. Children of women with hypothyroxinemia (fT4 
<10th percentile) at 12 weeks’ gestation had delayed mental and motor function 
compared to controls (children of women with fT4 between the 50th and 90th 
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percentile). In addition, improvement of fT4 concentrations during the 2nd and 3rd 
trimester of pregnancy of case mothers led to similar development scores as compared 
to controls.  
 
In 2006, Kooistra et al (60) reported an examination of the neurobehavioral profile of 
neonates who are born to women with hypothyroxinemia by using the Neonatal 
Behavioral Assessment Scale (NBAS) at 3 weeks of age. Infants who were born to women 
with first-trimester fT4 concentrations ≤10th percentile (n=108) had significantly lower 
scores on the NBAS orientation index than children of mothers with high fT4 values 
(n=96). Similarly, regression analysis showed that first-trimester maternal fT4 but not 
maternal TSH or fT4 later in gestation was a significant predictor of orientation scores.  
 
Iodine supplementation trials in pregnancy 
   
Several randomized, controlled trials of iodine supplementation in pregnancy have been 
published, involving a total of 596 women with mild-to-moderate ID in Europe. These 
studies have been reviewed by Zimmermann et al (61) (Table 1.7). As can be seen in 
Table 1.7, none of the trials measured long-term clinical outcomes, such as maternal 
goiter or infant development. Therefore, the full impact of mild-to-moderate iodine 
deficiency during pregnancy remains unclear.  
 
In 2009, two randomized trials were published investigating the effect of iodine 
supplementation in pregnant women. Berbel et al (62) recruited three groups of 
pregnant women living in Spain at different gestational ages. All women received 200 
µg of iodine until the end of lactation. The Brunet-Lezine scale was used to estimate the 
neurobehavioral development of children at 18 months of age. The development 
quotient of children in mothers supplemented in the first group (4-6 weeks gestation, 
n=13) was significantly higher than that of children whose mothers received 
supplements from 12-14 weeks gestation (n=12; p<0.05) or near term (37-40 weeks 
gestation, n=19; p<0.001). The authors also concluded that a delay in maternal  
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Table 1.7 Summary of trials of iodine supplementation in pregnancy with mild-to-moderate iodine deficiency 
 Reference/      
Year 
Subject               
characteristics 
Design Treatment Results                                                                         
(In treated group vs. control group) 
Romano et al            
1991            
(65) 
Moderate ID,    
treated n=17      
control n=18 
Randomized, 
double blind 
controlled trial 
120-180 µg I2 / 
day (iodized salt)           
1st trimester to 
term 
- No change in TSH level                                                                  
- Median UI 3-fold increase vs. no change                                                     
- Thyroid size: no change vs. 16% increase 
Pedersen et al     
1993            
(66) 
Mild ID,       
treated n=28      
control n=26 
Randomized, 
double blind 
controlled trial 
200 µg I2 /day         
(KI solution)          
17 wks to term 
- No differences in maternal or cord T4, T3, and 
TSH                                         
- Median UI: 2-fold increase vs. no change                                            
- Thyroid volume: 16% increase vs. 30% increase 
Gilnoer et al   
1995         
(67) 
Moderate ID,  
treated n=60 
control n=60 
Randomized, 
double blind 
controlled trial 
100 µg I2/day,    
~14 wks to term 
- No effect on maternal or cord T3, fT4, and 
T3/T4 ratio                                
- Maternal and newborns UI: higher vs. lower                                        
- Maternal and newborns thyroid volume: 
smaller volume vs. bigger volume                                                          
- Maternal and newborns TSH, Tg: lower level vs. 
higher level 
Liesenkötter   
et al 1996        
(68) 
 
Moderate ID, 
treated n=38 
control n=70 
Quasi-random,  
double blind 
controlled trial 
230 µg I2 /day    
11 wks to term 
- No effect on maternal TSH, T3, T4, thyroid 
volume, or Tg                               
- No effect on newborn TSH                                              
- Median UI 2-fold increase vs. no change                                     
- Thyroid volume in newborns: lower volume 
(0.7 ml) vs. higher volume (1.5 ml) 
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Table 1.7 Summary of trials of iodine supplementation in pregnancy with mild-to-moderate iodine deficiency (cont.) 
 Reference/  
Year 
Subject 
characteristics 
Design Treatment Results                                                               
(In treated group and control group) 
Nohr et al   
2000        
(69) 
Moderate ID, 
TPO-Ab 
positive,   
treated n=42 
control n=24 
Placebo-controlled, 
randomized, 
double blind trial 
150 µg I2/day,    
11 wks to term 
- No differences in maternal TSH, fT4, Tg                                         
- No differences in prevalence of Tg-Ab, 
TPO-Ab                                
- Maternal median UI: higher vs. lower                                   
- % developed PPTD: 60% vs. 46%  
Nohr et al   
2000        
(70) 
Mild-to- 
moderate ID, 
treated n=50 
control n=96 
Prospective trial 
(not blinded, 
randomized) 
150 µg I2/day, 
during 
pregnancy 
- No differences in T3/T4 ratios (both mothers 
and neonates)                            
- Maternal TSH, Tg: lower level vs. higher level                            
- Maternal fT4: higher level vs. lower level                                
- Neonates TSH: higher level vs. lower level  
 Antonangeli  
et al 2002         
(71)   
Mild ID, 
treated-A n=32 
treated-B n=35 
Prospective, 
randomized,  
open label trial  
A: 200 µg I2/day 
B: 50 µg I2/day  
18-26 to 29-33 
wks 
- No differences in maternal fT4, fT3, TSH, Tg, 
thyroid volume                            
- No differences in TPO-Ab, Tg-Ab, prevalence 
of PPTD                                 
- Median UI significantly higher in group A 
than group B  
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iodine supplementation at the beginning of gestation increases the risk of 
neurocognitive development delay in their offspring. A second Spanish study conducted 
in an area of mild ID by Velasco et al (63) found that children of mothers (n=133) 
supplemented with 300 µg of iodine daily in the first trimester had higher Bayley 
Psychomotor Development scores than children from mothers who did not start 
supplementation (n=61) until the last month of pregnancy (p=0.02).  
 
Recently, Murcia et al (64) assessed the association between maternal iodine intake 
from diet and supplements during pregnancy, maternal and neonatal thyroid function 
and infant development. In this pre-birth cohort from Valencia, Spain, the Mental 
Development Index (MDI) and Psychomotor Development Index (PDI) for 691 children 
were obtained between 2005 and 2007 using the Bayley Scales of Infant Development 
at 1 year of age. The authors reported that maternal UIC, iodized salt consumption, or 
dietary intake of food with high iodine content was not associated with infant 
development. In addition, maternal intake of ≥150 µg/day of supplementary iodine was 
associated with a decrease in PDI of 5.2 points (95% CI: 2.2-8.1) and with a 1.8-fold 
increase in the odds of a PDI<85 (95% CI: 1.0-3.3). Maternal hyperthyrotropinemia 
(TSH > 4 mIU/L) was related to an increased risk of a PDI<85 (95% CI: 1.3-9.5) and a 
decrease in PDI score (95% CI: -12.3-0.0). 
 
Maternal overweight/obesity and pregnancy outcomes 
 
The relationship between overweight/obesity and thyroid status in adults has been 
described. In 2003, Sari et al (72) reported an increase of serum TSH and a decrease of 
serum fT3 and fT4 concentration in obese women compared to normal weight women. 
Similarly, a positive association between BMI and serum TSH and a negative association 
between BMI and serum fT4, but no association in serum fT3 levels were found in the 
study of Knudsen et al (73). In a recent study (74), a higher TSH and lower fT4 
concentrations in overweight adults as compared to normal weight adults was reported, 
and this confirmed that adiposity is associated with thyroid hypofunction. In pregnant 
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women, a higher maternal BMI was shown to be correlated with their fT3/fT4 ratio, but 
not with their fT4 concentration (75).  
        
Although information of the relationship between maternal weight and thyroid function 
is limited, several studies reported that maternal obesity was associated with adverse 
pregnancy outcomes. Mothers who are overweight or obese during pregnancy are 
known to be at risk of various pregnancy complications including miscarriage, 
pregnancy induced hypertension (PIH), gestational diabetes, pre-eclampsia, 
macrosomia, preterm delivery, cesarean section and neural tube defects (NTDs) in 
newborns (76-82). 
 
In Thailand, the prevalence of overweight and obesity of the general population is 
increasing, from 18.2% and 3.5% in 1991 to 36.5% and 9.0% in 2009, respectively (83). 
In a study among 3,715 pregnant women who delivered at Rajavithi hospital in 
Bangkok (84), the percentage of maternal overweight and obesity was 13% and 4%, 
respectively. Furthermore, the authors stated that the overweight and obese mothers had 
significantly higher risk for cesarean section, pre-eclampsia, diabetes mellitus, 
macrosomia and postpartum hemorrhage. However, no data have been reported on the 
association between maternal obesity and thyroid status in Thailand.         
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Rationale, study objectives and outline of the thesis 
 
Iodine deficiency remains a major public health problem in many regions of the world 
especially in South/Southeast Asia. Several studies confirmed that all degrees of ID affect 
thyroid function of the mother and the neonate as well as the neurocognitive 
development of the child. Therefore, an effective strategy for ID correction is needed for 
this population. As shown in Table 1.7, effects of iodine intervention on thyroid function 
in mild-to-moderate ID pregnant women varied considerably. These studies showed 
primarily that iodine supplementation increased UIC, and decreased maternal thyroid 
volume, TSH and Tg concentrations.  
 
Although, three recent studies also reported on the effect of iodine supplementation in 
mild-to-moderate ID pregnant women on neurodevelopment in their children, these 
studies were not randomized, double-blind, placebo-controlled trials. It was speculated 
that neurodevelopment in the child may be adversely affected by mild-to-moderate ID 
but they were certainly not definite.  
 
Therefore, we set up two large RCT studies in Thailand and India in 2008 with a similar 
study protocol, aimed to determine the effects of daily oral iodine supplementation (200 
µg) or placebo in pregnant women with mild-to-moderate ID on thyroid function, 
pregnancy outcomes and long-term (2 years) follow up of infant development (the 
MITCH study). In this thesis, only the study in Thailand is described and only short-term 
(6 weeks) infant follow up is reported.  
 
We started by conducting a cross-sectional study to determine the iodine status of 
pregnant women living in Bangkok area and confirmed that the ID problem during 
pregnancy still existed. We, then performed a randomized, double-blind, 
placebo-controlled trial, involving oral administration of iodine in pregnant women 
recruited from the Outpatient Department (OPD) of Obstetrics and Gynecology at 
Ramathibodi Hospital, Mahidol University, a large teaching hospital in Bangkok.  
 
CHAPTER 1 
36 
Inclusion and exclusion criteria were the following: 
Inclusion criteria: 
 Pregnant women, aged 18-40 years old 
 Gestational age ≤14 weeks 
 Single pregnancy 
 Non-lactating 
 Generally healthy 
 Not taking iodine supplement 
Exclusion criteria: 
 Hypothyroid (TSH concentration >6.0 mIU/L) 
 
At the first hospital visit, all participants were fully informed about the aims and 
procedures of the study and written consent was obtained. All subjects were 
randomized into two treatment arms, with one treatment group receiving a daily 
supplement of 200 μg iodine (as potassium iodide tablets, donated by Merck KGaA, 
Darmstadt, Germany) until delivery, and the control group receiving an identical tablet 
without iodine (Merck KGaA, Darmstadt, Germany) until delivery. In addition, all 
pregnant women received multi-vitamin and -mineral tablets (without iodine) 
throughout the study.  
 
Anthropometric measurements, blood and spot urine sample collection and thyroid 
gland volume measurement were performed in both mothers and newborns during the 
study period. For infants, the NBAS test was performed at 6-week postpartum in order 
to assess early infant development. A brief overview of the study design is presented in 
Figure 1.2.  
 
Ethical approval for the study was obtained from the review committees of Ramathibodi 
Hospital, Mahidol University and Wageningen University. The study was registered into 
the clinical trials database at ClinicalTrials.gov with its identifier: NCT00791466. 
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In Chapter 2, we report on a pilot study in which the UIC of pregnant mothers is 
assessed and compared to the UIC of their school-aged children. In Chapter 3, we did a 
cross-sectional analysis with the baseline data of the trial to identify predictors of 
thyroid dysfunction in early pregnancy. In Chapter 4, we report the results of the 
MITCH study on maternal thyroid function, pregnancy outcomes and newborn 
development. In Chapter 5, we related pre-pregnancy BMI and maternal gestational 
weight gain to pregnancy outcomes. In the final chapter, Chapter 6, a summary of the 
main findings of the research conducted for this thesis is given, as well as a reflection on 
methodological considerations and opportunities for future research.  
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Control group (placebo tablets) 
Iodine group (KI tablets, 200 μg iodine/d) 
 
Enrollment /  
Baseline                                       Delivery    6 wks                 12 mo          24 mo  
                          
             20-24 wks        30-34 wks 
  S  
  A              A               A                        A                     A              A   
  D              D              D                        D                     D              D  
  B              B               B               B        B                     B               B   
  U              U              U               U        U                     U              U  
                                                           I                     I               I 
 
                          THIS THESIS                          BEYOND THIS THESIS 
 
 
S = Socio-demographic information  
A = Anthropometric measurement  
D = Dietary assessment  
B = Biological samples  
U = Ultrasound  
I = Infant development 
Figure 1.2 Overview of the study protocol 
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Abstract  
 
The median urinary iodine concentration (UI) in school-aged children is recommended 
for assessment of iodine nutrition in populations. If the median UI is adequate in 
school-aged children, it is usually assumed iodine intakes are also adequate in the 
remaining population, including pregnant women. But iodine requirements sharply 
increase during pregnancy.  
 
In this study, our aim was to measure UI in pairs of pregnant women and their 
school-aged children from the same family, who were sharing meals, to directly assess 
whether a household food basket that supplies adequate iodine to school-aged children 
also meets the needs of pregnant women.  
 
UI was measured in spot urine samples from pairs (n=302) of healthy pregnant mothers 
and their school-aged children in metropolitan Bangkok, Thailand. A dietary 
questionnaire was completed. 
 
The UI [median (range)] in the pregnant women {108 (11–558) µg/L [0.85 (0.086–4.41) 
µmol/L]} were lower than those of their school-aged children {200 (25–835) µg/L 
[1.58 (0.20–6.52) µmol/L]} (P<0.001), indicating optimal iodine status in the children 
but mild-to-moderate iodine deficiency in their pregnant mothers. The estimated iodine 
intakes in the 2 groups were in the range of 130–170 µg/d. There was a modest positive 
correlation between UI in the pairs (r=0.253; P<0.01). A higher frequency of seafood 
meals was a significant predictor of UI in both groups, but household use of iodized salt 
was not.  
 
These data suggest the median UI in school-aged children should not be used as a 
surrogate for monitoring iodine status in pregnancy in central Thailand; pregnant 
women should be directly monitored. 
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Introduction 
 
Iodine deficiency causes a broad spectrum of adverse health effects that result from 
inadequate thyroid hormone production, termed the iodine deficiency disorders (IDD) 
(1,2). The fetus is particularly vulnerable and in utero iodine deficiency can cause 
irreversible cognitive and motor deficits (3,4). Iodine requirements sharply increase 
during pregnancy because of the transfer of iodine and thyroid hormone to the fetus, an 
increase in maternal needs for thyroid hormone, and a likely increase in maternal renal 
iodine clearance (4). Thus, recommended iodine intakes during pregnancy are 250 µg/d 
compared with 150 µg/d for nonpregnant women (1). The corresponding median 
urinary iodine concentration (UI) that indicates optimal iodine nutrition increases from 
100–199 µg/L in nonpregnant women to 150–250 µg/L during pregnancy (1). 
 
Although pregnancy is a critical time to optimize iodine and IDD monitoring should 
include pregnant women, measurements in school-aged children are often used for 
assessment of IDD in populations because of the vulnerability of children to iodine 
deficiency (5,6) and easy access in school-based surveys (1). Most national or 
subnational IDD surveys have been conducted in school-aged children (7) and if the 
median UI in school-aged children is 100–199 µg/L, it is generally assumed that all 
population groups, including pregnant women, have adequate iodine nutriture (1). 
However, recent cross-sectional surveys have suggested this assumption may not be 
valid (8–12). 
 
To clarify this issue, measuring UI from pairs of pregnant women and their school-aged 
children from the same family would be valuable. The value of matched pairs within a 
family is that both groups share most meals from the same household food basket. Thus, 
a study of pairs can directly assess whether a diet that supplies adequate iodine to 
school-aged children also meets the needs of pregnant women in the household. 
 
In Thailand, although ~66% of households use iodized salt, recent surveys have 
suggested iodine status in pregnancy may not be optimal (13). Therefore, our study 
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question was: if the median UI is adequate in school-aged children, can one assume the 
median UI is also adequate in pregnant women? If so, then the median UI in 
school-aged children could continue to be used as a surrogate for monitoring iodine 
status in pregnancy; if not, then pregnant women would need to be directly monitored. 
 
Subjects and Methods 
 
The study was carried out in Bangkok, Thailand and the surrounding metropolitan area. 
To recruit families with a range of socioeconomic backgrounds, pregnant women were 
consecutively recruited from 2 large antenatal clinics in central Bangkok (Ramathibodi 
Hospital and Rajavithi Hospital), a small district hospital (Putthamonthon Hospital), and 
in 3 factories in the city suburbs. We aimed to recruit a sample of 300 women and their 
children to assess iodine status in the 2 groups using spot urine samples (14). Inclusion 
criteria (assessed by self-report) were: 1) confirmed pregnancy; 2) in good general 
health without thyroid disorders, other chronic illnesses, or medications; 3) no history 
of iodine supplement use by the family; and 4) at least 1 child 5–14 y old living and 
sharing meals in the same household. 
 
Once enrolled, the women completed a questionnaire that included: 1) age of mother 
and child; 2) sex of the child; 3) gestational age (at the hospital clinics, this was taken 
from the hospital record, based on the date of the last menstrual period; at the factories, 
this was by self-report from the mother); 4) parity; 5) monthly income of the family 
(this figure was used to estimate socioeconomic status); 6) number of meals shared with 
the child per day; 7) whether more salt or more fish sauce was used in the household 
(these 2 condiments are used widely in Thailand, but fish sauce is not iodized and only a 
portion of table salt is iodized); 8) estimated household consumption of salt; and 9) 
frequency of household seafood consumption per week: never, 1–2 times, 3–4 times, 
or >4 times. 
 
A spot urine sample was collected from each woman at the clinic or the factory and 
from the child at the home. The samples were collected within 1–2 d of each other and 
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were obtained from the mothers and children at any time during the day. Data were 
collected from May 2007 to July 2008. Because the climate and the diet are fairly 
uniform in Bangkok year round, there was unlikely to be considerable seasonal 
variability in dietary sources of iodine. Informed written consent was obtained from all 
women and assent from their children. The Swiss Federal Institute of Technology Zurich, 
Switzerland and Mahidol University Hospital, Bangkok, Thailand reviewed and 
approved the study protocol. 
 
Laboratory analyses. The urine samples were transported on ice to the Institute of 
Nutrition of Mahidol University, divided into aliquots, and stored at –20C until analysis. 
At Mahidol, the iodine concentration in urine was measured using the Pino 
modification of the Sandell-Kolthoff reaction (15). The intra-assay CV at a mean UI of 
72 and 242 µg/L (n=10 each) was 7.1 and 1.5%, respectively. External control was 
provided by the Laboratory of Human Nutrition at the Swiss Federal Institute of 
Technology Zurich using the same method and the inter laboratory CV (percent) at a 
mean UI of 100 µg/L and 212 µg/L (n=10 each) was 7.6 and 6.1%, respectively. 
 
Data and statistical analyses. The statistical analyses were carried out using SPSS 16.0 
and Microsoft Excel (XP 2002, Microsoft). The formula of the U.S. Institute of Medicine 
(16) was used to estimate iodine intakes from UI and body weight in the children: 
 
UI (µg/L) x 0.0235 x body weight (kg) = daily iodine intake (µg) 
 
Values in the text are means ± SD or, if not normally distributed, are medians (ranges). 
Because UI values in both women and children were skewed to the right, for both the 
primary and secondary outcomes, Mann-Whitney tests were used for comparisons with 
a Bonferroni correction, when needed. Proportions were compared using chi-square 
tests. We performed Spearman correlations to look for associations. In the Mann 
Whitney and Bonferroni tests, P-values <0.05 and <0.005, respectively, were 
considered significant. 
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Results 
 
We recruited 302 pairs of pregnant women and their school-aged children; the refusal 
rate for participation in the study was <2%. The median UI, monthly income, and 
dietary variables comparing women recruited in the clinics to those recruited at the 
factories did not differ. Just over one-half of the women were in their third trimester 
and 77% of families reported using household salt labeled as iodized (Table 2.1). About 
50% of the pairs shared 3 meals per day and 50% shared 1 to 2 meals per day. The 
median UI (range) in the pregnant women was 108 (11–558) µg/L and the median UI 
in their school-aged children was 200 (25–835) µg/L; these were significantly different 
(P<0.001). Whereas only 14.2% of the school-aged children had a UI value <100 µg/L, 
69.2% of pregnant women had a UI value <150 µg/L (Figure 2.1). There was a modest 
positive correlation between the UI of pregnant women and their school-aged children 
(r=0.253; P<0.01) that was stronger in the 50% of women and children who shared 3 
meals/d (r=0.426; P <0.001). 
 
Using the formula of the U.S. Institute of Medicine (16) to estimate iodine intakes from 
UI and body weight in children 7–15 y old, a median of 200 µg/L in Thai children with 
a mean age of 7.7 y and a mean body weight at this age of ~26 kg (17) would 
correspond to a median iodine intake of 130 µg/d. Assuming a daily urine volume of 
1.5 L and 92% dietary iodine bioavailability in the pregnant women, their median UI of 
108 µg/L would correspond to a daily iodine intake of ~170 µg (16). 
 
The median (range) UI of the pregnant women in the first, second, and third trimesters 
was 102 (19–506) µg/L, 122 (12–482) µg/L, and 106 (11–558) µg/L, with no difference 
in UI between trimesters (P=0.64). Maternal age and parity were not predictors of UI 
(P=0.45), nor was socioeconomic level of the family (P=0.49). The median UI in 
pregnant women and school-aged children who ate 0, 1–2, 3–4, and >4 seafood 
meals/wk were 58 and 157 µg/L, 107 and 201 µg/L, 110 and 228 µg/L, and 116 and 
180 µg/L, respectively. The families who ate 1 or more seafood meals/wk had higher UI 
values in both pregnant women and school-aged children than in families that ate none 
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(P<0.05). The UI values comparing families who ate between 1 and >4 seafood 
meals/wk did not differ (P=0.24). 
 
Table 2.1 Characteristics and dietary intake data of the matched pairs of Thai pregnant 
women and their school-aged children1 
Variable  
Age, y 
     Children 
     Pregnant women 
Child’s sex 
     Male: female, n:n 
Trimester of pregnancy, % 
     1 
     2 
     3 
Parity, % 
     1 
     2 
     ≥3 
Use of iodized salt in the household, % 
     Yes 
     No 
     Don’t know 
Use of salt, % 
     For cooking 
     As condiment 
     Both uses 
 
7.7 ± 2.8 
31.7 ± 4.8 
 
54 : 46 
 
24.5 
25.2 
50.3 
 
63.9 
27.5 
8.6 
 
77.2 
16.8 
6.0 
 
85.9 
10.4 
3.7 
1 Values are mean ± SD, n=302 or percentages. 
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Table 2.1 Characteristics and dietary intake data of the matched pairs of Thai pregnant 
women and their school-aged children1 (cont.) 
Variable  
Greater household consumption of, % 
     Salt 
     Fish sauce 
     No preference 
Household seafood consumption per 
week, % 
     Never 
     1-2 times 
     3-4 times 
     >4 times 
Meals shared by mother-child pair per 
day, % 
     1 
     2 
     3 
 
31.6 
63.3 
5.1 
 
 
3.6 
54.2 
28.6 
13.6 
 
 
20.8 
27.7 
51.5 
1 Values are mean ± SD, n=302 or percentages. 
 
 
Figure 2.1 Frequency distribution of spot 
UI in matched pairs of Thai pregnant 
women and their school-aged children 
(n = 302).                                     
The recommended ranges for the median 
UI for pregnant women and children are 
shown. 1 µg iodine/L = 0.0079 µmol/L. 
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UI concentrations did not differ between women and children from families who used 
iodized salt and those from families that did not (P=0.29), between women and children 
recruited at the hospital clinics and those recruited at factories (P=0.51), between 
women and children who consumed more salt and those who consumed more fish 
sauce (P=0.27), or between children who consumed all 3 meals at home with their 
mother and those who consumed 1 or 2 of their meals outside the home (P=0.38). 
 
Discussion 
 
Despite sharing a common household food basket, the median UI in our school-aged 
children was nearly double that of their pregnant mothers (P<0.001). According to the 
WHO criteria for assessing iodine nutrition, the median UI in our school-aged children 
(200 µg/L) indicated optimal iodine nutrition, at the top end of the recommended range 
(1). Additionally, in iodine-sufficient school-aged children, no more than 20% of UI 
values should be below 50 µg/L (1); in our children, only 2% had a UI value below this 
cut-off. Thus, both the median UI and the distribution show clear iodine sufficiency in 
school-aged children in the metropolitan Bangkok area. In sharp contrast, the median 
UI of 108 µg/L in pregnant women from the same households indicated a clear iodine 
deficiency (1). Approximately 1 in 6 pregnant women had a UI value <50 µg/L. These 
data support Thai surveys from the years 2001 to 2004, when the median UI in 
pregnant women declined from 150 to 110 µg/L (18). 
 
Several recent studies have suggested suboptimal iodine status in pregnant women from 
areas with only partial household coverage with iodized salt, such as Italy, India, and 
the US (8–12). Our study confirms these previous findings and demonstrates a similar 
relationship within families eating from the same household food basket. In contrast, 
countries with long standing, successful iodized salt programs (China, Iran, and 
Switzerland) have reported an optimal median UI in pregnant women (19–23). 
 
The most likely explanation for why Thai school-aged children (200 µg/L) had a 
sharply higher median UI than their pregnant mothers (108 µg/L) is that dietary iodine 
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intakes in both school-aged children and pregnant women are in the range of 130–170 
µg/d. If so, the median UI concentration in primary school-aged children with smaller 
daily urine volumes would be higher than that of pregnant women with higher water 
intakes and greater urine volumes. 
 
The median 24-h urine volume for children 7–15 y old is ~0.9mL/(h·kg) (24). Based on 
a mean body weight of 26 kg (17) at this age in our children, their 24-h urine volume 
would be ~600 mL. In contrast, the 24-h urine volume for adult women is ~1.5 L and 
is likely higher in pregnancy (25). Thus, dietary iodine intakes of ~130 µg/d are 
sufficient for the children and this will be reflected in a median UI >100 µg/L indicating 
adequate iodine intake (1). But their pregnant mothers would need to consume 
substantially more iodine-containing foods from the household food basket to attain 
their recommended iodine intake for pregnancy of 250 µg/d and thereby achieve the 
recommended median UI of >150 µg/L (1). However, we can only assume daily urine 
volumes varied between the women and children in this study, because we did not 
measure 24-h urine volumes and there are no available data from other comparative 
studies of children and pregnant women in Thailand. 
 
Our findings suggest several ways that iodine intakes could be increased in Thai 
pregnant women. Thai iodized salt legislation recommends iodization of salt that is sold 
directly to the consumer, but it is not legally binding (18). The legislation could be 
modified to recommend iodization of salt used for food processing and specifically for 
fish sauce production (16,26). Regular consumption of seafood products (27), if not 
contaminated by heavy metals (28), should be encouraged during pregnancy. 
Alternatively, targeted iodine supplementation of pregnant women may be preferable in 
this setting. 
 
There are several limitations to our study design. The use of iodized salt was 
self-reported rather than collected and directly tested by titration. The findings would 
be more convincing had a larger proportion of meals been shared between mothers and 
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their children and if additional biochemical measures of iodine status were measured in 
the pregnant women. Also, it would have been useful to have a nonpregnant control 
group to help ascertain whether lower UI concentrations during pregnancy could be 
attributed to pregnancy itself or to different dietary choices between adults and children 
in this population. Although we enrolled a sample of 300 women and their children to 
assess iodine status in the 2 groups using spot urine samples (14), this sample size may 
have not been adequate to make comparisons among subgroups of the populations, and 
this may have introduced a  error to some of the comparisons. Finally, this was a 
convenience sample and it is possible the sample was not representative of 
middle-income families in the region. 
 
Our findings indicate that in this region of Thailand, the median UI in school-aged 
children may not be an adequate surrogate for monitoring iodine nutrition in pregnant 
women. These data need to be confirmed in other populations with varying dietary 
habits and iodine intake but suggest adequate monitoring of IDD in populations should 
include specific monitoring of pregnant women. 
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Abstract 
 
Hypothyroxinaemia early in pregnancy may impair fetal brain development. Increased 
body weight has been associated with low thyroxine concentrations in non-pregnant 
women. In pregnant women, morbid maternal obesity is a risk factor for thyroid 
dysfunction. But whether lesser degrees of overweight that are much more common 
could be a risk factor for hypothyroxinaemia in pregnancy is unclear. 
 
The objective of this study was to investigate if overweight increases risk for thyroid 
dysfunction, and specifically hypothyroxinaemia, in iodine deficient pregnant women.  
 
We performed a cross-sectional study at first hospital visit among healthy Thai 
pregnant women. We measured weight and height, urinary iodine concentration (UIC), 
serum thyroid hormones and thyroglobulin. Pre-pregnancy weight and relevant dietary 
factors were determined by questionnaire, and body mass index (BMI) was used to 
classify weight status.  
 
Among 514 women (mean gestational age, 11 weeks) with a median UIC of 111 µg L-1, 
indicating mild iodine deficiency, 12% had low free thyroxine (fT4) concentrations: 3% 
had overt hypothyroidism; 7% had subclinical hypothyroidism; and 8% had isolated 
hypothyroxinaemia. Based on pre-pregnancy BMI, 26% of women were overweight or 
obese. In a multiple regression model, BMI was a negative predictor of fT4 (β=-0.20, 
P<0.001). Compared to normal weight women, the prevalence ratio (95% CI) of a low 
fT4 in overweight women was 3.64 (2.08–6.37) (P<0.01).  
 
Iodine-deficient pregnant Thai women who are overweight have a 3.6-fold higher risk 
of hypothyroxinaemia in the first trimester compared to normal weight women. 
Targeted screening should consider overweight a potential risk factor for thyroid 
dysfunction in pregnant women in iodine-deficient areas. 
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Introduction 
 
Adequate maternal iodine status is essential during pregnancy for maternal and fetal 
thyroid hormone synthesis. Iodine deficiency increases risk of maternal thyroid 
dysfunction and hypothyroxinaemia, which can adversely affect pregnancy outcome 
and infant development (Wasserstrum & Anania 1995; Montoro 1997; Davis et al. 
1998; Smallridge & Ladenson 2001).  
 
Mild to moderate hypothyroxinaemia during pregnancy may impair neurodevelopment 
of the offspring (Haddow et al. 1999; Pop et al. 2003; Kooistra et al. 2006; Berbel et al. 
2009; Costeria et al. 2011). The iodine requirement is sharply increased during 
pregnancy to meet increased maternal and fetal requirements. Therefore, the World 
Health Organization (WHO), the International Council for Control of Iodine Deficiency 
Disorders (ICCIDD) and the United Nations Children’s Fund (UNICEF) recommends a 
daily iodine intake of 250 mg day-1 for pregnant women (WHO/ICCIDD/UNICEF 2007). 
 
In generally iodine-sufficient Western populations, about 2–3% of pregnant women are 
subclinical hypothyroid and 10–15% are positive for anti-thyroid peroxidase antibodies 
(anti-TPO Abs) (Stagnaro-Green et al. 1990 & Allan et al. 2000). The prevalence of 
these thyroid disorders in iodine-deficient pregnant women has not been well defined. 
Mild to moderate iodine deficiency remains common in pregnant women in both high- 
and low-income countries (Zimmermann & Delange 2004). Globally, screening of 
thyroid disorders in early pregnancy is controversial, and experts generally recommend 
targeted high risk case finding (Abalovich et al. 2007). 
 
Adiposity is associated with thyroid hypofunction, and overweight adults tend to have 
higher thyroid stimulating hormone (TSH) and lower free thyroxine (fT4) 
concentrations than normal weight adults (Biondi 2010). In iodine-deficient adults 
without overt thyroid dysfunction, higher body mass index (BMI) predicts a lower fT4 
concentration (Knudsen et al. 2005), and in pregnant women at mid-gestation, high 
maternal BMI is positively correlated with the free triiodothyronine (fT3)/fT4 ratio 
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(Bassol et al. 2011). Currently, expert guidelines on screening for thyroid dysfunction in 
pregnancy recommend that women with morbid obesity (BMI ≥40 kg m-2) be screened, 
but do not recommend screening for overweight women (Stagnaro-Green et al. 2011). 
 
Although iodine status of school-aged children in Thailand is adequate, many Thai 
pregnant women are iodine deficient (Gowachirapant et al. 2009). In 2009, the median 
urinary iodine concentration in pregnant women in the Bangkok metropolitan area was 
108 µg L-1, and 69% of women had a UIC <150 µg L-1, (the cut-off indicating iodine 
deficiency) (Gowachirapant et al. 2009). Therefore, our study aim was to measure 
iodine status and thyroid function in healthy pregnant women in the first trimester in 
Bangkok and to assess risk factors for thyroid dysfunction. Specifically, we determined if 
overweight (defined as BMI ≥23 kg m-2) increases risk for hypothyroxinaemia in 
iodine-deficient pregnant women. 
 
Subjects and methods 
 
Subjects 
This cross-sectional study was performed on Thai pregnant women who presented for 
their first prenatal visit between October 2008 and October 2010 at Ramathibodi 
Hospital of Mahidol University in Bangkok, Thailand. Inclusion criteria for this study 
were: (1) confirmed single pregnancy; (2) age 18–40 years; (3) gestational age ≤14 
weeks; (4) nonlactating; (5) apparently healthy with no history of thyroid disorders; and 
(6) not taking any iodine supplements. All women gave written informed consent. The 
ethical review boards of Wageningen University in the Netherlands and Ramathibodi 
Hospital in Thailand approved the study. The study was registered into the clinical trials 
database at http://www.clinicaltrials.gov/ with its identifier: NCT00791466. 
 
Methods 
Maternal characteristics, including dietary intakes and pre-pregnancy weight, were 
recorded by using a questionnaire. Four questions on seafood consumption and salt use 
were included in the questionnaire for assessing iodine intakes. Weight and height were 
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Key messages 
• This study confirms that pregnant Thai women are facing mild-to-moderate iodine deficiency. 
• Most of Thai pregnant women are euthyroid in the first trimester of pregnancy. 
• In iodine-deficient pregnant women, overweight women have a higher risk of  
hypothyroxinaemia than normal-weight women. 
• Not only morbidly obese women but also women who are overweight should be screened for  
thyroid dysfunction. 
 
measured using standard methods. Pre-pregnancy BMI and baseline BMI were 
calculated. Because the association of BMI and health risk in Caucasian and Asian 
populations is different, women were classified by weight status using BMI reference 
ranges for Asian populations: <18.5 kg m-2 (underweight), 18.5–22.9 kg m-2 (normal 
range), 23.0–24.9 kg m-2 (overweight), and ≥25.0 kg m-2 (obese) (WHO/IASO/IOTF 
2000). 
 
A spot urine sample was collected, aliquoted, stored at -20°C and UIC was measured 
using the Pino modification of the Sandell–Kolthoff reaction (Pino et al. 1996) at the 
Institute of Nutrition, Mahidol University. This laboratory successfully participates in 
the EQUIP external control program for UIC analysis from the CDC in Atlanta, USA. The 
UIC range indicating optimal iodine nutrition in pregnancy is 150–249 µg L-1 
(Zimmermann 2008). Salt samples from the households of a subsample of pregnant 
women in this study were collected (n=112) and analysed for iodine (Sullivan et al. 
1995). 
 
Whole blood samples were collected by venipuncture into vacutainer tubes without 
anticoagulant, centrifuged, and the serum aliquoted into cryovials and frozen at -20°C. 
Serum samples were analysed for TSH, total T4 (tT4), free T4 (fT4), total T3 (tT3), free 
T3 (fT3), thyroglobulin (Tg), and anti-TPO Abs by enzyme-labelled chemiluminescent 
competitive immunoassay (IMMULITE 2000, SIEMENS, Munich, Germany) at the 
Laboratory for Human Nutrition, ETH Zurich, Switzerland. With the exception of TSH, 
we used the manufacturer’s reference ranges: 58–161 nmol L-1 for tT4, 0.89–1.76 ng 
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dL-1 for fT4, 1.3–2.6 nmol L-1 for tT3, 1.8–4.2 pg mL-1 for fT3, ≤55 ng mL-1 for Tg, and 
<35 IU mL-1 for anti-TPO Abs. For TSH in the first trimester of pregnancy, we used the 
reference range of 0.2–2.5 mIU L-1 (Patil-Sisodia & Mestman 2010). 
 
Maternal thyroid gland volume measurement was performed by a portable echocamera 
(Aloka, Mure, Japan), using a 7.5-MHz linear transducer. Thyroid volume was 
calculated by using the following equation: Volume of each lobe (mL) = anteroposterior 
(AP) diameter (cm) x mediolateral (ML) diameter (cm) x craniocaudal (CC) diameter 
(cm) x 0.479, and the total lobe volumes from both sides were summed (Brunn et al. 
1981). Normative thyroid volume was defined as 8.0–18.0 mL (WHO/UNICEF/ICCIDD 
1993). 
 
Results 
 
Characteristics of the pregnant women are shown in Table 3.1 and 514 pregnant 
women participated at a mean gestational age of 11 weeks. More than half of women 
had pre-pregnancy BMI (58%) and baseline BMI (54%) within the normal range (18.5–
22.9). Prepregnancy BMI was strongly correlated with baseline BMI (r=0.95, P<0.001). 
Twenty-six percent of the population was overweight or obese as defined by 
pre-pregnancy BMI ≥23. Despite the fact that fish sauce was used more frequently 
(74%) as a cooking ingredient than salt (25%), 89% of the pregnant women usually 
bought iodised salt and 75% used salt for cooking. Sixty–nine percent of women 
consumed seafood once to twice a week. Salt samples obtained from a subsample of 
pregnant women (n=112) had a mean±SD iodine concentration of 60±35 ppm, 
indicating adequate levels of salt iodisation. There were no statistical differences in the 
characteristics listed in Table 3.1 between normal weight and overweight women. With 
the exception for age, we used chi-square test for all variables: parity (P=0.645), usually 
buying iodised salt (P=0.251), salt use (P=0.571), use of salt and fish sauce (P=0.246), 
and weekly seafood consumption (P=0.284). We used independent-samples t-test for 
comparing mean age between normal weight and overweight women (P=0.148). 
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Table 3.1 Characteristics of pregnant women participating in the study (n=514) 
Variables n Values1 
Age (years)2 
Pre-pregnancy BMI (kg m-2)3 
     <18.5 
     18.5-22.9 
     23.0-24.9 
     ≥25.0 
Baseline BMI (kg m-2)3 
     <18.5 
     18.5-22.9 
     23.0-24.9 
     ≥25.0 
Parity 
     1 
     2 
     3 
     4 
     >4 
Usually buying iodised salt 
Salt use 
     No 
     For cooking 
     As a condiment 
     Both 
Use of salt and fish sauce 
     More salt 
     More fish sauce 
     Equal amounts 
Weekly seafood consumption 
     None 
     1-2 times 
     3-4 times 
     >4 times 
514 
513 
87 
295 
52 
79 
513 
71 
279 
67 
96 
 
224 
177 
87 
20 
6 
453 
 
5 
385 
96 
26 
 
125 
377 
7 
 
30 
352 
91 
39 
30 ± 5 
20.9 (19.1, 23.1) 
17 
57.5 
10.1 
15.4 
21.5 (19.5, 23.7) 
13.8 
54.4 
13.1 
18.7 
 
43.6 
34.4 
16.9 
3.9 
1.2 
88.5 
 
1.0 
75.2 
18.8 
5.0 
 
24.6 
74.1 
1.3 
 
5.9 
68.8 
17.8 
7.5 
BMI, body mass index. 1Values are percentages unless stated otherwise. 
2Mean ± SD. 3Median (first, third quartiles). 
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Thyroid function tests, UICs and thyroid gland volume are shown in Table 3.2. In more 
than 80% of women, all thyroid parameters were within normal ranges. However, 12% 
of the women had a low fT4 concentration and 17% had elevated anti-TPO Abs. The 
median UIC was 111 µg L-1, indicating mild ID: 23% had a UIC 100–149 µg L-1, 32% 
had a UIC 50–99 µg L-1, and 10% had a UIC <50 µg L-1. None of the women had 
increased thyroid volume by ultrasound. The median thyroid volume of overweight 
women (8.50 mL) was lower than in normal weight women (8.69 mL); however, there 
was no statistical difference between these two values (Mann–Whitney test, P=0.903). 
 
Based on Spearman correlation tests, there were no significant correlations between 
iodine intake (data from questionnaire) and TFTs (P>0.05) (data not shown). 
 
The median of fT4 among overweight women was significantly lower than among 
normal weight women (P<0.001) (Figure 3.1). 
 
Prevalences of thyroid dysfunctions are shown in Table 3.3. Three percent of women 
had overt hypothyroidism, 7% had subclinical hypothyroidism and 8% had isolated 
hypothyroxinaemia. 
 
Table 3.4 shows the adjusted regression models for TSH, fT4, Tg and thyroid volume as 
dependent variables. In simple and multiple linear regression analysis, there were no 
significant predictors of anti-TPO Abs (data not shown). There was a significant inverse 
relationship between pre-pregnancy BMI and fT4 concentration (P<0.001). There was 
also a significant inverse relationship between baseline BMI and fT4 concentration 
(P<0.001). In addition, there was a significant inverse association between thyroid size 
and TSH concentration (P<0.01). In contrast, there was a positive relationship between 
pre-pregnancy BMI and Tg concentration (P<0.05). Parity was positively correlated 
with thyroid size (P<0.01). 
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Table 3.2 Thyroid hormones, urinary iodine concentration (UIC) and thyroid volume of pregnant women1 
Indicators2 Normal weight (n=296) Overweight (n=131) All3 (n=514) 
TSH (mIU/L)4 
     < 0.2 
     0.2 – 2.5 
     > 2.5 
Total T4 (nmol/L)4 
     < 58 
     58 - 161 
     > 161 
Free T4 (ng/dL)4 
     < 0.89 
     0.89 – 1.76 
     > 1.76 
Total T3 (nmol/L)4 
     < 1.3 
     1.3 – 2.6 
     > 2.6 
Free T3 (pg/mL)4 
     < 1.8 
     1.8 – 4.2 
     > 4.2 
TG (ng/mL)4 
     ≤ 55  
     > 55 
Anti-TPO Abs (IU/mL)4 
     < 35  
     ≥ 35  
UIC (µg/L)4          
     < 50 
     50 – 99 
     100 – 149 
     ≥ 150 
Thyroid gland volume (ml)4 
T3/T4 ratio4 
1.03 (0.55, 1.60) 
9.3 
81.7 
9.0 
119.0 (102.0, 138.0) 
0.3 
90.4 
9.2 
1.08 (1.00, 1.19) 
7.3 
91.3 
1.4 
1.82 (1.51, 2.11) 
8.5 
84.7 
6.8 
3.12 (2.72, 3.60) 
0.4 
91.1 
8.5 
9.11 (4.94, 16.15) 
97.6 
2.4 
18.6 (13.5, 26.9) 
84.5 
15.5 
113.20 (74.69, 172.98) 
11.5 
29.5 
22.4 
36.6 
8.69 (7.23, 10.4) 
0.015 (0.013, 0.017) 
1.11 (0.71, 1.89) 
7.0 
82.2 
10.9 
116.0 (100.5, 138.3) 
0.8 
93.1 
6.2 
1.00 (0.88, 1.12) 
25.4 
73.0 
1.6 
2.06 (1.61, 2.40) 
10.9 
73.6 
15.5 
3.45 (2.87, 3.90) 
- 
83.9 
16.1 
10.33 (6.78, 17.15) 
95.3 
4.7 
21.7 (15.6, 31.4) 
84.0 
16.0 
111.89 (76.25, 169.59) 
6.3 
35.2 
25.0 
33.6 
8.50 (7.53, 10.0) 
0.017 (0.015, 0.020) 
1.07 (0.60, 1.73) 
8.5 
81.5 
10.0 
118.0 (101.0, 138.0) 
0.6 
91.7 
7.7 
1.08 (0.97, 1.19) 
11.8 
86.3 
1.9 
1.85 (1.54, 2.17) 
8.8 
82.2 
9.0 
3.16 (2.73, 3.64) 
0.4 
89.6 
10.0 
9.53 (5.09, 16.7) 
96.8 
3.2 
19.8 (14.1, 27.4) 
83.0 
17.0 
111.66 (74.72, 169.79) 
10.4 
32.3 
22.6 
34.7 
8.41 (7.18, 10.2) 
0.016 (0.014, 0.018) 
Tg, thyroglobulin; TSH, thyroid-stimulating hormone. 1Values are percentages unless stated otherwise. 2Cut-offs to categorise 
thyroid hormone concentration are based on manufacturer’s reference range, except for TSH for which a pregnancy-specific 
cut-off range was used. 3Including underweight women (BMI<18.5 kg m-2). 4Median (1st,3rd quartiles). 
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Table 3.3 Thyroid dysfunction of pregnant women (n=498) in their first trimester1 
Thyroid dysfunction2,3 n Percentages 
Overt hyperthyroidism 
Subclinical hyperthyroidism 
Overt hypothyroidism  
Subclinical hypothyroidism 
Hypothyroxinaemia 
5 
34 
14 
34 
42 
1.0 
6.8 
2.8 
6.8 
8.4 
1Number of pregnant women who had free T4 concentration.                                                         
2Cutoffs to categorise thyroid hormone concentration are based on manufacturer’s reference range, except for 
thyroid-stimulating hormone (TSH) for which a pregnancy-specific cut-off range was used.                                 
3Classified by using the definition of Helfand & Redfern (1998): overt hyperthyroidism: low TSH + high free T4; 
subclinical hyperthyroidism: low TSH + normal free T4; overt hypothyroidism: high TSH + low free T4; subclinical 
hypothyroidism: high TSH + normal free T4; hypothyroxinaemia: normal TSH + low free T4. 
 
Table 3.4 Multiple regression model of predictors for thyroid function in pregnant women1 
Model Predictors R2 Beta (95% CI) Sig. 
TSH 
FT4 
 
TG 
Tvol 
Tvol 
Tvol 
BMI 
BMI 
Parity 
0.019 
0.079 
0.079 
0,011 
0.016 
-0.137 (-0.114, -0.025) 
0.222 (0.016, 0.037) 
-0.200 (-0.019, -0.008) 
0.105 (0.086, 1.145) 
0.126 (0.083, 0.441) 
0.002 
0.000 
0.000 
0.023 
0.004 
BMI, body mass index; CI, confidence interval. 1Stepwise regression. 
 
As shown in Table 3.5, risk for a low fT4 was significantly increased in women with a 
pre-pregnancy BMI ≥23.0 kg m-2 (3.64, 95% CI: 2.08–6.37). Risk for elevated anti-TPO  
Abs (≥35 IU mL-1) was significantly decreased in women with a smaller thyroid gland 
volume (0.40, 95%CI: 0.20–0.83). 
 
Discussion 
 
The present study confirms that pregnant women living in Bangkok are iodine deficient 
with median UIC of 111 µg L-1. In an earlier study in pregnant women from the same 
area, we reported a similar median UIC of 108 µg L-1 (Gowachirapant et al. 2009). 
Other studies have found suboptimal iodine status among pregnant women in Thailand. 
In 2007, Rajatanavin (2007) reported the median UICs of mothers in Bangkok and six 
OVERWEIGHT INCREASES RISK OF FIRST TRIMESTER HYPOTHYROXINEMIA 
69 
rural provinces in Thailand were 85 and 103 µg L-1, respectively. In southern Thailand, 
the median maternal UIC ranges from 51 to 106 µg L-1 (Jaruratanasirikul et al. 2009). 
 
Table 3.5 Prevalence ratios of predictors in relation to iodine status and thyroid function in first 
trimester pregnant women 
Independent 
variables 
Prevalence ratios (95% CI) 
UIC 
< 150 µg/L 
TSH 
> 2.5 mIU/L 
Free T4 
< 0.89 ng/dL 
Anti-TPO Abs 
≥ 35 IU/mL 
Age (yrs) 
   < 25 
   25-30 
   > 30 
BMI (kg/m2) 
   < 18.5 
   18.5-22.9 
   ≥ 23.0 
Parity 
   1 
   2 
   > 2 
Tvol (ml)1 
   < 7.18 
   7.18-10.20 
   > 10.20 
Seafood (times/wk) 
   None 
   1 – 2  
   3 – 4 
   > 4 
Iodized salt use 
   Yes 
   No 
 
Ref. 
0.87 (0.64-1.19) 
0.87 (0.64-1.18) 
 
1.11 (0.83-1.48) 
Ref. 
1.04 (0.81-1.35) 
 
Ref. 
0.99 (0.78-1.27) 
0.92 (0.69-1.23) 
 
1.08 (0.83-1.40) 
Ref. 
1.11 (0.85-1.43) 
 
Ref. 
1.02 (0.64-1.62) 
0.98 (0.59-1.65) 
0.82 (0.44-1.53) 
 
Ref. 
1.13 (0.79-1.62) 
 
Ref. 
1.15 (0.49-2.70) 
1.08 (0.46-2.52) 
 
1.30 (0.63-2.70) 
Ref. 
1.20 (0.63-2.30) 
 
Ref. 
1.09 (0.59-2.01) 
0.83 (0.38-1.81) 
 
0.96 (0.51-1.82) 
Ref.  
0.50 (0.22-1.13) 
 
Ref. 
1.43 (0.34-5.98) 
2.02 (0.45-9.04) 
1.21 (0.20-7.28) 
 
Ref. 
0.90 (0.32-2.49 
 
Ref. 
0.83 (0.39-1.75) 
0.90 (0.44-1.87) 
 
1.03 (0.41-2.55) 
Ref. 
3.64 (2.08-6.37)** 
 
Ref. 
1.60 (0.89-2.87) 
1.24 (0.62-2.49) 
 
1.09 (0.62-1.91) 
Ref. 
0.36 (0.15-0.85)* 
 
Ref. 
1.86 (0.45-7.68) 
2.33 (0.53-10.27) 
0.41 (0.04-4.47) 
 
Ref. 
1.37 (0.62-3.01) 
 
Ref. 
1.21 (0.55-2.68) 
1.88 (0.89-4.00) 
 
0.74 (0.37-1.46) 
Ref. 
1.03 (0.61-1.72) 
 
Ref. 
1.10 (0.66-1.85) 
1.22 (0.69-2.15) 
 
0.40 (0.20-0.83)* 
Ref. 
1.03 (0.62-1.70) 
 
Ref. 
0.78 (0.31-1.97) 
1.39 (0.52-3.67) 
0.77 (0.22-2.66) 
 
Ref. 
1.07 (0.49-2.33) 
CI, confidence interval; TSH, thyroid-stimulating hormone; UIC, urinary iodine concentration; *P < 0.05, 
**P < 0.01 (compared with reference group). 1Categorised by percentiles. 
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There may be several reasons why iodine intakes are low in Thai pregnant women. The 
salt iodisation program in Thailand, begun in 1995, currently covers only 60–70% of 
Thai households with adequately iodised salt, below the national goal of at least 90% 
coverage (World Health Organization, Regional Office for South-East Asia 2004; 
Division of Nutrition, Ministry of Public Health 2005; UNICEF & National Statistical 
Office, Thailand 2006; Jaruratanasirikul et al. 2009). In many rural areas, salt from 
local small producers is often not iodised. Moreover, in Thailand and throughout 
Southeast Asia, fish sauce is a more popular household seasoning than salt, reducing the 
contribution of iodised salt to dietary iodine intakes. In the present study, three of four 
women used mainly fish sauce for household seasoning, whereas only one in four used 
mainly salt. In the urban households of the women in this study, all salt samples 
analysed were adequately iodised (≥15 ppm) (Keetman 2010). Thus, use of iodised salt 
in the production of fish sauce, or, alternatively, direct iodisation of fish sauce, are likely 
to be the effective dietary interventions to increase intakes in this population. Iodine 
supplementation during pregnancy could also increase iodine intakes, but most Thai 
women present for prenatal care near the end of the first trimester. Therefore, prenatal 
supplementation would likely not be effective in increasing intakes during the first 
trimester, the period during which the fetus is most vulnerable to ID. 
 
Figure 3.1 Box plot of free T4 
concentration (ng dL–1) and 
pre-pregnancy body mass index 
(BMI) (kgm-2).                  
Outliers are indicated by * 
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However, despite their low iodine intakes, most pregnant women in this study were 
euthyroid and all had normal thyroid volume. Glinoer et al. (1995) suggested an 
increased T3/T4 ratio >0.025 reflects excessive thyroid stimulation during pregnancy 
due to iodine deficiency. In our sample, the median T3/T4 ratio was 0.016, evidence that 
thyroid function was normal in many of these women. Spot UIC is a useful indicator for 
assessing recent iodine intake of this population because about 90% of daily ingested 
iodine is excreted in the urine. But this method has large day-to-day variation and 
should not be used to classify an individual’s iodine status. Therefore, a 24-h urine 
sample collection or repeated spot urine samples may be more useful for categorizing 
individual status. A combination of UIC and thyroid function tests may provide the most 
accurate assessment of iodine status of pregnant women. 
 
Because iodine intakes in the general Thai population are adequate, many of these 
women likely entered pregnancy with ample stores of intrathyroidal iodine, enough to 
support increased needs for iodine in the early stages of pregnancy. Although none of 
the women had evidence of increased thyroid volume, thyroid volume was inversely 
correlated with TSH and positively correlated with fT4. This pattern, in the first 
trimester of pregnancy, is thought to be due to high circulating human chorionic 
gonadotropin that stimulates thyroid hormone production and TSH (Haddow et al. 
2008). In addition, we found that higher parity was associated with greater thyroid 
volume, as has been previously reported in iodine deficient European populations 
(Rotondi et al. 2000; Knudsen et al. 2002). Thus, repeated pregnancy maybe a risk 
factor for goitre, particularly in iodine deficient areas. 
 
Although most women in our study were euthyroid, 12% of women had low fT4 
concentration: 3% had overt hypothyroidism; 7% had subclinical hypothyroidism; and  
8% had isolated hypothyroxinaemia. These prevalences are about three fold higher than 
those reported for iodine sufficient Western populations, where generally 2–3% of 
pregnant women are hypothyroid, of whom 0.3–0.5% have overt hypothyroidism and 
2–2.5% have subclinical hypothyroidism. In a recent study in iodine-sufficient Asian 
women early in pregnancy (n=2899) (Wang et al. 2011), the prevalence of overt or 
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subclinical hypothyroidism was 7.5% and the prevalence of hypothyroxinaemia was 
only 0.9%. Thus, our results suggest that low iodine intakes in Thai pregnant women 
increase risk for hypothyroxinaemia, and thus improving iodine intakes should be a 
public health priority. 
 
The novel finding in this study is the clear inverse relationship between body weight 
and fT4 in mildly iodine-deficient pregnant women. In general, overweight adults tend 
to have slightly higher TSH and, in some studies, lower fT4 concentrations than normal 
weight adults (Lindeman et al. 2003; Biondi 2010). Greater subcutaneous fat is 
associated with lower fT4 in overweight adults, independent of age, gender and 
smoking (Alevazaki et al. 2009). The link between body weight and thyroid function is 
less well studied in areas of iodine deficiency. In iodine-deficient Danish adults without 
overt thyroid dysfunction, higher BMI was associated with lower fT4, but not fT3 
(Knudsen et al. 2005). In pregnant Spanish women at mid-gestation, higher maternal 
BMI was directly correlated with the fT3/fT4 ratio, but not with fT4 alone (Bassol et al. 
2011).  
 
Several mechanisms may contribute to a higher prevalence of thyroid hypofunction in 
overweight pregnant women who are iodine deficient. Obese adults may be more likely 
to develop autoimmune hypothyroidism leading to mild thyroid failure (Marzullo et al. 
2010). However, in our subjects, there was no correlation between anti-TPO Abs and 
either BMI or fT4. Inflammatory cytokines released by adipose tissue may impair the 
hypothalamic–pituitary–thyroid axis (Toni et al. 2004) but this should result in negative 
associations between BMI and serum TSH as well as fT4, a pattern not visible in our 
subjects. Circulating oestrogen metabolites maybe increased in pregnant women who 
are overweight, and 2-methoxyestradiol has been shown to have detrimental effects on 
thyroid cells in culture (Wang et al. 2000). A leptin-induced increase in TSH secretion 
may occur in obesity via hypothalamic effects (Zimmermann-Belsing et al. 2003), but 
this would increase TSH and thyroid hormone secretion, a pattern not found in our 
subjects. Finally, there may be a higher peripheral conversion of T4 to T3 in obesity due 
to increased deiodinase activity as a compensatory mechanism to improve energy 
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expenditure (Biondi 2010). This could accentuate the preferential thyroidal secretion of 
T3 over T4 in iodine deficiency and lead to lower fT4 levels. However, in our subjects 
the median T3/T4 ratio was not increased compared to previous reports in 
iodine-deficient pregnant women (Glinoer et al. 1995), and there was no correlation 
between BMI and the T3/T4 ratio. 
 
Because thyroid dysfunction during early pregnancy is associated with poor offspring 
development, many expert groups, including the Endocrine Society (Abalovich et al. 
2007), recommend a case-finding approach where women at high risk for thyroid 
disorders are screened. But this approach has been questioned. In a recent large Chinese 
study (Wang et al. 2011), despite using a recommended case finding screening strategy, 
82% of pregnant women with hypothyroidism were missed. Thus, the optimal screening 
criteria to identify women with hypothyroidism in early pregnancy remain uncertain. 
Current guidelines (Stagnaro-Green et al. 2011) recommend targeted screening based 
on weight status only in morbidly obese women (BMI ≥40 kg m-2). However, our data 
suggest milder degree of maternal adiposity (BMI ≥23 kg m-2 in Asian populations) 
should be considered a potential risk factor for thyroid dysfunction, particularly in 
iodine-deficient areas. 
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Abstract 
 
Background: Severe iodine deficiency (ID) during pregnancy causes many adverse 
effects both in the mother and newborn. Although iodine supplementation in mildly 
deficient pregnant women is widely recommended, long-term effects and safety of 
supplementation remain uncertain.  
  
Objectives: To evaluate the effects of iodine supplementation on maternal thyroid 
function, pregnancy and birth outcomes, and newborn development. 
 
Methods: An RCT with 200 µg iodine/d or placebo given to 511 mildly iodine-deficient 
pregnant Thai women from 11 weeks to term. Maternal thyroid function, urinary 
iodine concentration (UIC) and thyroid volume were measured at baseline, 2nd and 3rd 
trimester, at delivery and 6-week postpartum. Birth outcomes were collected from 
hospital records. Neonatal thyroid function, UIC and thyroid volume were measured at 
delivery and 6 weeks after birth. At 6 weeks, the Neonatal Behavioral Assessment Scales 
(NBAS) was used to assess newborn development.  
       
Results: Median UIC increased significantly from baseline in both groups, and the 
increase was higher in the iodine group (p<0.001). At 30 weeks of gestation, only 2% of 
the women in the placebo group and 7% in the iodine group reported a median UIC 
>500 µg/L. Maternal thyroid function, thyroid volume and the prevalence of all thyroid 
dysfunction subtypes did not differ significantly between treatment groups (p>0.05). At 
6-week postpartum, the prevalence of postpartum thyroiditis (hyperthyroidism) was 
significantly lower in the iodine group (3%) as compared to the placebo group (9%) 
(OR: 95%CI, 0.17: 0.04-0.70). There were no significant differences between newborn 
groups in thyroid function, thyroid volume, birth characteristics, UIC and NBAS score 
(p>0.05).   
  
Conclusion: Supplementation with 200 µg iodine/day in mildly iodine-deficient 
pregnant Thai women was effective in increasing iodine intakes into the adequate range 
and was safe. However, it had no benefit on antenatal maternal thyroid function or 
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newborn outcomes out to 6 weeks. Iodine supplementation significantly reduced the 
risk of maternal postpartum thyroid dysfunction.   
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Introduction 
 
According to WHO/UNICEF/ICCIDD, an optimal daily iodine intake for pregnant 
women should be at least 250 µg/day and a spot urinary iodine concentration (UIC) of 
less than 150 µg/L indicates iodine deficiency (ID) in the population 
(WHO/UNICEF/ICCIDD 2007). Currently, severe ID is rare on the national level 
(Benoist, McLean et al. 2008), but mild-to-moderate ID continues to affect many 
countries in Europe, Asia and Africa and has recently recurred in Australia and in the 
UK (Caldwell 2005; Li 2006; Haddaw 2007; Vanderpump 2011). In Thailand, pregnant 
women are at risk for mild to moderate ID (Rajatanavin 2007; WHO/UNICEF/ICCIDD 
2007; Jaruratanasirikul 2009; Gowachirapant 2014). Globally, iodine deficiency during 
pregnancy is thought to be one of the leading preventable causes of hypothyroidism in 
both mothers and neonates, and when severe, its adverse consequences on growth and 
neurodevelopment of the child are well recognized (Hetzel 1979; Hetzel 1987; Delange 
1994; Delange 2001; Pop 2003; Escobar 2007). The fetal thyroid begins to concentrate 
iodine at 10-12 weeks of gestation, and the synthesis and secretion of thyroid hormone 
ensues at ca. 20 weeks of gestation (Brown 2004). The fetus is therefore fully dependent 
on maternal iodine stores and thyroid hormone supply across the placenta until 
mid-gestation. It has been suggested that not only severe ID but also mild to moderate 
ID in pregnancy may impair the cognitive ability of offspring (Zimmermann 2007; 
Zimmermann 2008; Bath 2013). However, this hypothesis has not been tested in a 
randomized controlled trial of maternal iodine supplementation. 
 
Several iodine supplementation trials in pregnant women with mild-to-moderate ID 
reported an increase in maternal UIC and a decrease in thyroid size and/or serum 
thyroglobulin (Tg) in the treated group, but none found a clear improvement in 
maternal thyroid function (Zimmermann 2009). It may be that pregnant women are 
able to draw sufficient iodine from intrathyroidal stores to maintain adequate thyroid 
hormone production, even when they have mildly deficient intakes. However, these 
studies had small sample sizes, and therefore the effects and safety of iodine 
supplementation on maternal thyroid function remain uncertain. Recommendations on 
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iodine supplementation during pregnancy are still under debate: WHO does not 
recommend maternal supplementation if the general population is iodine sufficient 
(WHO/UNICEF 2007); in contrast, many expert medical groups advise maternal 
supplementation with 150 to 250 µg/day. There is a clear lack of data on the effects of 
iodine supplementation in pregnancy on long-term outcomes such as postpartum 
maternal thyroid function, birth outcomes, growth and infant development. A recent 
systematic review of randomized controlled trials of iodine supplementation in 
pregnancy (Zhou 2013) confirmed the lack of quality evidence of the effect of prenatal 
iodine supplementation on cognitive function of the offspring. Therefore, in the present 
study, we aimed to assess the effect of oral iodine supplementation in mildly 
iodine-deficient pregnant women on maternal thyroid stimulating hormone (TSH), free 
thyroxine (fT4) and thyroglobulin (Tg) concentrations as the primary outcomes. In 
addition, we determined effects on other thyroid function indicators, pregnancy and 
birth outcomes, and newborn development as secondary endpoints. 
 
Subjects and methods 
 
Subjects 
This randomized double blind controlled trial was conducted in pregnant Thai women 
who registered at Ramathibodi Hospital of Mahidol University in Bangkok, Thailand 
between October 2008 and August 2011. Further follow up continued until June 2013, 
but those results are not reported here. Inclusion criteria were: 1) singleton pregnancy; 
2) age 18 to 40 y; 3) gestational age ≤14 weeks; 4) non-lactating; 5) generally healthy 
with no history of thyroid disorders; and 6) not taking any iodine supplements. Women 
who had thyroid stimulating hormone (TSH) concentration >6.0 mIU/L at screening 
were excluded from the study. All women gave signed informed consent. The study was 
approved by the ethical review committees of Ramathibodi Hospital in Thailand and by 
Wageningen University in the Netherlands, and supervised by an external data safety 
and monitoring board (DSMB). It was registered at http://www.clinicaltrials.gov/ with 
its identifier: NCT00791466. 
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Methods 
After eligibility screening, pregnant women were allocated to two treatment groups by 
simple randomization; half of the women received a daily supplement of 200 µg iodine 
(as potassium iodide tablets, Merck, Darmstadt, Germany) until delivery. Another half 
received an identical tablet without iodine (Merck, Darmstadt, Germany) until delivery. 
All of the women received a multi-vitamin and -mineral (without iodine) tablet until 
delivery. 
 
At the beginning of the study, maternal characteristics including pre-pregnancy weight, 
salt usage patterns and seafood consumption were recorded by using a questionnaire. 
Weight and height were measured by using standard methods. Pre-pregnancy body 
mass index (BMI) was calculated, and women were classified by weight status using 
international BMI reference ranges: <18.5 kg/m2 (underweight), 18.5-24.9 kg/m2 
(normal range), 25.0-29.9 kg/m2 (overweight), and ≥ 30.0 kg/m2 (obese) (WHO 2004). 
 
During the study, maternal thyroid function, UIC and thyroid gland volume were 
measured at baseline, 2nd and 3rd trimester, at delivery and post-delivery (6 weeks after 
delivery). For infants, birth characteristics from hospital records and thyroid gland 
volume were measured at delivery and 6 weeks after birth, and a spot UIC was 
measured at 6 weeks after birth. 
  
For UIC, spot urine samples were collected, aliquoted, stored at -20C and UIC was 
measured using the Pino modification of the Sandell-Kolthoff reaction (Pino, Fang et al. 
1996) at the Institute of Nutrition, Mahidol University. This laboratory successfully 
participates in the EQUIP external control program for UIC analysis from the CDC in 
Atlanta, USA (http://www.cdc.gov/labstandards/equip.html). The UIC reference ranges 
for pregnant women during pregnancy and post-delivery are 150-249 µg/L and 
100-199 µg/L, respectively (WHO/UNICEF/ICCIDD 2007). For infants, UIC ≥100 µg/L 
was used to indicate optimal iodine nutrition (WHO/UNICEF/ICCIDD 2007). 
 
IODINE SUPPLEMENTATION IN MILDLY IODINE-DEFICIENT PREGNANT THAI WOMEN 
83 
Whole blood samples were collected from pregnant women by venipuncture into tubes 
without anticoagulant, and at delivery cord blood samples were collected. Blood 
samples were centrifuged, and the serum aliquoted and frozen at -20°C. Serum samples 
were analyzed for TSH, total T4 (TT4), free T4 (fT4), total T3 (TT3), free T3 (fT3), 
thyroglobulin (Tg), and anti-TPO Abs (TPO-Abs) by enzyme-labeled chemiluminescent 
competitive immunoassay (IMMULITE 2000, SIEMENS, Germany) at the Laboratory for 
Human Nutrition, ETH Zurich, Switzerland. With the exception of TSH and TT4 during 
pregnancy, we used the manufacturer’s reference ranges: 0.4-4.0 mIU/L for TSH, 
58-161 nmol/L for TT4, 0.89-1.76 ng/dL for fT4, 1.3-2.6 nmol/L for TT3, 1.8-4.2 
pg/mL for fT3, ≤ 55 ng/mL for Tg, and < 35 IU/mL for TPO-Abs (SIEMENS, Germany). 
For TSH, during pregnancy, we used trimester specific reference ranges: 0.1-2.5 mIU/L 
for 1st trimester, 0.2-3.0 mIU/L for 2nd trimester, and 0.3-3.0 mIU/L for 3rd trimester 
(Stagnaro-Green 2011). For TT4, we multiplied the non-pregnancy reference range by 
1.5 and used the resulting range of 87-241.5 nmol/L as a reference (Mandel 2005).  
 
From infants, a heel-prick blood sample was collected within 72 hours after birth, 
spotted onto filter paper and dried at room temperature. Dried blood spots (DBS) were 
stored in low gas permeable plastic bags and frozen at -20°C and transported to the 
Laboratory of Human Nutrition, ETH, Zurich, Switzerland. DBS-TSH was analyzed using 
Delfia Neonatal hTSH Kits and the Genetic Screening Processor (GSP) machine 
(PerkinElmer, Wallac, Turku, Finland) at the Protein and Hormone Laboratory, 
Children's Hospital Zurich, Switzerland.  
 
Maternal thyroid gland volume was measured by using a portable echocamera (Aloka, 
Mure, Japan), using a 7.5-MHz linear transducer. Neonatal thyroid size measurement 
was performed by an iU22 ultrasound system (Philips, Bothell, WA) using 17-5 MHz 
probe. Measurements were done under supervision of an experienced radiologist at 
Ramathibodi hospital. Thyroid volume was calculated by using the following equation: 
volume of each lobe (ml) = AP diameter (cm) x ML diameter (cm) x CC diameter (cm) x 
0.479, and the total lobe volumes from both sides were summed. Normative thyroid 
volume of healthy adults was defined as 8.0-12.0 ml (WHO/UNICEF/ICCIDD 2007). 
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At 6 weeks postpartum, the Neonatal Behavioral Assessment Scales (NBAS) test was 
carried out by a trained nurse in order to assess newborn development. The NBAS 
contains 28 behavioral items, 18 neurologic reflex items, and 7 supplementary items 
that measure the quality of responsiveness and the amount of input that the infant 
needs from the examiner to show their best performance. Scores on the NBAS were 
reduced to the following 7 clusters: 1) habituation; 2) orientation; 3) motor; 4) range of 
state; 5) regulation of state; 6) autonomic stability; and 7) reflexes, including 
supplementary items (Brazelton and Nugent 1995). 
  
Low birth weight (LBW) was defined as weight at birth of <2,500 grams (WHO 2013) 
and preterm birth was defined as babies born alive before 37 weeks of pregnancy 
(WHO 2013). Small-for-gestational age (SGA) was defined as birth weight less than the 
10th percentile for a given gestational age and sex using the Alexander reference 
(Alexander 1996). Ponderal index (PI) was calculated as birth weight (kg)/length(m)3 
and defined as less than the 10th percentile using gestational age-specific percentiles for 
PI (Landmann, Reiss et al. 2006). Compliance with supplement use was measured by 
counting tablets returned after delivery; good compliance was defined as 80% of 
protocol prescribed treatment taken. All serious adverse events (SAE) during pregnancy 
were recorded and reported to the DSMB.  
   
Data analyses    
                           
Samples size was calculated based on an anticipated decrease in the prevalence of 
elevated newborn TSH (>10 mIU/L at postnatal days 2-4) with treatment. The study 
need to have 80% power to detect a decrease of 0.8 (from an anticipated incidence of 
10% in the control to 2% with treatment) in the proportion of elevated newborn TSH 
values with a significance level of 0.05. The calculation indicates a sample size of 250 
pregnant women (125 women in each treatment arms). In addition, when 10% loss to 
follow-up was considered, a total of 275 pregnant women were enrolled. 
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All data were double-entered, cross-checked for entry mistakes and stored in a central 
database in Excel (2007; Microsoft). Data analyses were done with SPSS 21.0 (IBM, 
USA). Distributions of variables were checked for normality by using the 
Kolmogorov-Smirnoff test. Variables with non-normal distribution were 
log-transformed before analysis. Variables were expressed as means ± SD for normally 
distributed data and medians (1st, 3rd quartiles) for non-normally distributed data. 
Primary analysis was per protocol, and included the effect on repeated follow-up 
measures of the primary endpoints (fT4, Tg and TSH) up till week 30 of gestation. 
Differences in effects between groups were tested by using Linear Mixed Models 
(LMM). In these models, treatment and gestational age (in months) at each time point 
were modeled as fixed effects. Other potentially explanatory co-variables including age, 
parity and pre-pregnancy BMI were added to the model as random effects and 
evaluated for significant effects on the model and its goodness of fit by using the -2 log 
likelihood. LMM analysis was conducted as well for all continuous secondary 
parameters. Generalized Linear Mixed Models (GLMM) analysis was used for binary 
secondary endpoints, as described for the primary analysis. For data from women 6 
weeks postpartum, linear regression and logistic regression were used for continuous 
and binary data, respectively. Models were adjusted for possible co-variables including 
maternal age, parity, gestational age at delivery, BMI at 6-week, duration from delivery 
to 6-week appointment, and baseline values of each dependent variable. For neonatal 
data analysis, linear regression and logistic regression were used for continuous and 
binary data, respectively. Models were adjusted for possible co-variables including age, 
parity, pre-pregnancy BMI, gestational age at delivery, and baseline values of each 
dependent variable for thyroid function data. A value of p<0.05 was considered 
statistically significant. 
 
Results 
 
Five hundred and eleven pregnant women were enrolled in the study and randomly 
assigned to the intervention groups. Loss to follow up was similar in both intervention 
groups, and reasons for declining participation were not notably different (Figure 4.1). 
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Figure 4.1 Flow diagram of the MITCH Thailand study 
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At baseline, 40% of women in the placebo group and 47% in the iodine group were 
uniparous. The prevalence of overweight and obesity in the groups did not differ 
significantly (13% and 3.8% in the placebo group, 10% and 3.6% in the iodine group, 
respectively). Most of the women were purchasing iodized salt for their households 
(88% in the placebo group and 89% in the iodine group) and were using salt for 
cooking (73% in the placebo group and 78% in the iodine group).  
 
There were no differences in median UIC between the two groups at baseline (p>0.05) 
(Table 4.1). Median UIC increased significantly from baseline in both groups (from 
110.1 µg/L to 154.6 µg/L in the placebo group and from 112.0 µg/L to 233.3 µg/L in the 
iodine group), and the increase was greater in the iodine group (p<0.001). At 30 weeks 
of gestation, 44% of the women in the placebo group and 29% in the iodine group had a 
median UIC 50-149 µg/L, 4% of the women in the placebo group and 2% in the iodine 
group had a median UIC < 50 µg/L. In addition, at 30 weeks, only 2% of the women in 
the placebo group and 7% in the iodine group reported a median UIC > 500 µg/L. 
 
  Table 4.1 Urinary iodine concentrations (µg/L) of Thai pregnant women given 200 µg iodine daily or placebo1 
 
Baseline (Week 11) Week 20 Week 30 
  Placebo Iodine Placebo Iodine Placebo Iodine 
 (n=260) (n=248) (n=152) (n=167) (n=185) (n=171) 
Median  110.1 112.0 143.8 223.9 154.6  233.3 
(IQR)2 (69.2, 172.2) (75.2, 165.0) (86.3, 237.3) (132.3, 345.7) (107.9, 212.4) (140.0, 314.8) 
    500 2 (0.8) 2 (0.8) 0 (0.0) 13 (7.8) 3 (1.6) 12 (7.0) 
   150- 500 92 (35.0) 80 (32.3) 70 (46.1) 106 (63.5) 94 (50.8) 105 (61.4) 
   100- 149 51 (19.6) 64 (25.8) 34 (22.4) 24 (14.4) 47 (25.4) 35 (20.5) 
   50 -99 87 (33.5) 77 (31.0) 39 (25.7) 20 (12.0) 34 (18.4) 15 (8.8) 
   < 50 28 (10.8) 25 (10.1) 9 (5.9) 4 (2.4) 7 (3.8) 4 (2.3) 
1n(%), 2per intention-to-treat, using linear mixed models (p=0.000)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
Maternal thyroid function tests, TPO-Abs and thyroid volume are summarized in Table 
4.2a and 4.2b, for both the per protocol and intention-to-treat LMM analysis. There 
were no significant differences between groups in any of the measured variables during 
the study using either of the analytic approaches. Within both groups, there was no 
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Table 4.2a Thyroid function and thyroid volume of Thai pregnant women given 200 µg iodine daily or placebo1 
 
Baseline (Week 11) Week 20 Week 30 p value3 
 
Placebo Iodine Placebo Iodine Placebo Iodine 
 
 
(n=101) (n=105) (n=86) (n=101) (n=99) (n=101) 
 TSH (mIU/L) 1.24 (0.78, 1.66) 0.95 (0.46, 1.48) 1.27 (0.83, 1.70) 1.17 (0.79, 1.71) 1.24 (0.85, 1.72) 1.17 (0.72, 1.81) 0.349 
     Elevated2 9 (9.3) 9 (8.7) 3 (3.6) 6 (6.5) 3 (3.3) 4 (4.4) 0.328 
     Low2 3 (3.1) 5 (4.9) 1 (1.2) 2 (2.2) 2 (2.2) 4 (4.4) - 
fT4 (ng/dL) 1.11 (1.02, 1.18) 1.09 (0.99, 1.20) 0.82 (0.79, 0.89) 0.78 (0.71, 0.88) 0.81 (0.71, 0.88) 0.77 (0.68, 0.83) 0.062 
     < 0.89 6 (6.3) 6 (5.9) 64 (75.3) 73 (78.5) 72 (76.6) 81 (85.3) 0.402 
      1.76 0 (0.0) 3 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) - 
TT4 (nmol/L) 118.0 (102.0, 134.0) 116.0 (98.3, 138.0) 119.0 (105.0, 133.0) 114.0 (101.8, 128.0) 119.0 (102.0, 134.5) 113.0 (100.3, 129.0) 0.853 
     < 87 8 (8.0) 7 (6.8) 5 (5.9) 12 (12.8) 10 (10.8) 11 (11.5) 0.927 
      241.5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) - 
fT3 (pg/mL) 3.00 (2.60, 3.72) 3.06 (2.65, 3.52) 3.24 (2.72, 3.76) 3.27 (2.79, 3.82) 3.38 (2.89, 3.75) 3.33 (2.99, 3.86) 0.732 
     < 1.8 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.2)   1 (1.1)   0 (0.0) - 
    4.2 10 (10.5) 7 (6.9) 8 (10.1) 10 (11.9) 13 (14.8) 10 (11.2) 0.864 
TT3 (nmol/L) 1.77 (1.50, 2.08) 1.82 (1.57, 2.13) 2.34 (1.99, 2.68) 2.39 (2.03, 2.71) 2.36 (2.13, 2.71) 2.46 (2.11, 2.70) 0.932 
     < 1.3 9 (9.0) 9 (8.6) 1 (1.2) 1 (1.0) 0 (0.0) 1 (1.0) - 
      2.6 5 (5.0) 9 (8.6) 28 (33.3) 29 (29.9) 37 (40.2) 36 (37.5) 0.467 
Tg (ng/mL) 9.76 (5.46, 17.25) 9.41 (4.56, 17.80) 10.15 (5.66, 16.10) 8.93 (4.65, 15.70) 11.50 (6.28, 22.20) 9.85 (5.26, 16.22) 0.532 
      38.5 6 (6.4) 6 (6.2) 6 (7.7) 5 (5.7) 8 (8.8) 5 (5.7) 0.928 
TPO-Abs (IU/mL) 17.1 (12.4, 24.2) 16.7 (10.9, 25.7) 14.2 (10.1, 21.2) 12.8 (10.0, 23.3) 11.6 (10.0, 18.9) 14.8 (10.0, 20.3) NA4 
     ≥ 35 11 (10.9) 13 (12.4) 4 (4.6) 12 (12.2) 3 (3.0) 7 (7.0) 0.078 
TT3/TT4 ratio 0.0150 0.0156 0.0191 0.0206 0.0202 0.0213 0.609 
 (0.0137, 0.0166) (0.0134, 0.0180) (0.0171, 0.0224) (0.0175, 0.0230) (0.0177, 0.0244) (0.0179, 0.0249)  
fT3/fT4 ratio 2.6720 2.7710 3.9763 4.0488 4.1578 4.4050 0.372 
 (2.3398, 3.4177) (2.3907, 3.2337) (3.1884, 4.4622) (3.3960, 5.1250) (3.6408, 5.1237) (3.8490, 5.2224)  
Tvol (ml) 8.7 (7.2, 10.4) 8.3 (7.5, 10.3) 8.5 (7.2, 9.5) 8.2 (7.0, 9.7) 8.0 (6.7, 9.6) 8.1 (7.2, 9.1) 0.480 
      12 8 (7.9) 3 (2.9) 3 (3.5) 3 (3.0) 2 (2.0) 3 (3.0) 0.545 
1median (IQR) or n(%), 2trimester-specific reference ranges (1st=0.1-2.5 mIU/L, 2nd=0.2-3.0 mIU/L, 3rd=0.3-3.0 mIU/L), 3per protocol, using linear mixed models for 
continuous data; generalized linear mixed models for binary data, 4Not available, data could not be normalized 
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Table 4.2b Thyroid function and thyroid volume of Thai pregnant women given 200 µg iodine daily or placebo1 
 
Baseline (Week 11) Week 20                  Week 30 p value3 
  Placebo Iodine Placebo Iodine Placebo Iodine   
 
(n=262) (n=249) (n=171) (n=185) (n=190) (n=176) 
 TSH (mIU/L) 1.11 (0.67, 1.72) 1.00 (0.56, 1.75) 1.24 (0.78, 1.71) 1.22 (0.78, 1.79) 1.30 (0.84, 1.80) 1.13 (0.71, 1.72) 0.952 
     Elevated2 26 (10.1) 24 (9.8) 7 (4.2) 13 (7.5) 4 (2.3) 7 (4.5) 0.375 
     Low2 13 (9.9) 13 (5.2) 4 (1.5) 5 (2.0) 4 (1.5) 7 (2.8) 0.416 
fT4 (ng/dL) 1.07 (0.95, 1.18) 1.08 (0.98, 1.20) 0.81 (0.74, 0.88) 0.78 (0.72, 0.88) 0.79 (0.71, 0.87) 0.77 (0.68, 0.84) 0.490 
     < 0.89 35 (13.6) 24 (10.0) 128 (79.0) 137 (78.3) 147 (79.5) 138 (85.7) 0.376 
      1.76 2 (0.8) 7 (2.8) 1 (0.4) 1 (0.4) 0 (0.0) 0 (0.0) - 
TT4 (nmol/L) 117.0 (102.0, 135.0) 118.0 (101.0, 138.0) 116.0 (102.0, 131.0) 114.0 (102.0, 129.0) 116.5 (101.0, 131.0) 113.0 (99.7, 129.0) 0.564 
     < 87 19 (7.3) 19 (7.7) 11 (6.6) 21 (12.0) 15 (8.2) 15 (9.3) 0.305 
      241.5 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) - 
fT3 (pg/mL) 3.21 (2.77, 3.69) 3.13 (2.70, 3.58) 3.22 (2.87, 3.74) 3.35 (2.82, 3.99) 3.38 (2.90, 3.85) 3.32 (2.96, 3.85) 0.519 
     < 1.8 1 (0.4) 1 (0.4) 1 (0.7) 2 (1.2)    1 (0.6) 1(0.7) - 
    4.2 27 (10.3) 21 (8.4) 18 (6.8) 20 (8.0) 28 (10.6) 17 (6.8) 0.323 
TT3 (nmol/L) 1.85 (1.54, 2.19) 1.85 (1.56, 2.16) 2.34 (2.00, 2.68) 2.38 (2.03, 2.77) 2.42 (2.13, 2.86) 2.44 (2.12, 2.74) 0.923 
     < 1.3 22 (8.4) 23 (9.3) 2 (1.2) 2 (1.1) 1 (0.5) 1 (0.6) - 
      2.6 20 (7.6) 25 (10.0) 52 (19.8) 59 (23.5) 75 (28.5) 62 (24.7) 0.877 
Tg (ng/mL) 9.57 (6.35, 17.00) 9.38 (4.63, 16.58) 10.40 (5.58, 15.90) 8.60 (4.63, 15.50) 11.90 (6.35, 22.30) 9.78 (5.46, 18.10) 0.269 
      38.5 11 (4.6) 11 (4.7) 10 (6.6) 7 (4.2) 18 (10.3) 9 (6.0) 0.184 
TPO-Ab (IU/mL) 16.2 (11.0, 26.2) 17.7 (11.5, 24.7) 14.2 (10.0, 21.8) 13.7 (10.0, 21.7) 11.7 (10.0, 18.9) 12.8 (10.0, 19.6) NA4 
     ≥ 35 40 (15.2) 37 (14.7) 15 (8.8) 21 (11.5) 13 (6.8) 11 (6.5) 0.828 
TT3/TT4 ratio 0.0155 0.0155 0.0198 0.0207 0.0211 0.0216 0.766 
 (0.0139, 0.0145) (0.0135, 0.0179) (0.0176, 0.0228) (0.0176, 0.0234) (0.0181, 0.0251) (0.0179, 0.0253)  
fT3/fT4 ratio 2.9274 2.8325 4.0044 4.2073 4.2285 4.3709 0.159 
 (2.4951, 3.5984) (2.4390, 3.4800) (3.4522, 4.7820) (3.4171, 5.1010) (3.6561, 5.1296) (3.7534, 5.3018)  
Tvol (ml) 8.5 (7.1, 10.2) 8.3 (7.3, 10.1) 8.5 (7.3, 9.6) 8.4 (7.0, 9.7) 8.1 (7.1, 9.4) 8.0 (7.0, 9.1) 0.113 
      12 15 (5.7) 5 (2.0) 5 (2.9) 7 (3.8) 4 (2.1) 7 (4.0) 0.523 
1median (IQR) or n(%), 2trimester-specific reference ranges (1st=0.1-2.5 mIU/L, 2nd=0.2-3.0 mIU/L, 3rd=0.3-3.0 mIU/L), 3per intention-to-treat, using linear mixed 
models for continuous data; generalized linear mixed models for binary data, 4Not available, data could not be normalized 
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significant change in TSH but a significant decrease in fT4 from baseline to 30 weeks. 
Median Tg concentration increased significantly in the placebo group during the 
intervention (p<0.05).  
 
At baseline, 4.7% of women had subclinical hyperthyroidism and 8.6% of women had 
subclinical hypothyroidism (Table 4.3). The prevalence of all subtypes of thyroid 
dysfunction did not differ significantly during the study (p>0.05). 
 
Table 4.3 Prevalence of thyroid dysfunction among Thai pregnant women given 200 µg iodine daily or placebo1 
Thyroid dysfunction2 Baseline (Week 11) Week 20 Week 30 p  
  Placebo Iodine Placebo Iodine Placebo Iodine  value3 
Hyperthyroidism 12 (4.6) 13 (5.2) 4 (2.4) 4 (2.1) 4 (2.1) 7 (4.0) 0.715 
  Overt hyperthyroidism 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) - 
  Subclinical hyperthyroidism 12 (4.6) 12 (4.8) 4 (2.4) 4 (2.1) 4 (2.1) 7 (4.0) - 
Hypothyroidism 26 (9.9) 24 (9.6) 6 (3.6) 13 (7.2) 4 (2.1) 7 (4.0) 0.708 
  Overt hypothyroidism 4 (1.5) 2 (0.8) 0 (0.0) 2 (1.1) 0 (0.0) 1 (0.6) - 
  Subclinical hypothyroidism 22 (8.4) 22 (8.8) 6 (3.6) 11 (6.1) 4 (2.1) 6 (3.4) - 
Isolated hypothyroxinemia 15 (5.7) 17 (6.8) 11 (6.4) 19 (10.4) 14 (7.3) 13 (7.4) 0.609 
1n(%), 2overt hyperthyroidism: low TSH + high TT4; subclinical hyperthyroidism: low TSH + normal TT4; overt 
hypothyroidism: high TSH + low TT4; subclinical hypothyroidism: high TSH + normal TT4; isolated hypothyroxinemia: 
normal TSH + low TT4. 3per intention-to-treat, using generalized linear mixed models.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
At 6-week postpartum (Table 4.4), median Tg, TT4 and TT3 concentrations were 
significantly higher in the placebo group than in the iodine group (p=0.043, 0.010, and 
0.003, respectively). There were no significant differences in other thyroid functions, 
thyroid volume or the prevalence of TPO-Abs (p>0.05). The prevalence of 
hyperthyroidism was significantly lower in the iodine group (3%) as compared to the 
placebo group (9%) (OR: 95%CI, 0.17: 0.04-0.70). Of the women who were 
hypothyroid in the postpartum, six women had elevated TPO-Abs. The percentage of 
women with a TT3 concentration less than 1.3 nmol/L was significantly greater in the 
iodine group (23%) as compared to the placebo group (11%) (OR: 95%CI, 2.77: 
1.27-6.05). Sixty-one percent of women in the placebo group and 73% in the iodine 
group had a UIC value greater than 100 µg/L (p>0.05). 
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Table 4.4 Thyroid function, thyroid volume and urinary iodine concentration of Thai women at 6 weeks 
postpartum after being given 200 µg iodine daily or placebo during pregnancy1 
 Placebo (n=135) Iodine (n=129) Beta p value2 R square 
Thyroid function 
  TSH (mIU/L) 
        < 0.4 
    > 4.0      
  Free T4, ng/dL 
    < 0.89 
     1.76 
  Total T4, nmol/L 
    < 58 
     161 
  Free T3, pg/mL 
    < 1.8 
     4.2 
  Total T3, nmol/L 
    < 1.3 
     2.6 
  Tg (ng/mL) 
     38.5    
  TPO-Abs, IU/mL  
    ≥ 35 
  TT3/TT4 ratio 
 
  fT3/fT4 ratio 
 
Thyroid volume, ml 
     12 
Thyroid dysfunction3 
   Hyperthyroidism 
      Overt hyperthyroidism 
      Subclinical hyperthyroidism 
   Hypothyroidism 
      Overt hypothyroidism 
      Subclinical hypothyroidism 
   Isolated hypothyroxinemia             
Urinary iodine concentration, µg/L 
      ≥ 100 
      50 – 99 
      20 – 49 
      < 20 
 
1.26 (0.87, 1.73) 
13 (9.6) 
1 (0.8) 
1.01 (0.93, 1.13) 
19 (17.3) 
3 (2.2) 
85.6 (74.3, 97.8) 
6 (5.0) 
1 (0.7) 
3.01 (2.64, 3.41) 
0 (0) 
6 (4.4) 
1.56 (1.40, 1.80) 
12 (10.5) 
2 (1.5) 
9.51 (4.79, 15.90) 
6 (4.4) 
34.3 (23.7, 47.1) 
58 (48.3) 
0.0186 
(0.0161, 0.0224)  
2.9630 
(2.5086, 3.3952) 
7.2 (6.1, 8.4) 
4 (3.0) 
 
12 (9.1) 
3 (2.3) 
9 (6.8) 
1 (0.8) 
0 (0.0) 
1 (0.8) 
18 (13.5) 
93.6 (60.3, 159.8) 
61 (48.4) 
47 (37.3) 
17 (13.5) 
1 (0.8) 
 
1.21 (0.74, 1.65) 
6 (4.6) 
1 (0.9) 
1.02 (0.92, 1.09) 
23 (21.1) 
2 (1.5) 
81.3 (69.5, 94.4) 
8 (7.0) 
2 (1.5) 
2.85 (2.53, 3.21) 
0 (0) 
3 (2.3) 
1.50 (1.31, 1.65) 
26 (22.5) 
1 (0.8) 
7.94 (4.89, 15.30) 
5 (3.8) 
34.4 (25.1, 52.2) 
57 (49.6) 
0.0187 
(0.0157, 0.2161) 
2.7700 
(2.4420, 3.2877) 
7.3 (5.8, 9.0) 
8 (6.2) 
 
4 (3.2) 
2 (1.6) 
2 (1.6) 
1 (0.8) 
1 (0.8) 
0 (0.0) 
20 (15.5) 
115.5 (73.0, 155.3) 
73 (58.9) 
38 (30.6) 
13 (10.5) 
0 (0) 
 
0.093 
 
 
-0.078 
 
 
-0.154 
 
 
-0.116 
 
 
-0.183 
 
 
-0.105 
 
0.036 
 
 
 
 
 
-0.002 
 
 
 
 
 
 
 
 
 
0.063 
 
 
 
0.147 
 
 
0.225 
 
 
0.010 
 
 
0.079 
 
 
0.003 
 
 
0.043 
 
0.470 
 
 
 
 
 
0.975 
 
 
 
 
 
 
 
 
 
0.305 
 
 
 
0.135 
 
 
0.181 
 
 
0.253 
 
 
0.155 
 
 
0.210 
 
 
0.471 
 
0.446 
 
 
 
 
 
0.295 
 
 
 
 
 
 
 
 
 
0.122 
 
 
CHAPTER 4 
92 
1median (IQR) or n(%), 2linear regression (adjusted for age, gestational age at delivery, BMI at 6wk, parity, baseline                 
value of each dependent variable and duration from delivery to w6).                                                                                                           
3classified by using the definition of Helfand & Redfern (1998): overt hyperthyroidism: low TSH + high free T4; 
subclinical hyperthyroidism: low TSH + normal free T4; overt hypothyroidism: high TSH + low free T4; subclinical 
hypothyroidism: high TSH + normal free T4; isolated hypothyroxinemia: normal TSH + low free T4. 
OR(95% CI) using logistic regression for the prevalences: 1.08(0.07-17.43) for TSH>4.0mIU/L; 1.55(0.76-3.17) for 
fT4<0.89ng/dL; 1.99(0.61-6.55) for TT4<58nmol/L; error for fT3<1.8 pg/mL; 2.77(1.27-6.05) for TT3<1.3nmol/L;                                                                                                                               
0.94(0.21-4.20) for Tg>38.5ng/mL; 1.00(0.55-1.83) for TPO-Ab≥35IU/mL; 2.29(0.65-8.06) for thyroid volume>12ml;                                                                                                             
0.17(0.04-0.70) for hyperthyroidism; error for hypothyroidism; 1.19(0.57-2.51) for isolated hypothyroxinemia.       
 
Newborn thyroid function, thyroid volume and birth characteristics, as well as UIC and 
NBAS score at 6 weeks postpartum are shown in Table 4.5. The percentage of low birth 
weight and preterm birth were higher in the placebo group (8.8% and 10.6%, 
respectively) than in the iodine group (5.4% and 5.4%, respectively), but these 
differences were not statistically significant. Length of gestation also did not differ 
significantly between groups (placebo 268.7 ± 11.9 days, iodine 270.5 ± 8.9: p=0.143). 
There were no significant differences between newborn groups in any of the other 
variables measured. After the newborns who were born at gestational age <35 weeks 
were excluded, no significant differences were seen in median NBAS scores between the 
groups (p>0.05).   
 
Discussion 
 
This study is the largest randomized controlled trial of iodine supplementation in mildly 
ID pregnant women that has been done to date. The iodine supplementation regimen 
was well tolerated by the women and significantly increased iodine intakes into the 
adequate range as judged by a median UIC >150 µg/L at 20 and 30 weeks. In the 
intention-to-treat analysis, there were no significant differences in maternal thyroid 
functions, thyroid disorders or thyroid volume during the study. However, at 6 weeks 
postpartum, thyroid hormone concentrations and Tg were higher in women in the 
placebo group and there was a significantly increased risk of postpartum 
hyperthyroidism, most of it mild and subclinical. Among the newborns, there were no 
significant differences in thyroid functions, thyroid volume, or in development scores 
and UICs at 6 weeks postpartum. There was tendency for reduced risk of low birth  
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Table 4.5 Neonatal characteristics, thyroid function, thyroid volume, urinary iodine concentration and 
Neonatal Behavioral Assessment Scales score in Thai newborns born to women who were given 200 µg 
iodine daily or placebo during pregnancy (N=324)1  
 Placebo n Iodine n Beta p value3  R 
square 
At delivery 
Characteristics 
   Sex; female:male 
   Birth weight, gram2 
       < 2500, n(%) 
   Preterm, n(%)      
   Head circumference, cm      
   Ponderal index2 
       < 10th percentile, n(%) 
   Small-for-gestational age,   
        n(%) 
Thyroid function (cord blood ) 
   TSH (mIU/L) 
   fT4 (ng/dL)              
   TT4 (nmol/L) 
   fT3 (pg/mL) 
   TT3 (nmol/L) 
   Tg (ng/mL)       
   TPO-Abs (IU/mL) 
Thyroid volume, ml2     
Post-delivery 
Within 72 hrs after delivery 
DBS-TSH, mIU/L 
   > 5, n(%)           
Week 6 postpartum 
Urinary iodine concentration,  
   µg/L 
   < 100, n(%) 
NBAS score 
   Habituation 
   Social-interactive 
   Motor system 
   State organization 
   State regulation 
   Autonomic system 
   Reflexes 
   Supplementary items      
 
 
87 : 83 
3092 ± 478 
15 (8.8) 
18 (10.6) 
34.0 (33.0, 35.0) 
25.0 ± 2.2 
5 (3.0) 
 
24 (14.1) 
 
5.630 (3.545, 8.320) 
1.09 (0.96, 1.18) 
119.0 (103.0, 138.0) 
1.76 (1.42, 2.32) 
0.86 (0.72, 1.49) 
53.0 (31.2, 84.1) 
11.5 (10.0, 17.0) 
0.72 ± 0.2 
 
 
1.4 (0.9, 2.2) 
4 (3.4) 
 
 
193.3 (136.7, 303.5) 
9 (11.8) 
 
7.6 (6.8, 8.1) 
6.9 (6.0, 8.1) 
5.8 (5.2, 6.4) 
3.8 (3.0, 4.1) 
4.0 (2.6, 4.7) 
6.7 (5.3, 7.3) 
3.0 (2.0, 4.0) 
6.3 (5.1, 8.1) 
 
 
 
170 
 
 
164 
166 
 
 
 
 
165 
162 
167 
139 
88 
165 
173 
67 
 
 
118 
 
 
 
76 
 
 
18 
68 
72 
53 
40 
71 
75 
55 
 
 
80 : 69 
3120 ± 392 
8 (5.4) 
8 (5.4) 
34.0 (33.0, 35.0) 
25.4 ± 2.0 
1 (0.7) 
 
26 (17.4) 
 
5.240 (3.290, 8.490) 
1.06 (0.95, 1.17) 
114.0 (96.7, 138.5) 
1.72 (1.39, 2.40) 
0.86 (0.71, 1.71) 
41.6 (18.3, 81.5) 
11.2 (10.0, 17.1) 
0.63 ± 0.3 
 
 
1.4 (0.9, 2.5) 
2 (2.0) 
 
 
168.7 (97.3, 305.7) 
21 (25.3) 
 
7.0 (5.4, 8.3) 
7.4 (6.4, 8.0) 
6.0 (5.3, 6.6) 
3.8 (2.8, 4.0) 
4.0 (3.3, 4.5) 
6.7 (6.0, 7.3) 
3.0 (1.8, 4.0) 
6.7 (5.3, 8.3) 
 
 
 
149 
 
 
147 
147 
 
 
 
 
147 
141 
146 
114 
79 
145 
151 
64 
 
 
101 
 
 
 
83 
 
 
22 
66 
73 
48 
38 
61 
74 
48 
 
 
 
0.010 
 
 
-0.062 
0.085 
 
 
 
 
-0.010 
-0.037 
-0.041 
0.062 
0.137 
-0.059 
0.014 
-0.095 
 
 
0.008 
 
 
 
0.039 
 
 
-0.321 
0.091 
0.051 
-0.059 
-0.041 
0.105 
0.005 
0.040 
 
 
 
0.831 
 
 
0.256 
0.142 
 
 
 
 
0.866 
0.547 
0.492 
0.364 
0.108 
0.337 
0.716 
0.274 
 
 
0.927 
 
 
 
0.660 
 
 
0.109 
0.343 
0.584 
0.606 
0.747 
0.288 
0.959 
0.714 
 
 
 
0.326 
 
 
0.185 
0.066 
 
 
 
 
0.017 
0.024 
0.018 
0.070 
0.039 
0.029 
0.543 
0.142 
 
 
0.026 
 
 
 
0.040 
 
 
0.213 
0.062 
0.026 
0.071 
0.164 
0.056 
0.012 
0.101 
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1median (IQR), 2mean ± SD, 3linear regression (adjusted for age, pre-pregnancy BMI, parity, gestational age at baseline, 
gestational age at delivery, UIC at w30,and baseline value of each dependent variables for thyroid function).                     
OR(95% CI) using logistic regression for the prevalence: 0.92(0.31-2.75) for low birth weight; 0.48(0.19-1.19) for 
preterm; 0.22(0.03-1.92) for PI<10th percentile; 1.06(0.56-2.01) for SGA; 0.30(0.03-2.69) for DBS-TSH>5mIU/L; 
1.69(0.68-4.19) for UIC<100µg/L.                                                                                                                                                                                                                                   
  
weight and preterm birth in the iodine group, but this did not reach statistical 
significance. Therefore, in summary, although iodine supplementation was safe and 
effective in normalizing iodine intakes, it had no measured benefit for the mother 
during pregnancy and no benefit on newborn variables out to 6 weeks. However, it did 
reduce the risk of postpartum thyroid dysfunction in the mothers.  
  
Similar to our study, previous iodine supplementation studies in pregnant women, also 
showed a 2- to 3-fold increase of UIC in the treated group (Romano 1991; Pedersen 
1993; Liesenkotter 1996). However, in our study, an increment of UIC was also found 
in the placebo group, which may be caused by an increase of renal clearance over 
pregnancy (Delange 2004). However, we did not find such a difference in UIC between 
trimesters in an earlier cross-sectional study in women from the same area 
(Gowachirapant 2009). It may be due to increased awareness of the importance of 
iodine intake during pregnancy, women in the study may have changed their habits. 
Nevertheless, there was a distinct difference in UIC between groups in the 2nd and 3rd 
trimester of pregnancy. When a median UIC of >500 µg/L was used for indicating 
iodine excess, only a few women in this population reported a median UIC above the 
cut-off. It can be concluded that supplementation with 200 µg iodine per day appears 
to be a good dose for this mild-to-moderate ID pregnant women, effective at increasing 
intakes into the recommended range of UIC without causing excess iodine intakes.  
 
There have been several controlled trials of iodine treatment in mild-to-moderately 
iodine deficient pregnant women in Europe that have measured maternal and newborn 
thyroid function. Romano et al (Romano 1991) gave 120-180 µg iodine as iodized salt 
or control daily beginning in the 1st trimester to healthy pregnant Italian women (n=35; 
median UIC 31-37 µg/L). Iodine supplementation increased median UIC 3-fold and 
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maternal thyroid volume was lower, but there was no effect on maternal TSH. Pedersen 
et al (Pedersen 1993) randomized pregnant Danish women (n=54) to receive either 200 
µg iodine/day as KI solution or no supplement from 17 weeks to term. Median UIC 
increased from 55 µg/L to 90-110 µg/L in the treated group. Maternal thyroid volume 
increased 16% in the treated group vs. 30% in controls. Maternal Tg and TSH, and cord 
Tg were significantly lower in the treated group, but there were no significant group 
differences on maternal or cord T4, T3, and fT4. In a double-blind, placebo-controlled 
trial, Glinoer et al (Glinoer 1995) supplemented pregnant Belgian women with 
biochemical criteria of excess thyroid stimulation (n=120; median UIC 36 µg/L) with 
100 µg iodine/day or control from 14 weeks to term. Treatment had no significant 
effect on maternal or cord T3, fT4, and T3/T4 ratio. Iodine treatment resulted in 
significantly higher maternal UIC, and lower thyroid volume, TSH and Tg 
concentrations. Newborns of the treated group also had significantly higher UIC, lower 
thyroid volume and Tg concentrations. Liesenkotter et al (Liesenkotter 1996) gave 230 
µg iodine/day or control from 11 weeks to term in pregnant German women (n=108; 
median UIC 53 µg/g creatinine; goiter rate 42.5%). In the iodine group, median UIC 
increased to 104 µg/g creatinine and newborn thyroid volume was significantly lower, 
but there were no significant group differences in maternal TSH, Tg, T3, T4, or thyroid 
volume, or newborn TSH. In a placebo-controlled, double-blind trial, Nohr et al (Nohr 
2000) gave a multinutrient supplement containing 150 µg iodine/day or control to 
pregnant Danish women positive for antithyroid peroxidase antibodies (n=66) from 11 
week to term, and found no differences in maternal TSH, fT4 or Tg between groups. 
Finally, Antonangeli et al (Antonangeli 2002) supplemented pregnant Italian women 
(n=67; median UIC 74 µg/g creatinine) with 50 µg or 200 µg iodine/day from 18-26 
week to near term but found no significant differences in maternal fT4, fT3, TSH, Tg or 
thyroid volume between groups. 
 
Our study population with a baseline median UIC of ca. 110 µg/L, was less iodine 
deficient than these European populations and our sample size was much larger. Our 
findings that maternal and newborn thyroid functions did not differ between groups 
confirm the previous European studies in that none of those studies showed a significant 
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impact of supplementation on maternal and newborn total or free thyroid hormone 
concentrations. In the European studies, although iodine supplementation generally 
reduced thyroid size compared to controls, only two of six studies reported that 
maternal TSH or Tg was lower with supplementation. In contrast, in our study, there 
were no group differences in maternal or newborn TSH, Tg or thyroid volume. Taken 
together, these studies suggest that when maternal iodine deficiency is moderate 
(baseline median UIC <100 µg/L), the maternal thyroid is able to adapt to meet the 
increased need for thyroid hormone by a small increase in thyroid stimulation manifest 
as a small increases in thyroid volume and, in some instances, a modest increase in TSH 
or Tg. In more mild iodine deficiency (median maternal UIC 100-150 µg/L), the thyroid 
is able to adapt without a measurable increase in thyroid stimulation. Iodine intake in 
the general Thai population is adequate (Gowachirapant 2009; Gowachirapant 2014) 
and many of the women in our study are likely to have entered pregnancy with 
abundant stores of intrathyroidal iodine. Once pregnant, although their daily iodine 
requirement increases and their iodine intakes are mildly deficient, the thyroid is able to 
draw on iodine from the thyroidal iodine pool (which can be 10-20 mg in healthy 
adults) in order to meet needs for thyroid hormone synthesis and maintain 
euthyroidism (Zimmermann 2009). 
 
Postpartum thyroiditis (PPT) is the occurrence of thyroid dysfunction in the first 
postpartum year in women who prior to pregnancy were euthyroid (Stagnaro-Green 
2011). Its overall prevalence is approximately 5%, but PPT develops in 33-50% of 
women who are TPO-positive in the first trimester (Smallridge 2000; Stagnaro-Green 
2012). In the classic form (ca. 25% of cases), transient hyperthyroidism is followed by 
hypothyroidism, which may be permanent in 10-50% of cases; another 32% of cases 
present with isolated hyperthyroidism (Stagnaro-Green 2011; Stagnaro-Green 2012). 
In our study, at 6 weeks postpartum, there was significantly more PPT in the placebo 
group than in the iodine group (9.9% vs. 4.0%, respectively) and nearly all of the PPT 
was mild hyperthyroidism without clinical symptoms. The OR (95% CI) for 
hyperthyroidism in the iodine group was 0.17 (0.04-0.70), and TT3 and TT4 
concentrations were also significantly higher in the placebo group than in the iodine 
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group. The prevalence of TPO-positivity in the women with PPT was 49% but positivity 
rates and median TPO-Abs concentrations did not differ significantly between groups 
(Table 4.4). Whether iodine intake during pregnancy and the postpartum period is a 
risk factor for PPT remains unclear. Three randomized studies have examined the effects 
of iodine supplementation on PPT. In a mildly iodine-deficient German population, 
women with no previous thyroid disease (n=70) received either 50 or 250 µg/day iodine 
postpartum; there were no differences in PPT prevalence over 8 months postpartum 
between groups (Reinhardt 1998). In an iodine sufficient Swedish population, 
TPO-positive women (n=58) received 150 µg/day iodine or control postpartum, and the 
iodine exacerbated the hypothyroid phase of PPT (Kampe 1990). In the third study, 
moderately iodine deficient TPO-positive Danish pregnant women (n=66) were given 
150 µg/day iodine (as a part of a multivitamin -mineral containing 50 µg/day of 
selenium) or the same supplement without iodine; the supplement was given during 
pregnancy only or during pregnancy and the postpartum. There were no significant 
differences in frequency or severity of PPT over 9 months postpartum between groups 
(Nohr 2000). In contrast to these previous studies that suggested iodine has no effect or 
may aggravate PPT, our data suggest iodine supplementation during pregnancy reduces 
risk of PPT in mildly iodine deficient women. 
 
In this study, we saw a trend toward a beneficial effect of iodine supplementation on 
prevalence of low birth weight and preterm delivery. Severe ID during pregnancy is 
known to cause stillbirths, congenital cretinism and dwarfism (WHO/UNICEF/ICCIDD 
2001). Because thyroid hormone stimulates growth hormone secretion and modulates 
the effects of growth hormone receptor (Crews 1989; Samuels 1989; Hochberg 1990), 
which may explain effects of iodine on growth. Furthermore, insulin-like growth factor 
(IGF)-1 and insulin-like growth factor-binding protein (IGFBP)-3 are also dependent 
on thyroid hormone status (Burstein 1979; Geary 1989; Angerva 1993; Miell 1993; 
Nanto-Salonen 1993). Our modest findings are supported by an Algerian study where 
0.5 ml of oral iodized oil given to moderately ID pregnant women before or during the 
first trimester of pregnancy increased birth weight (Chaouki 1994). More data from 
controlled studies on the effects of iodine supplementation on fetal growth and 
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gestational length are needed to draw firm conclusions. Of interest, and confirming 
findings of previous studies linking maternal thyroid autoimmunity to preterm birth 
(Negro 2006), 11 of 16 preterm babies were born to mothers who were TPO positive in 
the first trimester. 
 
The Neonatal Behavioral Assessment Scales (NBAS) has been used in several studies to 
examine the effects of pre- and perinatal risk factors (Ferrari 1986; Anderson 1989; 
Rizzo 1991; Oyemade 1994), obstetric medication and mode of delivery on neonatal 
behavior (Gathwala 1990; Steinberg 1992). Results of a study among 209 low birth 
weight and/or premature Japanese infants confirmed the usefulness of the NBAS for 
predicting the risk of later developmental disabilities (Ohgia 2003). In the present study, 
we did not see any differences in NBAS scores between newborns born to mothers from 
either group. This may be a logical consequence of the fact that the intervention did not 
provide an explicit improvement of thyroid function both in mothers and their 
newborns. However, when concerning low birth weight infants, the NBAS cluster scores 
of state regulation and supplementary items were significantly lower in low birth 
weight infants compared to normal weight infants (data not shown). 
       
The high percentage of loss to follow up in the study is a limitation of this trial. Loss to 
follow up can bias the results and may lead to erroneous interpretation. Despite the fact 
that all women were asked for their intention to stay in the same area of residence for 
the duration of the study, most of the loss-to-follow up was caused by women or their 
newborns moving back to their hometown. In Thailand, it is common that infants born 
in an urban area will grow up with relatives in a rural area, sometimes far away from 
their parents. However, in our study, loss to follow up was similar in both intervention 
groups, and reasons for decline were not different. Therefore, we are confident that the 
loss to follow up was not caused by the study treatment itself, and therefore inferences 
still can be made. 
 
In conclusion, supplementation of 200 µg iodine/day in mildly iodine deficient pregnant 
Thai women beginning at the end of the first trimester was safe and well-tolerated. 
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Iodine supplementation increased maternal iodine intakes into the adequate range but 
did not significantly improve maternal or newborn thyroid function, birth outcomes, or 
newborn development at 6 weeks postpartum. However, it modestly but significantly 
reduced the risk of postpartum thyroiditis. Further data analysis in the mothers and 
infants over the first two years postpartum will reveal whether iodine supplementation 
has led to any maternal benefits or improvement in child development at later ages. 
Furthermore, results from a second study site in India are currently being analyzed to 
see if they support the findings of this study.  
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Abstract 
 
Maternal pre-pregnancy body mass index (BMI) and gestational weight gain (GWG) 
have been reported to be associated with pregnancy outcomes, especially with birth 
weight. Due to the nutritional transition in Thailand, the double burden of malnutrition 
is increasing and this may have negative consequences on birth outcomes. 
 
This study aimed to investigate the relationship between pre-pregnancy BMI and GWG 
with pregnancy outcomes. 
 
We performed a secondary analysis of data obtained from an RCT of iodine 
supplementation in mildly iodine deficiency (ID) pregnant Thai women. Pre-pregnancy 
BMI was classified using the WHO classification. GWG was categorized using the IOM 
recommendation. Binary and multinomial logistic regressions were used to investigate 
the relationship between pre-pregnancy BMI and GWG with pregnancy outcomes.  
 
Among 378 pregnant women, the prevalence of pre-pregnancy underweight (BMI 
<18.5 kg/m2) and overweight (BMI ≥25 kg/m2) were 17.2% and 14.3%, respectively. 
Normal weight women had the highest median GWG [15.0 (12.0, 19.0)] when 
compared to underweight [13.7 (11.4, 18.5)] and overweight women [13.2 (9.0, 16.3)]. 
Forty one percent of women had excessive GWG, while 23% of women gained weight 
inadequately. Women with a high pre-pregnancy BMI had an 11-fold higher risk of 
having a large for gestational age infant. Women who had excessive GWG were 5.6 
times more likely to deliver a newborn with macrosomia.  
 
In conclusion, both high pre-pregnancy maternal weight and excessive weight gain 
during pregnancy increase risk of infant macrosomia. Therefore, maintaining normal 
body weight before and throughout pregnancy should be recommended in order to 
reduce the risk of excessive infant birth weight and its associated complications.  
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Introduction 
 
Despite a rising trend in overnutrition in young children and in non-communicable 
diseases among adults,1,2 the prevalence of low birth weight (LBW) in Thailand has 
remained at a constant level of 8-10% over the last 10 years.3 
  
Undernutrition, both before and during pregnancy, results in poor fetal growth, LBW, 
and preterm birth.4,5 In contrast, overnutrition is associated with higher risk of 
macrosomia, cesarean delivery, and other pregnancy complications such as gestational 
diabetes and preeclampsia.4-6 Maternal nutrition may not only affect the immediate 
pregnancy outcomes. Since fetal and early postnatal life is a period of rapid growth and 
development, nutritional perturbations during this period may predispose to health and 
diseases later in life.7-9 
  
The relationship between pre-pregnancy nutritional status and gestational weight gain 
(GWG) with birth weight has been investigated in many studies in Thailand.10-14 The 
evidence showed that low pre-pregnancy BMI and less GWG was one of the 
determinants of LBW in Thai population.11,14 On the other hand, high GWG was 
associated with high birth weight.10,12,13 The evidence of the relationship between 
maternal nutritional status on timing of delivery was also documented. High 
pre-pregnancy BMI increased risk of preterm delivery.15,16 Among high pre-pregnancy 
BMI women, low GWG was associated with an increased risk of preterm delivery.17 
 
In order to obtain collective evidence on these associations, studies are needed to assess 
the risk for both LBW and macrosomia related to maternal body weight in populations 
presently undergoing the nutrition transition, such as Thailand. This knowledge can 
guide us to more appropriate recommendations in Thailand and other countries in the 
region that are also facing the double burden of malnutrition. Therefore, this study 
aimed to investigate the association between pre-pregnancy BMI and GWG with 
pregnancy outcomes. 
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Participants and Methods 
 
Participants 
This study is a secondary analysis of data obtained from a randomized double blind 
controlled trial on the effect of iodine supplementation in mild-to-moderately 
iodine-deficient pregnant women on thyroid function, pregnancy outcomes and early 
infant development in Thailand. The intervention study was conducted among pregnant 
Thai women who had attended antenatal clinic at Ramathibodi Hospital of Mahidol 
University in Bangkok, Thailand between October 2008 and June 2013. Inclusion and 
exclusion criteria were explained in previous publication.18 Pregnant women were 
followed-up until delivery. The analyses were limited to 380 women who had birth 
outcome data.  
 
The ethical review boards of Wageningen University, the Netherlands and Ramathibodi 
Hospital, Thailand approved the study protocol. The study was registered into the 
clinical trials database at http://www.clinicaltrials.gov/ and its identifier number is 
NCT00791466. 
 
Methods 
At enrolment, maternal characteristics of the women including age, parity, education 
and occupation were recorded using a questionnaire. Data on birth weight and date of 
delivery were obtained from the hospital records. Self-reported pre-pregnancy weight 
and measured height at the enrolment were used for pre-pregnancy BMI (kg/m2) 
calculation. Weight at the first antenatal visit (4%) or at the enrolment (1%) was used in 
women whom pre-pregnancy weight was not available. Pre-pregnancy BMI was 
classified using the international cut-off points proposed by WHO; underweight (<18.5 
kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), or obese 
(≥30.0 kg/m2).19 Due to small number of obese women (n=15, 4%), women with BMI 
≥25.0 kg/m2 were considered as overweight. 
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GWG was estimated as the difference in kilograms between the delivery weight and 
pre-pregnancy weight. GWG was categorized as inadequate, adequate, and excessive, 
according to the IOM recommendations.20 Adequate GWG was defined as 12.5–18, 
11.5–16, 7–11.5, and 5–9 kg for underweight, normal weight, overweight, and obese 
women, respectively. 
 
Low birth weight was defined as weight at birth of <2500 grams, while macrosomia 
was defined as weight at birth ≥4000 grams. Preterm was defined as babies born alive 
before 37 weeks of pregnancy. 
  
Maternal blood sample was collected at baseline, 2nd and 3rd trimester, and at delivery 
for hemoglobin (Hb) concentration measurement. Hb concentration was analysed using 
flow cytometry method (automated blood count analyzer, Sysmex, USA) at Ramathibodi 
Hospital.  
 
Statistical analyses 
 
Participant’s characteristics are presented as means±SD, medians (first, third quartiles), 
or percentages, where appropriate. Participant’s characteristics were compared by 
pre-pregnancy BMI and GWG categories using Chi-square test for discrete variables 
and analysis of variance (ANOVA) with Tukey’s post hoc or Kruskal-Wallis test with 
Mann-Whitney U test for continuous data. Binary and multinomial logistic regressions 
were used to assess the relationship between pre-pregnancy BMI and GWG with 
pregnancy outcomes including birth weight and preterm delivery. The models were 
adjusted for parity, pre-pregnancy BMI or GWG, Hb at 3rd trimester, sex of baby, 
gestational diabetes mellitus, preeclampsia, treatment group, and preterm delivery (for 
birth weight outcome only). All statistical analyses were performed using SPSS version 
19 (SPSS Inc., Chicago, IL).  
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Results 
 
Of 380 pregnant women, 2 women were excluded from data analyses because of the 
uncertainty in GWG (GWG less than 0.5 kg). Hence, the data of 378 pregnant women 
were analyzed. Maternal characteristics presented by pre-pregnancy BMI are shown in 
Table 5.1. The prevalence of underweight and overweight were 17.2% and 14.3%, 
respectively. Underweight women tended to be younger than normal and overweight 
women (p<0.01). Median GWG in normal weight women [15.0 (12.0, 19.0) kg] was 
higher than in underweight [13.7 (11.4, 18.5) kg] and overweight women [13.2 (9.0, 
16.3) kg] (p<0.01). According to the IOM recommendation for GWG, 22.8 %, 36.2 %, 
and 41.0 % of women had inadequate, adequate, and excessive weight gain, respectively 
(Table 5.2). Median Hb concentrations were not different by both pre-pregnancy BMI 
and GWG categories (p>0.05) (Table 5.1, 5.2).  
 
The average birth weight of infants born to underweight women was lower than that of 
infants born to overweight women (2988±478 g vs. 3224±579 g, p<0.05). However, 
the average birth weight of infants born to normal weight women did not differ from 
that of infants born to underweight and overweight women (Table 5.3). Similarly, the 
average birth weight of infants born to inadequate GWG women was lower than that of 
those born to excessive GWG women (3021±407 g vs. 3189±495 g, p<0.05) but it was 
similar to that of infants born to adequate GWG women (p>0.05). 
 
The relationships between pre-pregnancy BMI and birth weight and preterm delivery 
are shown in Table 5.4. In unadjusted multinomial logistic regression model, women 
who were underweight before pregnancy were 2.7 times (crude OR: 2.65, 95%CI: 
1.08-6.53) as likely to have LBW infants compared to normal weight women. However, 
this significant relationship disappeared in the adjusted model. In addition, women who 
were overweight before pregnancy were 6.1 times (crude OR: 6.12, 95%CI: 1.83-20.41) 
as likely to have macrosomic infants compared to normal weight women. The 
relationship was stronger after adjusting for possible confounders (adjusted OR: 11.48,  
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Table 5.1 Characteristics of participants classified by pre-pregnancy body mass index (BMI) 
 
Characteristics Pre-pregnancy BMI1 
Underweight Normal weight Overweight p-value2,3 
No. of participants (%) 65 (17.2) 259 (68.5) 54 (14.3) - 
Maternal age4, y 27.0 ± 4.8a 30.0 ± 4.8b 30.0 ± 5.2b 0.000 
Pre-pregnancy BMI5, kg 
m-2 
17.7a 
(17.1, 18.1) 
21.0b 
(19.7, 22.3) 
27.9c 
(26.4, 30.5) 
0.000 
Gestational weight gain, kg 13.7a,b 
(11.4, 18.5) 
15.0a 
(12.0, 19.0) 
13.2b 
(9.0, 16.3) 
0.036 
Gestational weight gain, % 
   Inadequate 
   Adequate 
   Excessive 
             
35.4         
40.0 
24.6 
            
22.4        
37.8 
39.8 
           
9.3        
24.1 
66.7 
         
0.000 
Parity, % 
   Primiparous 
   Multiparous 
            
55.4         
44.6 
           
39.0 
61.0 
          
35.2 
64.8 
         
0.035 
Education, % 
   <12 yr 
   12 yr 
   >12 yr 
             
4.6          
30.8          
64.6 
             
8.1         
36.3 
55.6 
          
13.0        
35.2       
51.9 
         
0.411 
Occupation, % 
   Officer workers 
   Owned business 
   General employee 
   Others 
             
52.3         
12.3         
10.8 
24.6 
            
50.2        
17.4        
15.1 
17.4 
           
46.3        
9.3        
25.9 
18.5 
         
0.193 
 
Hemoglobin at baseline, g/L 117 
112 (124) 
120 
(113, 127) 
120 
(116, 127) 
0.136 
Hemoglobin at 3rd trimester, 
g/L 
114 
(110, 122) 
116 
(110, 122) 
119 
(111, 123) 
0.289 
1BMI (kg m-2): underweight (<18.5), normal weight (18.5–24.9), and overweight (≥25.0) 
2Chi-square test for discrete data 
3ANOVA or Kruskal-Wallis test for continuous data; values in a row without a common letter differs 
4 Mean ± SD (all such values) 
5Median (first, third quartiles) (all such values) 
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Table 5.2 Characteristics of participants classified by gestational weight gain (GWG) 
 
Characteristics IOM gestational weight gain1 
Inadequate Adequate Excessive p-value2,3 
No. of participants (%) 86 (22.8) 137 (36.2) 155 (41.0) - 
Maternal age4, y 29.0 ± 5.9 30.0 ± 4.9 29.0 ± 4.5 0.139 
Pre-pregnancy BMI5, kg 
m-2 
20.6a 
(18.3, 22.3) 
20.4a 
(18.8, 22.5) 
21.3b 
(19.8, 24.3) 
0.001 
Gestational weight gain, 
kg 
10.0a 
(7.6, 11.0) 
13.7b 
(12.6, 15.0) 
19.0c 
(17.0, 22.0) 
0.000 
Parity, % 
   Primiparous 
   Multiparous 
             
38.4 
61.6 
            
37.2 
62.8 
            
46.5 
53.5 
        
0.230 
 
Education, % 
   <12 yr 
   12 yr 
   >12 yr 
            
10.5         
38.4 
51.2 
              
9.5          
32.1 
58.4 
              
5.8          
36.1 
58.1 
         
0.535 
 
Occupation, % 
   Officer workers 
   Owned business 
   General employee 
   Others 
            
43.0         
17.4         
17.4 
22.1 
            
50.4         
16.1         
18.2 
15.3 
            
53.5         
13.5         
15.9 
20.0 
         
0.566 
 
Hemoglobin at baseline, 
g/L 
120 
(113, 125) 
120 
(113, 126) 
120  
(114, 126) 
0.974 
Hemoglobin at 3rd 
trimester, g/L 
114 
(108, 122) 
118 
(111, 123) 
115 
(110, 123) 
0.252 
1Adequate gestational weight gain: 12.5–18, 11.5–16, 7–11.5, and 5–9 kg for underweight, normal weight, overweight,  
and obese women 
2Chi-square test for discrete data 
3ANOVA or Kruskal-Wallis test for continuous data; values in a row without a common letter differs 
4Mean ± SD (all such values), 5Median (first, third quartiles) (all such values) 
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Table 5.3 Pregnancy outcomes classified by pre-pregnancy BMI and gestational weight gain 
 
Pregnancy 
outcomes 
Pre-pregnancy BMI Gestational weight gain 
Underweight Normal weight Overweight p-value1,2 Inadequate Adequate Excessive p-value1,2 
No. of    
  participants 
65 259 54 - 86 137 155 - 
Birth weight3, g 2988 ± 478a 3116 ± 405a,b 3224 ± 579b 0.016 3021 ± 407 a 3074 ± 409 a,b 3189 ± 495 b 0.011 
Birth weight, % 
  < 2500 g          
  2500-2999 g 
  3000-3999 g 
  ≥4000g 
 
13.8 
29.2 
55.4 
1.5 
 
5.8 
30.5 
61.4 
2.3 
 
7.4 
33.3 
48.1 
11.1 
 
0.009 
 
10.5 
31.4 
57.0 
1.2 
 
7.3 
31.4 
59.9 
1.5 
 
5.8 
29.7 
58.1 
6.5 
 
0.189 
Gestational age  
 at delivery4,wk 
39  
(38, 40) 
39  
(38, 40) 
38.5      
(38, 39) 
0.719 39  
(38, 40) 
39 
(38, 39) 
39       
(38, 40) 
0.908 
Preterm   
  delivery, % 
10.8 6.6 7.9 0.345 11.6 5.8 7.7 0.296 
1Chi-square test for discrete data 
2ANOVA or Kruskal-Wallis test for continuous data; values in a row without a common letter differs 
3 Mean ± SD (all such values) 
4Median (first, third quartiles) (all such values) 
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Table 5.4 Crude and adjusted odds ratios (OR) for pregnancy outcomes classified by pre-pregnancy BMI 
 
 Crude OR Adjusted OR1 
Pre-pregnancy BMI (kg/m2) Pre-pregnancy BMI (kg/m2) 
< 18.5 18.5 – 24.9 ≥ 25.0 < 18.5 18.5 – 24.9 ≥ 25.0 
Birth weight (g)       
  < 2500 2.65 
(1.08-6.53)* 
Referent 1.63 
(0.50-5.30) 
2.36 
(0.76-7.35) 
Referent 1.42 
(0.32-6.37) 
  2500-2999 1.06 
(0.57-1.97) 
Referent 1.39 
(0.72-2.69) 
0.76 
(0.38-1.53) 
Referent 1.47 
(0.67-3.25) 
  3000-3999 Referent Referent Referent Referent Referent Referent 
  ≥ 4000 0.74 
(0.09-6.31) 
Referent 6.12 
(1.83-20.41)** 
0.76 
(0.12-4.87) 
Referent 11.48 
(3.17-41.63)** 
Preterm   
  delivery 
1.72 
(0.68-4.34) 
Referent 1.78 
(0.67-4.75) 
1.13 
(0.37-3.46) 
Referent 1.09 
(0.32-3.65) 
*p < 0.05, **p < 0.01, multinomial logistic regression for birth weight and binary logistic regression for preterm                                                                                                                                                          
1adjusted for parity, gestational weight gain, hemoglobin at 3rd trimester, baby sex, gestational diabetes mellitus, preeclampsia, treatment group  
(and preterm for birth weight model only) 
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Table 5.5 Crude and adjusted odds ratios (OR) for pregnancy outcomes classified by gestational weight gain 
 
 Crude OR Adjusted OR1 
Gestational weight gain Gestational weight gain 
Inadequate Adequate Excessive Inadequate Adequate Excessive 
Birth weight (g)       
  < 2500 1.51 
(0.57-3.96) 
Referent 0.82 
(0.32-2.12) 
0.84 
(0.25-2.88) 
Referent 0.53 
(0.16-1.77) 
  2500-2999 1.05 
(0.58-1.91) 
Referent 0.98 
(0.58-1.63) 
0.81 
(0.41-1.61) 
Referent 0.76 
(0.41-1.41) 
  3000-3999 Referent Referent Referent Referent Referent Referent 
  ≥ 4000 0.84 
(0.07-9.47) 
Referent 4.56 
(0.97-21.41) 
1.59 
(0.18-13.80) 
Referent 5.62 
(1.09-29.06)* 
Preterm   
  delivery 
2.12 
(0.80-5.61) 
Referent 1.35 
(0.54-3.42) 
2.36 
(0.75-7.43) 
Referent 1.18 
(0.38-3.65) 
*p < 0.05, multinomial logistic regression for birth weight and binary logistic regression for preterm                                                                                                                                                          
1adjusted for parity, pre-pregnancy BMI, hemoglobin at 3rd trimester, baby sex, gestational diabetes mellitus, preeclampsia, treatment group     
(and preterm for birth weight model only) 
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95%CI: 3.17-41.63). There was no significant relationship between pre-pregnancy BMI 
and preterm delivery (p>0.05). 
 
The relationships between GWG and birth weight and preterm delivery are summarized 
in Table 5.5. There was no relationship between inadequate GWG and having low or 
high birth weight (p>0.05). Nevertheless, the adjusted model showed that women who 
had excessive GWG were 5.6 times (adjusted OR: 5.62, 95%CI: 1.09-29.06) as likely to 
have macrosomic infants compared to women with normal GWG. GWG was not related 
to preterm delivery (p>0.05). 
 
Discussion 
 
Several publications reported the association between maternal pre-pregnancy BMI and 
GWG and pregnancy outcomes especially birth weight. Our findings from this 
secondary data analysis strengthened those results. Mothers who are underweight 
before pregnancy or gained weight inadequately tended to have a higher risk of having 
LBW infants when compared to overweight mothers or gained excessive weight. From 
the unadjusted multinomial logistic regression, underweight women had a 2.7-fold 
higher risk of having LBW infants, while overweight women had a 6-fold higher risk of 
having macrosomic infants compared to normal weight women. The relationship was 
stronger after adjusting for possible confounders, and overweight women had an 
11-fold higher risk of having macrosomic infants. In addition, women who had 
excessive GWG were 5.6 times as likely to have macrosomic infants compared to 
women with normal GWG. These findings confirmed that maternal body weight both 
before and during pregnancy influence birth weight. 
 
In accordance with our study, many investigators reported similar associations between 
pre-pregnancy BMI and birth weight. Fleten et al21 reported a direct association 
between BMI and birth weight among 43,705 Norwegian mothers. The authors 
concluded that a one-unit increase in BMI resulted in a 20.3 gram increase in birth 
weight. Moreover, a study among 292,568 singleton term Chinese pregnancies, 
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pre-pregnancy underweight was associated with an increased risk of delivering a LBW 
infant (OR 1.9, 95%CI 1.3-1.6), while overweight and obese women had a 2.5- and 
3.5-fold of giving birth to a macrosomic infant, respectively.5 The association between 
BMI and birth weight can be related to several explanations: 1) protein-energy 
availability; 2) micronutrient intakes; and 3) plasma volume. Fetuses of low 
pre-pregnancy weight women may receive inadequate nutrients from the mothers and 
hence the growth of the fetus is restricted.22 Previous evidence showed that 
micronutrient deficiencies which are common in developing countries contributed to 
intrauterine growth restriction (IUGR). Increased micronutrient intakes leads to an 
increase in infant birth size and a reduction of IUGR in low pre-pregnancy BMI 
women.23 Moreover, underweight women have smaller plasma volume compared to 
normal or overweight women. A low plasma volume leads to a low cardiac output. 
Consequently, a low cardiac output may result in a low utero-placental blood flow and 
thus a decrease in nutrient transfer from the mothers to the fetuses in underweight 
women.24 However, in the present study, a significant relationship between 
pre-pregnancy BMI and LBW disappeared in the adjusted regression model. This might 
be due to the reason that other pregnancy complications, such as preeclampsia, play a 
stronger role in explaining LBW in this population.  
 
Consistent with other reports, when GWG was taken into consideration, women who 
gained weight excessively during pregnancy showed a higher risk of having 
macrosomic babies when compared to women with normal GWG. In addition, a 
systematic review of the effect of maternal weigh gain during pregnancy on birth 
weight confirmed our findings that excessive GWG increased risk of high birth weight 
in normal and obese pregnant women.25 However, due to limited sample size, we were 
not able to categorize our population by both pre-pregnancy weight and GWG 
simultaneously.  
 
Although the international BMI cut-off points have been recommended and widely used 
as a tool for assessing individual nutritional status,26 an appropriate cut-off points for 
Asian population is still controversial. Some evidence showed that Asians generally have 
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a higher percentage of body fat than Europeans and the risks of type 2 diabetes and 
cardiovascular disease is substantial among Asians at BMI lower than the WHO cut-off 
point of 25 kg/m2. Therefore, this information calls for redefining a different BMI 
classification for a different ethnic population. Unfortunately, there is not sufficient data 
to date to support this hypothesis and indicate an explicit BMI cut-off for Asian 
population. Therefore, the WHO expert consultation recommended to continue using 
an international BMI cut-off.19        
 
Despite the fact that a lot of studies investigated the determinants of birth weight, a few 
studies assessed the effect of macro and micronutrient status simultaneously. 
Micronutrient deficiencies such as iron deficiencies have been known to be related to 
LBW.27,28 In this study, we were able to consider the effects of both macro and 
micronutrient status on birth weight by adjusting for anemia (Hb concentrations) in the 
data analysis models. In addition, since this is a secondary analysis of data obtained 
from an RCT with iodine supplementation, treatment group was also included as a 
co-variate in both binary and multinomial logistic regression models.   
              
In conclusion, our findings from the present study confirmed the strong association 
between pre-pregnancy BMI and GWG, and adverse birth outcomes. Therefore, women 
should be advised to maintain appropriate body weight before and during pregnancy in 
order to prevent any detrimental effects on pregnancy outcomes.  
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Mild-to-moderate iodine deficiency (ID) in pregnant women still remains a public 
health problem in many regions of the world including Thailand. The latest report on 
urinary iodine concentration (UIC) monitoring among pregnant Thai women displays 
the current situation, showing that pregnant women in 31 out of 77 provinces have a 
median UIC <150 µg/L, and 46.4% of pregnant women are estimated to live with 
mild-to-moderate ID (MOPH 2013). Globally, the health consequences of all degrees of 
ID in pregnancy have been acknowledged, ranging from increased risk of stillbirths, 
thyroid dysfunction of the mothers and neonates, as well as compromised 
neurocognitive development of the child (Hetzel 1983). These severe health 
consequences call for an effective strategy to correct and prevent ID in pregnant 
women, and iodine supplementation could be an effective solution. Currently, iodine 
supplementation is widely recommended in order to control ID in areas where salt 
iodization cannot adequately be implemented (WHO/UNICEF 2007). However, although 
several randomized trials with maternal iodine supplementation studies have been 
conducted in mildly ID areas, the efficacy and safety of iodine supplementation during 
pregnancy remains uncertain (Zimmermann 2004). 
 
In order to get clarity on the efficacy and safety of iodine supplementation in pregnancy 
in areas where low iodine intake is of mild to moderate health concern, we undertook 
the largest randomized controlled trial (RCT) to date. In this trial, we have evaluated the 
effects of daily intake of a 200 µg iodine supplement in mild-to-moderate ID pregnant 
Thai women on safety and long-term outcomes including newborn development at 
early stage of life. 
 
In the next sections, the main findings of this thesis are summarized, methodological 
issues and results are discussed in a broader perspective. Furthermore, implications for 
public health and future research are given.   
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6.1 Main findings 
 
The main findings of this thesis are summarized in Table 6.1. 
 
In a pilot study comprising 302 pairs of pregnant mothers and their school-aged 
children, we found that pregnant Thai women in the Bangkok area are indeed facing 
mild ID with a median UIC of 108 µg/L. In contrast, median UIC of their school-aged 
children living in the same household was 200 µg/L, indicating optimal iodine status. 
According to the recommendation of WHO/UNICEF/ICCIDD (WHO/UNICEF/ICCIDD 
2007), median UIC in school-aged children is commonly used as an indicator of iodine 
status of the general population in surveys. Therefore, we concluded that the median 
UIC in school-aged children does not reflect iodine status in pregnant women and 
pregnant women should be monitored seperately in iodine status surveys (chapter 2). 
 
As in most emerging economies, overweight and obesity is on the rise in Thailand. In a 
cross-sectional analysis of data collected at baseline for the RCT, we found that 26% of 
the participating pregnant women had entered their pregnancy either with overweight 
or being obese. In addition, maternal body mass index (BMI) was negatively associated 
with free thyroxine (fT4), and overweight pregnant women had a 3.6-fold higher risk 
of hypothyroxinemia in the first trimester when compared to normal weight women. 
This finding calls for attention to achieving appropriate maternal weight in preparation 
for pregnancy (chapter 3). 
 
As compared to placebo, iodine supplementation during pregnancy did not significantly 
improve maternal thyroid function and newborn development in our study population 
of 511 mild-to-moderate iodine-deficient pregnant women. However, the iodine 
supplementation modestly improved the percentage of newborns with low birth weight 
and preterm birth, and significnatly reduced risk of maternal postpartum thyroiditis. 
Moreover, only a few women in the iodine supplementation group had excessive intake 
as indicated by a median UIC >500 µg/L, and there were no detrimental effects on 
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maternal or newborn thyroid function. Therefore, daily iodine supplementation with 
200 µg of iodine during pregnancy can be considered to be safe (chapter 4). 
  
Pre-pregnancy body mass index (BMI) and weight gain during pregnancy were 
previously shown to be associated with pregnancy outcomes (Doherty 2006, Kiel 2007), 
and our results from a secondary data analysis confirmed this phenomenon. 
Overweight/obese (BMI≥25 kg/m2) mothers had an 11-fold higher risk of having 
newborn with macrosomia. Pregnant women who had excessive GWG were 5.6 times 
as likely to deliver babies with macrosomia. These findings stress the importance of 
maintaining normal body weight before and throughout pregnancy (chapter 5).  
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Table 6.1 Main findings of the studies described in this thesis 
 
Chapter Study design Population Objectives Main findings 
2 Cross-sectional 302 pairs of 
pregnant Thai 
mothers 
and their school- 
aged children 
To assess if UIC in 
school-aged 
children is 
indicative for 
iodine status of 
pregnant women. 
UIC was 108 µg/L in pregnant 
women and 200 µg/L in their 
children. Measurement of UIC 
in school-aged children should 
not be uesd for monitoring 
iodine status in pregnancy. 
3 Cross-sectional 514 pregnant Thai 
women in the first 
trimester of 
preganacy 
To assess 
determinants of 
maternal thyroid 
dysfunction. 
Overweight pregnant women 
have a 3.6-fold higher risk of 
hypothyroxinemia in the first 
trimester compared to normal 
weight women. 
4 Randomized , 
double-blind, 
placebo- 
controlled 
511 pregnant Thai 
women with 
mild-to-moderate 
ID at baseline 
To evaluate the 
effects of daily 
iodine (200 µg KI) 
supplementation 
in pregnant 
women on thyroid 
function, 
pregnancy 
outcomes and 
newborn 
development. 
No effects on maternal thyroid 
function and infant 
performance, but women in the 
iodine group were less likely to 
develop postpartum thyroiditis.  
Supplementation of 200 µg 
iodine daily in mildly ID 
pregnant women was safe.  
5 Secondary data 
analysis 
378 pairs of Thai 
mothers and their 
newborns  
To investigate the 
relationship 
between 
pre-pregnancy 
BMI, weight gain 
during pregnancy 
with pregnancy 
outcomes. 
Overweight/obese mothers had 
an 11-fold higher risk of 
having macrosomic infant. 
Women who had excessive 
GWG were 5.6 times as likely to 
deliver babies with 
macrosomia. 
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6.2 Overall methodological considerations 
 
In this part of the thesis, methodological aspects that may influence the results and 
interpretation of the study are critically discussed.         
 
6.2.1 Pilot study 
 
To verify iodine deficiency (ID) situation among pregnant Thai women, a 
cross-sectional study was conducted as a pilot project in Bangkok and in a nearby 
province. In addition to assessing the median UIC of pregnant women in the target 
population for our later RCT, we also aimed to investigate whether the presence of ID in 
school-aged children assessed with a cutoff of median UIC <100 µg/L is indicative for 
ID in pregnant women. Because 50% of iodine requirement increased during 
pregnancy, a median UIC cutoff for school-aged children seems to be an inappropriate 
value for pregnant women. For this, we recruited pregnant women who registered at 
the antenatal clinic in three hospitals (Ramathibodi and Rajavithi Hospital in Bangkok, 
and Putthamonthon Hospital in Nakhon Pathom) and three factories in the city suburbs 
with their school-aged children living in the same household.  
 
Our findings in Chapter 2 show that, although the mothers and their school-aged 
children lived in the same household and share meals together, median UIC of 
school-aged children was twice that of pregnant mothers. This strengthens the idea that 
using median UIC in school-aged children is inappropriate to assess iodine status of 
pregnant women. Some children participating in the pilot study took part in a school 
feeding program and this may have introduced iodine in their meals outside the home. 
UIC measurements were performed with the greatest care in the laboratory of INMU, 
which is participating in the EQUIP quality control program of the CDC, Atlanta, USA.  
 
Since the study population consisted of a convenience sample from the Bangkok area, 
median UIC in mothers and children in this study cannot be extrapolated to the total 
Thai population. Moreover, our findings could have been strengthened if other 
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biochemical indicators such as thyroid function would also have been measured. Taking 
all these points into consideration, we can conclude that our pilot study does not 
provide definite evidence for the inadequacy of using UIC in school-aged children as a 
means to monitor iodine status of pregnant women. Our findings should be 
corroborated with studies in other settings and in nationally representative ID 
monitoring surveys.    
 
6.2.2 Randomized controlled trial (RCT) 
 
6.2.2.1 Sample size  
 
At the time of writing the study protocol, we did not have a good estimate of 
concentrations of thyroid function indicators in pregnant women in Thailand, or of 
what magnitude of change to expect with iodine supplementation. Therefore, sample 
size was first calculated based on an anticipated decrease from 10% in the control to 2% 
with treatment in the prevalence of elevated newborn TSH (>10 mIU/L at postnatal days 
2-4) with treatment. During recruitment, the sample size was increased arbitrarily to 
over 250 women per treatment group in view of the anticipated high dropout rate at 
first follow-up. It can therefore be argued that the sample size has not been appropriate 
in view of the primary objective of the study. However, the present study is by far the 
largest iodine supplementation trial in mild-to-moderate iodine deficient pregnant 
population to date, and when effects have been missed these will likely have been small.   
 
6.2.2.2 Participants  
 
In view of the large number of pregnant women that had to be enrolled into the study, 
as well as the multitude of data and indicators to collect from both mothers and their 
children, we decided to conduct the study in the large hospital (Ramathibodi hospital) of 
Mahidol University in Bangkok. In this hospital, we would be able to recruit the 
required number of participants and also had confidence that all participants would be 
under the capable supervision of medical doctors and nursing staff. We had previously 
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confirmed in the pilot study that iodine status of pregnant women attending the 
antenatal clinic in this hospital was in the mild deficient range (Gowachirapant 2009). 
However, women in our study were for instance relatively high educated and are not 
representative for pregnant women in Thailand in general. Outcomes of the study may 
have shown a different picture in case the study would have been conducted in a more 
deprived area. 
  
6.2.2.3 Randomization and blinding 
 
Randomization 
To avoid any imbalance in baseline study population characteristics in our randomized 
controlled trial (RCT), participants were randomly divided into two treatment arms 
(iodine and placebo group). A simple randomization method was used, implying that 
each day of recruitment when the exact number of eligible pregnant women was 
known, an equivalent number of lots with alphabet “A” or “B” were prepared. By picking 
the lots, pregnant women were assigned to the two intervention groups. We can 
conclude that the randomization had been successful, since indicators at baseline did 
not differ between the two intervention groups. Furthermore, randomization was 
sustained throughout the study since we did not see any selective dropout at any 
timepoint of data collection. 
 
Blinding  
The study was conducted in a double-blind manner, with all subjects and field staff 
being blinded to study treatment. Also those involved in biochemical and data analysis 
up to the primary investigator was blinded to study treatment. 
        
6.2.2.4 Dosage 
 
Various doses of iodine (ranged 50–230 µg/day) have been used in iodine 
supplementation studies among European pregnant women. In 1991, Romano et al 
(Romano 1991) gave 120-180 µg iodine daily to healthy pregnant Italian women. Two 
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years later, in 1993, Pedersen et al (Pedersen 1993) used the dose of 200 µg iodine in 
their study. Half the dose used by Pedersen (100 µg iodine) was supplemented to 
Belgian pregnant women in 1995 (Glinoer 1995), while, in 1996, a high dose of iodine 
(230 µg) was used in the study of Liesenkotter et al (Liesenkotter 1996). In 2000, Nohr 
et al (Nohr 2000) gave a multinutrient supplement containing 150 µg iodine to 
pregnant Danish women who had positive TPO-Abs. Finally, among Italian pregnant 
women, a dose of 50 µg or 200 µg iodine was selected for supplementation in the study 
of Antonangeli et al (Antonangeli 2002). However, from all these intervention studies, 
the safe dose of iodine supplementation in pregnant women remains unclear.         
  
We based our treatment dose of 200 µg of iodine per day on the recommendation of 
WHO/UNICEF/ICCIDD that optimal daily iodine intake in pregnant women is 250 
µg/day (WHO/UNICEF/ICCIDD 2007) and assumed that participants could cover the 
remaining need of iodine (50 µg) from their food. Although we did not estimate iodine 
intake of pregnant women in this study, based on UIC in the iodine supplemented group 
we calculated that their intake at the end of the supplementation period was 380 
µg/day, hence was in the adequate iodine intake range. In addition, we did not detect 
any adverse effects of the supplementation dose of 200 µg of iodine per day during 
pregnancy in our study.   
   
6.2.2.5 Ethics 
 
In 2008, the year when this RCT started, iodine supplementation in pregnancy was not 
a policy in Thailand and depended on decision of the obstetricians/gynecologists. In 
general, pregnant women who were at risk of ID, were indicated by interview on 
thyroid disease history, before being supplemented with iodine. For this reason, the 
study protocol was approved by the ethical committee both at Ramathibodi hospital in 
Thailand and at Wageningen University in the Netherlands. However, in order to ensure 
that all pregnant women would receive an adequate amount of iron and folate, we 
decided to give them a multi-vitamin and -mineral (without iodine) until delivery. 
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6.2.2.6 Outcomes 
 
(1) Urinary iodine concentration (UIC) 
 
Since median UIC in the iodine group increased significantly into the adequate range in 
our study, we can conclude that the intervention has been successful. The increase was 
larger in the iodine group when compared to placebo. However, a rise of UIC was also 
found in the placebo group, which may either have been caused by an increase of renal 
clearance over pregnancy (Delange 2004), or by increased awareness about the 
importance of iodine in the entire study population. We have not monitored iodized salt 
use habits throughout the study, and dietary intake data have not yet been analyzed.  
      
(2) Thyroid function 
 
Iodine is an important precursor for thyroid hormone production in the thyroid gland, 
such as thyroxine (T4) and triiodothyronine (T3), which are crucial regulators of the 
metabolic rate and physical and mental development in humans. In the present study, 
seven thyroid function parameters were measured including total and free thyroid 
hormones (TT4, fT4, TT3, fT3), thyroid-stimulating hormone (TSH), thyroglobulin (Tg) 
and anti-thyroid peroxidase antibodies (TPO-Abs). Free T4 is an effective thyroid 
hormone which influences the brain development of newborn, while TT4, TT3 and fT3 
are indirect indicator of iodine status. TSH and Tg are effective indicator of thyroid 
stimulation. In addition, TPO-Abs was also measured because it can be used as indicator 
of iodine supplementation safety. With this, we have covered all relevant thyroid status 
indicators. 
 
However, since there are no (trimester) specific cutoffs of these parameters for pregnant 
women, except for TSH and TT4, we have used the reference ranges provided by the 
assay manufacturer (IMMULITE 2000, SIEMENS, Germany) for all other parameters. 
Although this was the best we could do with current knowledge, this may have led to 
some misclassification.   
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For defining thyroid dysfunction, usually TSH and fT4 concentrations of individuals are 
considered (Helfand 1998). Since no reference fT4 cutoff for pregnant women has been 
defined to date, we sought the advice of an expert in thyroid disease who suggested 
using TSH and TT4 concentrations for assessing the prevalence of thyroid dysfunction 
in pregnancy accurately. At post-delivery, we have applied the usual TSH and fT4 
cutoffs for non-pregnant women.  
        
(3) Thyroid volume 
 
Although normative values of thyroid volume in healthy adults and school-aged 
children have been formulated, thyroid volume is only a proper indicator for long-term 
ID and responds slowly to changes in iodine intake. Therefore, we did not see any 
changes in thyroid size of our participants during the study. Furthermore, according to 
the normative value of healthy adults’ thyroid volume (8.0-18.0 ml) provided by 
WHO/UNICEF/ICCIDD since 1993 (WHO/UNICEF/ICCIDD 1993), none of the 
participants in our study had an enlarged thyroid gland. However, when the upper 
value is reduced from 18.0 to 12.0 ml (WHO/UNICEF/ICCIDD 2007), only 4%, 3.3% 
and 3% of the women with thyroid volume above the cutoff was reported at baseline, 
2nd and 3rd trimester, respectively.                
  
Measuring infants’ thyroid volume was challenging, since it required expensive 
equipment and electricity. In addition, it has to be done under supervision of an 
experienced radiologist. Therefore, we had quite some missing data for this indicator. 
However, little data on infant’s thyroid volume have been published to date, and 
normative thyroid volume for healthy infants are still lacking. Our data can add to 
defining such normative values.       
   
(4) Newborn development 
 
Several studies have reported that ID during pregnancy induces irreversible impairment 
of newborn development (Pharoah 1984, Pop 1999, Delange 2001, Pop 2003, Kooistra 
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2006). Therefore, in this study, we also aimed to investigate the effects of iodine 
supplementation on newborn development at 6 weeks after birth and during the 
follow-up period (1 and 2 years). In order to get that information, two child 
development test tools were applied. For 6-week old newborns, the Neonatal Behavioral 
Assessment Scales (NBAS) was used, while the Bayley Scales of Infant Development 
(BSID) was tested at 1 and 2 years (results not reported in this thesis). 
 
The Neonatal Behavioral Assessment Scale (NBAS) focuses on the newborn’s capacity to 
control levels of stimulation using states of consciousness when adapted to the 
environment. The NBAS scores were reduced to the following 7 clusters: 1) habituation; 
2) orientation; 3) motor; 4) range of state; 5) regulation of state; 6) autonomic stability; 
7) reflexes, and include extra supplementary items. However, although this test seems to 
be an easy tool and has even been conducted in small babies, it was often quite 
challenging to collect complete scores because infants were often out of control. For 
instance, one set of the test (habituation) had to be done while the infant was sleeping 
but we could not force the newborns to sleep at the time of testing. This has led to a 
substantial number of missing data in the newborn development assessment.  
     
6.2.2.7 Dropout and compliance 
 
Dropout 
In general, dropout was rather high in the study (41% until 6 weeks post-delivery). 
There are two important reasons for this. First, a high number of dropouts occurred 
between delivery and the appointment at 6 weeks after delivery. Although all 
participating pregnant women were requested to reside in the area for the duration of 
the study (3 years) since at the beginning of the study, most of the women originally 
came from other provinces in Thailand, once they give birth, they moved back to their 
hometown to leave the children with their grandparents, according to Thai tradition 
with infants born in an urban area. Second, due to the women have their own health 
insurance at the hospital that is closest to their house, therefore, it is more convenient 
for them to re-register at those hospital for delivery. However, the number of dropouts 
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in the study was similar in both intervention groups. Therefore, we are confident that 
the dropout was not caused by the study treatment itself, and therefore inferences still 
can be made. 
 
Compliance 
One of the important issues in (biomedical) human studies is compliance assessment 
since it can refer to an awareness of participants and a success of the intervention study. 
Although there are many techniques for assessing compliance during an intervention 
study, two simple techniques were selected to use in this RTC. First, we directly 
measured the compliance by counting tablets returned after delivery. However, this 
method is limited by dependency on the women to return the exact number of unused 
tablets to us. Moreover, due to the high dropout rate, this measure does not provide us 
with a reliable estimate of compliance. Second, we used UIC measurement to assess 
compliance indirectly. Although this measure cannot be used as an individual tool, it 
reflects recent iodine intake of the study population groups. In the present study, we 
found a clear increase in UIC in the iodine group, indicating that iodine supplements 
were taken in by study participants.  
       
6.2.2.8 Data analysis (per protocol / per intention-to-treat)  
 
Although our trial was well planned and carefully conducted, as with any RCT many 
unexpected problems occurred during the study. In our data analysis plan, we planned 
to analyze the data per protocol.  
 
For this, we compared both treatment groups including only those participants that met 
all inclusion and exclusion criteria and with known adherence to treatment (Shah 
2011). This would reflect the maximal potential benefits to be expected from iodine 
supplementation. However, per protocol analysis can be biased due to exclusion of 
participants threatening the original comparability of the treatment groups at baseline 
characteristics, which may result in confounding (Sedgwick 2013). Due to the large 
number of women without known compliance data, per protocol analysis led to 
CHAPTER 6 
132 
exclusion of a large number of women. Therefore, sticking to the original plan of per 
protocol analysis would threaten the internal validity of the study.  
 
Intention-to-treat (ITT) analysis is a comparison of the treatment groups that includes 
all patients as originally allocated after randomization (Shah 2011). ITT analysis ignores 
noncompliance, protocol deviations, withdrawal, and anything that happens after 
randomization and maintains prognostic balance generated from the original random 
treatment allocation (Gupta 2011). However, missing data is a limitation of this method, 
which can be solved using imputation techniques when appropriate. 
  
In our study, both per protocol and ITT analysis were used (Table 4.2a and 4.2b) to 
compare the effects of iodine supplementation on maternal thyroid function. The results 
of data analysis did not differ between the two analysis methods except for fT4. In the 
per protocol analysis (Table 4.2a), a marginal significant difference in fT4 concentration 
between the treatment groups was detected, which disappeared in the ITT analysis 
(Table 4.2b). In per protocol analysis, a significantly larger number of women in the 
iodine group were found to have high TPO-Abs after delivery as compared to the 
placebo group. This difference also disappeared fully in ITT analysis. A higher number 
of participants in the ITT analysis when compared to per protocol analysis could be one 
possible explanation for this consequence. In retrospect, in view of the limitation 
regarding high dropout and lack of compliance data, we consider ITT as the preferred 
analysis method for our study. Therefore, we have based our conclusions on ITT analysis 
in order to avoid any bias of the results.              
 
6.3 Implications for public health 
 
Although our pilot study had a small sample size (302 pairs of mother and their 
school-aged children) and was not representative for the nation as a whole, publication 
of the results of our study has led to several other studies investigating the association 
between UIC in pregnant women and school-aged children. In 2012, Vandevijvere et el 
(Vandevijvere 2012) conducted a cross-sectional study and aimed to investigate 
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whether the median UIC among Belgian school-aged children reflects the iodine status 
of their nonpregnant mothers. They found a low median UIC in both school-aged 
children (113.1 µg/L) and their mothers (84.4 µg/L). The authors also concluded that 
the median UIC in children may not be an adequate surrogate measure of adults' iodine 
status and the monitoring iodine status should not be limited to children, but should be 
extended to women of child-bearing age. A study of Wong et al (Wong 2011) among 
8,622 pregnant Chinese women and 16,844 school-aged children also confirmed this: 
median UIC of school-aged children indicated adequate iodine intake, while inadequate 
iodine status in pregnant women was reported. In addition to our study, these reports 
led to wider attention to the direct monitoring of iodine status in pregnancy.      
 
Our findings from the RCT confirm that iodine supplementation with 200 µg/day in 
mildly iodine-deficient pregnant women is safe because only a few women had 
UIC >500 µg/L, indicating iodine excess, after the intervention from 11 weeks to term. 
Moreover, the intervention could also reduce postpartum thyroiditis of the women in 
the iodine supplemented group. This finding is important, since iodine supplementation 
in pregnancy is common practice in some countries for many years. In Thailand, for 
example, the Ministry of Public Health (MOPH) launched an iodine supplementation 
program for Thai pregnant women in October 2010, recommending two types of daily 
iodine tablets: 1) triferdine150 (iodine, iron and folate); 2) Iodine GPO150 (only iodine) 
for pregnant women having thalassemia. Based on the research described in this thesis, 
the recommendation of iodine supplementation in mild-to-moderate ID pregnant 
women living in areas where salt iodization is not adequately covered can be sustained.  
 
6.4 Future research 
 
As presented in Chapter 1, two large RCT of iodine supplementation studies in Thailand 
and India with a similar protocol and objectives were started in 2008. Therefore, we 
expect that further data analysis in the mothers and their children over the first two 
years will provide more additional information of iodine supplementation on maternal 
benefits or improvement in child development at later ages. Furthermore, the results 
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from another study site in India, where the mothers have adequate iodine intake 
indicated by median UIC >150 µg/L at the beginning of the study, are currently being 
analysed to determine the effects of daily iodine supplementation and to see whether 
those results support the findings of this study. Moreover, until now, information on the 
coverage of iodine tablets use during pregnancy in Thailand is still lacking. Monitoring 
of this program among pregnant Thai women including assessment of thyroid function 
can provide further evidence for future iodine supplementation planning.  
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Iodine deficiency (ID) during pregnancy remains a major global public health concern. 
WHO recommends that monitoring of iodine status in populations be done by assessing 
urinary iodine concentrations (UIC) of school-aged children and it is often assumed this 
will also reflect iodine status of pregnant women.  
 
Mild-to-moderate ID is not only of concern in developing countries such as Thailand, 
but mild ID has also reoccurred in several industrialized countries. In order to address 
adverse health effects of ID during pregnancy both for the mother and their children 
including offsprings’ neurocognitive development, daily iodine supplementation in 
pregnancy is widely recommended. However, the long-term benefits and safety of 
routine iodine supplementation in mild-to-moderate ID pregnant women is uncertain.  
 
Due to economic growth and changes in lifestyle of people, overweight and obesity is 
increasing in Thailand. In pregnancy, adiposity may have a negative impact on thyroid 
function, pregnancy and birth outcomes. 
 
In order to investigate these issues, a pilot study was carried out in which UIC of 
pregnant women and their school-aged children were assessed. Subsequently, an RCT 
was conducted with 200 µg iodine per day in mildly ID pregnant Thai women between 
October 2008 and June 2013. The overall aim was to evaluate the effects of iodine 
supplementation during pregnancy on maternal thyroid function, birth outcomes and 
newborn development up till 6 weeks postpartum. In addition, effect of pre-pregnancy 
weight and weight gain during pregnancy on maternal thyroid function and pregnancy 
outcomes was assessed.  
 
In Chapter 2, a cross-sectional study of UIC measurement among 302 pairs of pregnant 
mothers and their school-aged children in Bangkok and nearby provinces is described. 
It showed that although the school-aged children lived in the same household with the 
mothers, their median UIC (200 µg/L) was adequate and almost twice as high as 
compared to their mothers’ median UIC (108 µg/L) indicating mild ID. This finding 
confirms that UIC in school-aged children was not indicative for iodine status of their 
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pregnant mothers. Hence, iodine status in pregnant women should be monitored 
separately. 
 
Overweight during pregnancy can have various adverse health consequences. In 
Chapter 3, we used the baseline data of our RCT and determined the relationship 
between pre-pregnancy body mass index (BMI) and thyroid dysfunction in early 
pregnancy. In this cross-sectional study, we used the Asian BMI classification by which 
overweight was defined as BMI ≥23 kg/m2, which is lower when compared to 
international BMI cutoff for overweight (≥25 kg/m2). We found that overweight 
pregnant women with mild-to-moderate ID had a 3.6-fold higher risk of 
hypothyroxinemia in the first trimester. These findings suggest that not only morbidly 
obese women (BMI ≥40 kg/m2), but also overweight women in ID areas should be 
screened for thyroid dysfunction. 
 
In the RCT (Chapter 4), 200 µg of iodine (KI tablets) or placebo was supplemented daily 
to 511 mildly ID pregnant women from <14 weeks of gestation until delivery. In this 
study, iodine supplementation did not benefit thyroid function, thyroid volume, birth 
outcomes or NBAS score of newborns, but it did significantly increase UIC and reduce 
the prevalence of postpartum thyroid dysfunction in mothers. Moreover, since only a 
few women in the study population had a UIC >500 µg/L indicating iodine excess, and 
there were no detrimental effects on thyroid function of the mother or newborn, we can 
conclude that supplementation with 200 µg iodine per day in mildly ID pregnant 
women is safe.           
 
In Chapter 5, in a secondary analysis of data from the above RCT, pre-pregnancy BMI 
and weight gain during pregnancy were considered as possible predictors of negative 
pregnancy outcomes. We found that newborns born to overweight/obese (BMI≥25 
kg/m2) mothers had an 11-fold higher risk for macrosomia. Moreover, pregnant 
women with excessive GWG were 5.6 times more likely to deliver babies with 
macrosomia. These findings underline the importance of maintaining normal body 
weight before and during pregnancy should be recommended. 
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Finally, the main findings of the research described in this thesis are summarized and 
overall methodological considerations are discussed in Chapter 6. This also includes the 
implications for public health and future research are also presented. 
 
In conclusion, this study is the largest RCT of iodine supplementation in mildly ID 
pregnant women that has been done to date. The results indicate that maternal iodine 
supplementation is safe and effective in normalizing iodine intake of the mothers, but 
this findings should not be generalized to all Thai regions due to the differences of 
iodine status in rural and urban areas. Our findings suggest that routine iodine 
supplementation may not be necessary in mildly iodine-deficient pregnant women from 
areas with well-functioning, effective iodized salt program. This may be because 
adequate thyroidal iodine stores accumulated pre-pregnancy can contribute to iodine 
requirements during pregnancy. Furthermore, body weight of pregnant women 
(especially overweight) should be monitored, since this associated with thyroid 
dysfunction and unfavourable birth outcomes.  
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Jodiumtekort (ID) tijdens de zwangerschap is nog steeds een belangrijk wereldwijd 
volksgezondheidsprobleem. De WHO adviseert om de jodiumstatus in populaties te 
monitoren door middel van het bepalen van het jodiumgehalte in de urine (UIC) bij 
schoolgaande kinderen. Er wordt vaak aangenomen dat dit ook de jodiumstatus van 
zwangere vrouwen weerspiegelt. 
Mild tot matig jodiumtekort is niet alleen zorgwekkend in ontwikkelingslanden zoals 
Thailand, maar mild jodiumtekort komt ook voor in verschillende geïndustrialiseerde 
landen. Om de nadelige gezondheidseffecten van jodiumtekort tijdens de zwangerschap 
voor moeder en kind, als ook de neurocognitieve ontwikkeling van de nakomeling aan 
te pakken, wordt dagelijkse suppletie tijdens de zwangerschap algemeen aanbevolen. 
Echter, de voordelen op lange termijn en de veiligheid van routinematige jodium 
suppletie bij zwangere vrouwen met mild tot matig jodiumtekort zijn onduidelijk. 
Door de economische groei en leefstijlveranderingen zijn overgewicht en obesitas 
toegenomen in Thailand. Tijdens de zwangerschap zou adipositas in combinatie met 
jodiumtekort een negatieve invloed kunnen hebben op de schildklierfunctie, de 
zwangerschap zelf en de geboorte uitkomsten. 
Om deze kwesties te onderzoeken, werd een pilotstudie uitgevoerd waarbij UIC van 
zwangere vrouwen en hun schoolgaande kinderen werd onderzocht. Vervolgens werd 
tussen oktober 2008 en juni 2013 een gerandomiseerde, gecontroleerde trial (RCT) 
uitgevoerd met 200 μg jodium per dag bij zwangere Thaise vrouwen met mild 
jodiumtekort. Het hoofddoel van deze trial was het evalueren van de effecten van 
jodium suppletie tijdens de zwangerschap op maternale schildklierfunctie, geboorte 
uitkomsten en de ontwikkeling van de pasgeborene tot zes weken na de bevalling. 
Daarnaast werd het effect van het gewicht voor aanvang van de zwangerschap en 
gewichtstoename tijdens de zwangerschap op maternale schildklierfunctie en 
zwangerschapsuitkomsten onderzocht. 
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In Hoofdstuk 2, wordt een cross-sectionele studie beschreven waarin UIC is gemeten bij 
302 paren van zwangere moeders en hun schoolgaande kinderen in Bangkok en 
omliggende provincies. Het bleek dat, hoewel de schoolgaande kinderen in hetzelfde 
huishouden met de moeders woonden, hun mediane UIC (200 μg/L) voldoende en bijna 
twee keer zo hoog was in vergelijking met het mediane UIC van hun moeders (108 
μg/L), wat wijst op mild jodiumtekort. Deze bevinding bevestigt dat UIC van 
schoolgaande kinderen niet indicatief was voor jodiumstatus van hun zwangere 
moeders. Daarom moet jodiumstatus bij zwangere vrouwen apart onderzocht worden.  
Overgewicht tijdens de zwangerschap kan verschillende nadelige gevolgen voor de 
gezondheid hebben. In Hoofdstuk 3, hebben we de baseline gegevens van onze RCT 
gebruikt om de relatie te bepalen tussen body mass index (BMI) voor aanvang van de 
zwangerschap en schildklierafwijkingen in het begin van de zwangerschap. In deze 
cross-sectionele studie gebruikten we de Aziatische BMI-indeling waarbij overgewicht 
werd gedefinieerd als BMI ≥ 23 kg/m2, wat lager is in vergelijking met het 
internationale BMI-afkappunt voor overgewicht (≥ 25 kg/m2). Wij vonden dat 
zwangere vrouwen met overgewicht en mild tot matig jodiumtekort een 3,6-maal 
hoger risico hadden op hypothyroxinemie in het eerste trimester. Deze bevindingen 
suggereren dat niet alleen vrouwen met morbide obesitas (BMI ≥ 40 kg/m2), maar ook 
vrouwen met overgewicht in gebieden waar jodiumtekorten voorkomen, gescreend 
moeten worden op schildklierafwijkingen.  
In de RCT (Hoofdstuk 4), werden vanaf <14 weken zwangerschap tot aan de bevalling 
dagelijks supplementen met 200 μg jodium (KI tabletten) of placebo gegeven aan 511 
zwangere vrouwen met mild tot matig jodiumtekort. Uit deze studie bleek dat jodium 
suppletie niet de schildklierfunctie, het schildkliervolume, geboorte uitkomsten of NBAS 
score van pasgeborenen heeft bevorderd, maar dat het wel de UIC significant heeft 
verhoogd en de prevalentie van postpartum schildklierafwijkingen bij moeders heeft 
verlaagd. Aangezien slechts enkele vrouwen in de studiepopulatie een UIC > 500 μg/L 
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hadden, wat wijst op een teveel aan jodium, en er geen schadelijke gevolgen voor de 
schildklierfunctie van de moeder en de pasgeborene waren, kunnen we bovendien 
concluderen dat suppletie met 200 μg jodium per dag voor vrouwen met mild 
jodiumtekort veilig is. 
In Hoofdstuk 5, in een secundaire analyse van gegevens uit bovenstaande RCT, werden 
BMI voor aanvang van de zwangerschap en gewichtstoename tijdens de zwangerschap 
beschouwd als mogelijke voorspellers van negatieve zwangerschapsuitkomsten. We 
vonden dat pasgeborenen, geboren bij moeders met overgewicht of obesitas (BMI ≥ 25 
kg/m2), een 11-maal hoger risico op macrosomie hadden. Bovendien hadden zwangere 
vrouwen met overmatige gewichtstoename tijdens de zwangerschap 5,6 keer meer kans 
op baby’s met macrosomie. Deze bevindingen onderstrepen het belang van het 
handhaven van een normaal lichaamsgewicht voor en tijdens de zwangerschap.  
Tenslotte zijn in Hoofdstuk 6 de belangrijkste bevindingen van het onderzoek uit dit 
proefschrift samengevat en worden algemene methodologische overwegingen 
besproken. Dit hoofdstuk omvat ook de implicaties voor de volksgezondheid en 
toekomstig onderzoek.  
Tot besluit, deze studie is de grootste RCT van jodium suppletie bij zwangere vrouwen 
met mild jodiumtekort die tot nu toe is gedaan. De resultaten geven aan dat maternale 
jodium suppletie veilig en effectief is in het normaliseren van de jodiuminname van de 
moeders, maar deze bevindingen moeten niet gegeneraliseerd worden naar alle regio’s 
in Thailand vanwege de verschillen in jodiumstatus tussen rurale en stedelijke gebieden. 
Onze bevindingen suggereren dat routinematige jodium suppletie wellicht niet nodig is 
in zwangere vrouwen met mild jodiumtekort in gebieden met een goed functionerend, 
effectief gejodeerd zout programma. De reden hiervoor kan zijn dat adequate jodium 
voorraden in de schildklier, opgestapeld voor aanvang van de zwangerschap, kunnen 
bijdragen aan de jodiumbehoefte tijdens de zwangerschap. Bovendien dient het 
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lichaamsgewicht van zwangere vrouwen (vooral vrouwen met overgewicht) 
gecontroleerd te worden, omdat dit geassocieerd is met schildklierafwijkingen en 
ongunstige geboorte uitkomsten.  
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การขาดธาตุไอโอดีนในระหว่างตั้งครรภ์ยงัคงเป็นปัญหาสาธารณสุขท่ีส าคัญระดับโลก ดว้ยเหตุน้ี 
องคก์ารอนามยัโลก (World Health Organization, WHO) จึงแนะน าใหต้รวจติดตามภาวะไอโอดีนของ
กลุ่มประชากรทัว่ไปโดยการตรวจวัดปริมาณไอโอดีนในปัสสาวะของเด็กวยัเรียน และคาดการณ์ว่า
วิธีการดงักล่าวจะสามารถสะทอ้นถึงภาวะไอโอดีนของหญิงตั้งครรภไ์ด ้  
 
การขาดธาตุไอโอดีนระดบัไม่รุนแรงถึงปานกลาง (mild-to-moderate iodine deficiency) ไม่เพียงแต่
เป็นปัญหาในประเทศก าลังพฒันาอย่างประเทศไทย แต่ก าลงัยอ้นกลบัมากลายเป็นปัญหาในประเทศ
อุตสาหกรรมหลายๆประเทศในปัจจุบัน ทั้งน้ีเพื่อเป็นการป้องกนัปัญหาสุขภาพต่างๆจากการขาดธาตุ
ไอโอดีนในระหว่างตั้งครรภท่ี์อาจเกิดขึ้ นกบัทั้งมารดาและบุตร รวมไปถึงพฒันาการทางสติปัญญาของ
ลูกหลานรุ่นต่อไป จึงมีค าแนะน าอย่างแพร่หลายในการใหย้าเม็ดไอโอดีนเสริมส าหรับหญิงตั้งครรภ ์
อย่างไรก็ตาม ประโยชน์และความปลอดภัยจากการไดร้ับยาเม็ดไอโอดีนเสริมในหญิงตั้งครรภ์ท่ีมี
ภาวะการขาดธาตุไอโอดีนระดบัไม่รุนแรงถึงปานกลางยงัขาดความชดัเจน  
 
เน่ืองดว้ยภาวะทางเศรษฐกิจท่ีเติบโตอยา่งรวดเร็ว ประกอบกบัรูปแบบการด าเนินชีวิตท่ีเปล่ียนแปลงไป 
ส่งผลใหป้ระเทศไทยก าลังประสบกบัปัญหาประชากรท่ีมีน ้าหนักเกินและอว้นเพิ่มมากขึ้ น โดยเฉพาะ
ภาวะไขมนัในร่างกายสงูในหญิงตั้งครรภซ่ึ์งอาจส่งผลกระทบเชิงลบต่อการท างานของระบบต่อมไทรอยด ์
รวมไปถึงผลของการตั้งครรภต่์างๆและสุขภาพของบุตรดว้ย 
 
ดังน้ัน เพื่อเป็นการตรวจสอบประเด็นปัญหาต่างๆขา้งตน้ จึงด าเนินงานการวิจยัน าร่องเพื่อตรวจวัด
ปริมาณไอโอดีนในปัสสาวะของทั้งมารดาท่ีก าลงัตั้งครรภแ์ละบุตรท่ีอยูใ่นวยัเรียน หลงัจากน้ัน จึงท าการ
วิจยัหลกัซ่ึงเป็นการวิจยัเชิงทดลองแบบสุ่มและมีกลุ่มควบคุม (randomized controlled trial, RCT) ดว้ย
การใหย้าเม็ดไอโอดีนเสริมในปริมาณ 200 ไมโครกรมัต่อวนั ส าหรบัหญิงตั้งครรภช์าวไทยท่ีมีภาวะการ
ขาดธาตุไอโอดีนระดับไม่รุนแรง ระหว่างเดือนตุลาคม 2552 ถึงเดือนมิถุนายน 2557 โดยมี
วตัถุประสงคเ์พื่อประเมินผลของการไดร้บัยาเม็ดไอโอดีนเสริมในระหว่างตั้งครรภ ์ต่อระบบการท างาน
ของต่อมไทรอยด ์ผลของการตั้งครรภข์องมารดา รวมถึงการคลอดบุตร และพฒันาการของบุตรเมื่ออายุ
ครบ 6 สปัดาห ์นอกจากน้ัน ยงัศึกษาผลของน ้าหนักตัวก่อนตั้งครรภแ์ละการเพิ่มน ้าหนักตวัระหว่าง
ตั้งครรภข์องมารดาต่อระบบการท างานของต่อมไทรอยด ์และการตั้งครรภข์องมารดาดว้ย 
 
บทท่ี 2 เป็นรายงานผลจากการศึกษาแบบภาคตดัขวาง (cross-sectional study) โดยท าการตรวจวดั
ปริมาณไอโอดีนในปัสสาวะของคู่มารดาท่ีก าลังตั้งครรภแ์ละบุตรวยัเรียน จ านวน 302 คู่ ในพื้ นท่ี
กรุงเทพมหานครและจงัหวดัใกลเ้คียง ผลการศึกษาแสดงใหเ้ห็นว่า แมว้่าบุตรวยัเรียนจะอาศยัอยูใ่นบา้น
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เดียวกนักบัมารดาท่ีก าลงัตั้งครรภ ์แต่ค่ามธัยฐานของปริมาณไอโอดีนในปัสสาวะ (200 ไมโครกรมัต่อ
ลิตร) บ่งช้ีว่ามีระดบัไอโอดีนในร่างกายท่ีเพียงพอ และสูงกว่ามารดาเป็นสองเท่า (108 ไมโครกรมัต่อ
ลิตร) ซ่ึงบ่งช้ีถึงภาวะการขาดธาตุไอโอดีนระดับไม่รุนแรงของมารดา ผลการศึกษาน้ียืนยนัว่า การ
ตรวจวดัปริมาณไอโอดีนในปัสสาวะของเด็กวยัเรียน ไม่สามารถบ่งช้ีถึงภาวะไอโอดีนของมารดาท่ีก าลงั
ตั้งครรภ์ได ้ดังน้ัน หญิงตั้งครรภจ์ึงควรไดร้ับการตรวจติดตามภาวะไอโอดีนในระหว่างตั้งครรภ์แยก   
เป็นการเฉพาะ    
  
ปัญหาน ้าหนักเกินในระหว่างตั้งครรภอ์าจส่งผลกระทบอนัไม่พึงประสงคต่์อสุขภาพของทั้งมารดาและ
บุตร บทท่ี 3 เป็นการวิเคราะหข์อ้มลูโดยใชข้อ้มลูเบ้ืองตน้ของการวิจยัหลกั เพื่อตรวจสอบความสมัพนัธ์
ระหว่างดชันีมวลกายก่อนตั้งครรภ ์(pre-pregnancy body mass index) ของมารดากบัปัญหาความ
ผิดปกติของการท างานของต่อมไทรอยด์ (thyroid dysfunction) โดยการศึกษาแบบภาคตัดขวางน้ี 
อา้งอิงค่าดัชนีมวลกาย 23 กิโลกรัมต่อตารางเมตร ท่ีใชบ่้งช้ีภาวะน ้าหนักเกินส าหรบัประชากรชาว
เอเชีย ซ่ึงมีค่าต า่กว่าค่าอา้งอิงดชันีมวลกายสากล (25 กิโลกรมัต่อตารางเมตร) ผลการศึกษาพบว่า 
หญิงตั้งครรภท่ี์มีภาวะขาดธาตุไอโอดีนระดบัไม่รุนแรงถึงปานกลาง และมีปัญหาน ้าหนักเกินร่วมดว้ย มี
ความเส่ียงต่อปัญหาภาวะระดบัไทรอยดฮ์อรโ์มนในเลือดต า่ (hypothyroxinemia) ในช่วงการตั้งครรภ์
ไตรมาสแรก มากกว่าหญิงตั้งครรภท่ี์มีน ้าหนักปกติถึง 3.6 เท่า ผลการศึกษาน้ีบ่งช้ีว่า ไม่เพียงแต่หญิง
ตั้งครรภท่ี์เป็นโรคอว้น (ดชันีมวลกาย ≥ 40 กิโลกรมัต่อตารางเมตร) เท่าน้ัน ท่ีควรไดร้บัการตรวจคดั
กรองเพื่อป้องกันการเกิดปัญหาความผิดปกติของการท างานของต่อมไทรอยด์ แต่หญิงตั้งครรภ์ท่ีมี
น ้าหนักเกินและอาศยัอยูใ่นพื้ นท่ีท่ีมีการขาดไอโอดีนดว้ย ก็ควรไดร้บัการตรวจคดักรองดงักล่าวดว้ย         
 
การวิจยัหลกัซ่ึงเป็นการวิจยัเชิงทดลองแบบสุ่มและมีกลุ่มควบคุม (บทท่ี 4) เป็นการใหไ้อโอดีนเสริมใน
รปูของยาเม็ดโพแทสเซียมไอโอไดดป์ริมาณ 200 ไมโครกรมัต่อวนั หรือยาเม็ดหลอก ในหญิงตั้งครรภท่ี์
มีภาวะการขาดธาตุไอโอดีนระดบัไม่รุนแรงจ านวน 511 ราย ตั้งแต่อายุครรภ ์< 14 สปัดาห ์จนกระทัง่
คลอด พบว่า การได้รับไอโอดีนเสริมน้ี ไม่ท าใหร้ะบบการท างานของต่อมไทรอยด์ ขนาดของต่อม
ไทรอยด ์การคลอดบุตร และคะแนนการทดสอบพฒันาการของทารกดีขึ้ น แต่ท าใหป้ริมาณไอโอดีนใน
ปัสสาวะของมารดาเพิ่มขึ้ นอย่างมีนัยส าคญัทางสถิติ อีกทั้งยงัช่วยลดความชุกของปัญหาความผิดปกติ
ของการท างานของต่อมไทรอยดห์ลงัคลอดของมารดาดว้ย  ยิ่งไปกว่าน้ัน ยงัสามารถสรุปไดว้่า การให้
ไอโอดีนเสริมปริมาณ 200 ไมโครกรัมต่อวนั ในหญิงตั้งครรภท่ี์มีภาวะการขาดธาตุไอโอดีนระดับไม่
รุนแรงน้ี มีความปลอดภัย เน่ืองจากพบหญิงตั้งครรภ์จ านวนน้อย ท่ีมีป ริมาณไอโอดีนในปัสสาวะ        
> 500 ไมโครกรมัต่อลิตร ซ่ึงบ่งช้ีถึงภาวะการไดร้บัไอโอดีนเกิน และไม่พบว่าเกิดอนัตรายใดๆต่อผลการ
ท างานของระบบไทรอยดท์ั้งกบัมารดาและบุตร  
บทสรุป 
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บทท่ี 5 เป็นการวิเคราะหข์อ้มลูทุติยภมูิท่ีไดจ้ากการวิจยัหลกั เพื่อศึกษาความสมัพนัธร์ะหว่างดชันีมวล
กายก่อนการตั้งครรภแ์ละการเพิ่มน ้าหนักตวัระหว่างตั้งครรภ ์ซ่ึงอาจเป็นปัจจยัส าคญัท่ีสามารถท านาย
ผลอนัไม่พึงประสงคต่์อการตั้งครรภข์องมารดาได ้จากการศึกษาพบว่า ทารกท่ีเกิดจากมารดาท่ีมีปัญหา
น ้าหนักเกินหรืออว้นก่อนตั้งครรภ ์(ดชันีมวลกาย ≥ 25 กิโลกรมัต่อตารางเมตร) มีความเส่ียงต่อการมี
ขนาดตวัโตกว่าปกติ (macrosomia) มากกว่าทารกปกติทัว่ไป 11 เท่า นอกจากน้ันยงัพบอีกว่า หญิง
ตั้งครรภท่ี์มีการเพิ่มน ้าหนักตวัขณะตั้งครรภม์ากกว่าเกณฑท่ี์ก าหนด จะมีความเส่ียงเป็น 5.6 เท่า ใน
การใหก้ าเนิดทารกท่ีมีขนาดตวัโตกว่าปกติ เมื่อเทียบกบัหญิงตั้งครรภท่ี์มีการเพิ่มน ้าหนักอยู่ในเกณฑท่ี์
แนะน า จากผลการศึกษาน้ี ช้ีใหเ้ห็นถึงความส าคัญของการใหค้ าแนะน าในการดูแลน ้าหนักตัวของ
มารดาทั้งก่อนและระหว่างตั้งครรภใ์หเ้หมาะสม เพื่อป้องกนัปัญหาดงักล่าว 
 
บทท่ี 6 รวบรวมผลการศึกษาทั้งหมดท่ีไดจ้ากการวิจยัน้ี รวมถึงประเด็นขอ้จ ากดัและปัญหาอุปสรรค
ต่างๆของการวิจัย ทั้งในแง่ของขั้นตอนกระบวนการการท าวิจัย ปัญหาท่ีเกี่ยวขอ้งกับการวิเคราะห์
ตวัอยา่งชีวภาพ และอื่นๆท่ีเกี่ยวขอ้งกบัการวิเคราะหข์อ้มลูทางสถิติ นอกจากน้ัน ยงัไดใ้หข้อ้เสนอแนะใน
การน าผลการศึกษาไปประยุกต์ใชแ้ละประเด็นการศึกษาท่ีน่าสนใจและควรท าการศึกษาเพิ่มเติมใน
อนาคตอีกดว้ย 
 
โดยสรุป การศึกษาน้ีเป็นการวิจยัเชิงทดลองแบบสุ่มและมีกลุ่มควบคุม ท่ีท าการศึกษาผลของการให้
ไอโอดีนเสริมในหญิงตั้งครรภท่ี์มีภาวะขาดธาตุไอโอดีนระดับไม่รุนแรงท่ีมีขนาดใหญ่ท่ีสุดเท่าท่ี เคยมี
การศึกษามาจนถึงปัจจุบนั ผลการศึกษาบ่งช้ีว่า การไดร้บัไอโอดีนในระหว่างตั้งครรภม์ีความปลอดภยั
และมีประสิทธิผลในการช่วยรกัษาระดบัของไอโอดีนท่ีไดร้บัเขา้สู่ร่างกายของมารดาได ้แต่อย่างไรก็ตาม 
ผลจากการศึกษาน้ีไม่สามารถน าไปขยายผลในวงกวา้งส าหรับประชากรไทยทั ่วทั้งประเทศได ้ทั้งน้ี
เน่ืองจากมีความแตกต่างของภาวะไอโอดีนในประชากรท่ีอาศยัอยูใ่นเขตเมืองและชนบท ผลการศึกษาน้ี
ช้ีใหเ้ห็นว่า การใหไ้อโอดีนเสริมอาจไม่มีความจ าเป็นส าหรบัหญิงตั้งครรภท่ี์มีภาวะขาดไอโอดีนระดบัไม่
รุนแรงซ่ึงอาศัยอยู่ในพื้ นท่ีท่ีมีการด าเนินงานเร่ืองเกลือเสริมไอโอดีนอย่างมีประสิทธิภาพ ทั้งน้ีอาจ
เน่ืองมาจากระดับของไอโอดีนท่ีสะสมในร่างกายก่อนการตั้งครรภม์ีปริมาณท่ีเพียงพอและยงัสามารถ
ช่วยเติมเต็มความตอ้งการของไอโอดีนท่ีเพิ่มขึ้ นในระหว่างตั้งครรภไ์ด ้นอกจากน้ัน ประเด็นเร่ืองน ้าหนัก
ตัวของหญิงตั้งครรภ์โดยเฉพาะผูท่ี้มีปัญหาน ้าหนักเกินควรไดร้ับการดูแล เพราะมีความสัมพนัธ์กับ  
ความผิดปกติของการท างานของต่อมไทรอยดแ์ละอาจส่งผลกระทบอนัไม่พึงประสงคต่์อการตั้งครรภแ์ละ
การคลอดบุตรดว้ย 
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